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yesterday a child came out to wonder 
caught a dragonfly inside a jar 
fearful when the sky was full of thunder 
and tearful of at the falling of a star 
. 
then the child moved ten time round the seasons 
skated over ten clear frozen streams 
words like 'when you're older' must appease him 
and promises of someday make his dreams 
 
and the seasons they go round and round 
and the painted ponies go up and down 
we're captive on the carousel of time 
we can't return we can only look 
 behind from where we came 
and go round and round and round  
in the circle game 
 
sixteen springs and sixteen summers gone now 
cartwheels turn to car wheels thru the town 
and they tell him 'take your time, it won't be long now 
till you drag your feet to slow the circles down' 
 
so the years spin by an now the boy is twenty 
though his dreams have lost some grandeur coming true 
there'll be new dreams, maybe better dreams and plenty 
before the last revolving year is through 
 
 
 
 
 
 
 
The circle game. Words and music by Joni Mitchell. © 1966 (Renewed) Crazy Crow Music.  
All rights administered by SONY/ATV Music Publishing. All rights reserved. 
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NORMAL HEMATOPOIESIS AND LEUKEMIA 
Hematopoiesis 
The word hematopoiesis comes from the ancient Greek; haima translates to 'blood' and 
poiesis means 'to make': hematopoiesis describes the formation and development of bloods 
cells. Different types of blood cells are recognized. Red blood cells, the erythrocytes, are 
important for transport of oxygen throughout the body, white blood cells, B and T-
lymphocytes, are crucial for the immune response and granulocytes and monocytes are 
important for responses against infections. Platelets, which form clots to stop bleeding, are 
also formed by hematopoiesis.1  
Hematopoiesis is an intriguing process that continuously supplies the organism of new 
blood cells for its complete lifespan. In humans, the first primitive blood cells are formed in 
the blood island of the yolk sac (2 to 8 weeks of development).2 This is followed by blood cell 
formation in the fetal liver and the spleen. At five months of development the bone marrow is 
the site of production of blood cells and it continues to do so throughout life. 
The cells from the hematopoietic system are generated from the self-renewing 
hematopoietic stem cells (HSC) that reside mainly in the bone marrow.3,4,5 HSCs are divided 
in long-term (LT)-HSC and short-term (ST)-HSC (Figure 1). LT-HSC are slow-dividing cell 
populations that contain self-renewing cells that sustain long-term hematopoiesis, divide a-
symmetrically, and form ST-HSC. These cells are faster-dividing cell populations with limited 
self-renewal potentials and are more committed, ready-to-differentiate and produce the 
progeny of the different lineages. ST-HSC differentiate into nonself-renewing multipotent 
progenitors (MPP). This cell type differentiates into two oligolineage progenitors, the 
common myeloid progenitor (CMP) or common lymphoid progenitor (CLP). T-cells, natural 
killer (NK)-cells and B-cells are formed from the CLPs. CMPs differentiate into either 
megakaryotic/erythoid progenitors (MEP) that produce erythrocytes and platelets or 
granulocyte/monocyte progenitors (GMP). Dendritic cells are produced either from CMPs or 
CLPs.  
Each blood cell type is produced in different numbers, and this production is regulated 
strictly to meet the changes needed. The regulation is controlled by extracellular signals, 
such as interleukin-3 (IL-3) and granulocyte-macrophage colony stimulating factor (GM-
CSF). These signals are passed on within the cell by signaling cascades, including the Jak-
Stat pathway, the Raf/MEK/ERK pathway and the PI3K/Akt pathway.6,7 At the end of these 
pathways are many transcription factors that control the expression of genes.8,9 Each 
differentiation step requires the up and downregulation of a specific set of genes.  
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Figure 1. Cell lineages in hematopoiesis. Long-term (LT)-HSCs contain self-renewing cells and short-term (ST)-HSC consist of 
more commited cells that will differentiate into multipotent progenitor population (MPP). These cells differentiate into the so-
called oligolineage-restricted progenitors, the common myeloid progenitor (CMP) and the common lymphoid progenitor (CLP). 
Het CLPs give rise to indicated cells. Dendritic cells are formed from either CMPs or CLPs. The CMPs differentiate to 
megakaryocytes-erythrocytes progenitors (MEPs) and the granulocyte/monocyte progenitors (GMPs). These progenitors give 
rise to the mature cell types indicated. This figure is a simplified version of the one that appeared in Passegue et al.5 
Leukemia 
In leukemia, the differentiation and proliferation of blood cells is disturbed and cells 
accumulate in a pre-mature state and will overgrow the normal cell populations in the blood. 
Symptoms of leukemia include low red blood cell count (anemia), low platelet levels 
(thrombocytopenia) and low white blood cell count (neutropenia), leading to fatigue, easy 
bleeding, and failure to fight infections respectively.10 The main subgroups of leukemia are 
classified according to the cell lineage involved (myeloid or lymphoid) and the development 
of the disease (chronic or acute).  
The incidence rate for leukemia is 15 per 100.000 for the US.11 It accounts for 3% of 
all newly diagnosed cancer patients but still is among the ten leading cancer types for both 
males and females. The majority of patients are diagnosed with chronic lymphoid leukemia 
(CLL, 35% of cases) or acute myeloid leukemia (AML, 30% of cases). The remainder of the 
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patients has acute lymphoid leukemia (ALL) or chronic myeloid leukemia (CML) and other 
leukemia subtypes.  
Leukemias, and cancers in general, develop from a single cell that acquires multiple 
genetic and epigenetic changes, such as translocations (see below), pointmutations, 
amplifications and aberrant methylation patterns. These changes usually affect the self-
renewal and proliferation capacity of the cell. Within a tumor, not all cells are capable of 
initiating and sustaining tumor growth in vivo. Only cancer-initiating cells, also called cancer 
stem cells, have the capacity to do so.12 In case of leukemia this was already recognized in 
1994; transplantation of only a small subset of cells with stem cell like properties was able to 
engraft recipient mice.13  Leukemia is thus organized as a hierarchy similar to normal 
hematopoiesis: leukemic cells are sustained by a small number of leukemia stem cells 
(LSCs). These LSCs can arise from primitive stem cells with multilineage potential or from 
progenitors that are already differentiated into the lymphoid or myeloid pathway. The 
majority of adult leukemia cases arise from the more primitive stem cells whereas childhood 
leukemias usually have their origin in the lymphoid and myeloid-restricted progenitor cells.14 
 
CHROMOSOMAL ABNORMALITIES IN LEUKEMIAS 
Translocations 
In the early days of cytogenetics, it was already recognized that leukemias frequently are 
associated with the presence of translocations or other chromosomal abnormalities. In 1960, 
a minute chromosome that was associated with chronic granulocytic leukemia has been 
reported on a meeting in Philadelphia by Nowell and Hungerford.15 Later it was referred to 
as the philadelphia chromosome and turned out to be caused by a translocation between 
chromosome 9 and 22.16 In 1983 and 1984 it was shown that the genes BCR and ABL are 
involved.17,18  
Up to 65% of acute leukemias harbor a translocation. At the genetic level two types of 
translocations are recognized. Either a translocation causes deregulation of a gene by 
placement of the gene behind controlling elements of another gene (Figure 2A), or 
translocations create fusion genes by linking the exons of two genes that result in the 
production of fusion proteins (Figure 2B). The first type of translocations mostly involves 
rearrangements with immunoglobulin or T-cell receptor genes and the adjacent gene is 
upregulated. In the second type of translocations, many different classes of genes are 
involved. The majority, however, are transcription factors, tyrosine kinases, HOX genes, and 
nuclear receptors and growth factors. The fusion proteins display altered functions and 
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disturb pathways that are normally tightly regulated in steady-state hematopoiesis. One of 
the hallmarks of cancer is that cells acquire multiple characteristics during its development 
and that multiple changes in the genome are required to obtain these characteristics.19 This 
is also true for leukemias; besides a translocation, many more cooperating gene mutations 
are required that finally give the leukemic cells the proliferative advantage in combination 
with the impaired differentiation.20   
 
 
 
Figure 2. Two major types of translocations are recognised in hematological disorders. (A) The exon structure of a gene is not 
disturbed but the gene is deregulated by the translocation. The promoter regions of immunoglobulin or T-cell receptor genes 
are usually involved in these translocations. (B) A translocation results in fusion of genes. One gene contributes the promoter 
and 5’ exons and another gene, derived from the other chromosome, contributes the 3’ exons. Exons are incidated with a box, 
dashed line indicates the breakpoint. 
 
Translocation networks and distribution of translocations 
Some translocations have been diagnosed in leukemias show a high degree of specificity 
between the partner genes, for example the BCR and ABL translocation. Other 
translocations seem to be less specific for the partner that is involved. An example is 
translocations including the MLL locus. The MLL gene has been shown to translocate to 
over 20 different partners. The translocation networks for translocations found in 
hematological diseases are displayed in Figure 3. It shows that the number of key players is 
limited and this points to common mechanisms for leukemogenesis. The next subchapter 
discusses the most common translocations and the mechanisms involved in oncogenesis. 
The occurrence of these different translocations is not evenly distributed among the patients 
diagnosed with leukemia. Some translocations account for over 10% of all patients 
diagnosed with a particular leukemia subtype whereas others are only found in one or two 
patients. A list of the most commonly found mutations in acute leukemias in children and 
young adults is listed in Table 1. In this group of patients the AML1-ETO and CBFβ-MYH11 
fusion genes have been detected in 12% of AML cases each. In addition, 20% of ALL cases 
have been diagnosed with a TEL-AML1 fusion.21  
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Figure 3. Translocation networks in hematological disorders. Genes that are involved in a translocation are connected by a 
line or an arrow. The direction of the arrow indicates the direction of the fusion. For instance, the MN1 and TEL genes are 
fused and the arrow points towards TEL. This means that the 5’ part of the fusion gene consists of MN1 sequences and the 3’ 
part are TEL sequences. A line instead of an arrow indicates that it is unknown which one of the two possible combinations of 
gene fusions is leukemogenic. A blue box indicates that solely the regulatory sequences and no coding sequences of the gene 
are involved in the translocation, usually leading to upregulation of the translocated gene. Yellow indicates genes with tyrosine 
kinase activity. Green indicates the major players in the network. Information about translocations is gathered together from 
several review articles and chapter 5 of the book 'Leukemia'.21,22,23,24,25,26,27,28,29  
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abnormality gene(s) involv ed abnormality gene(s) involved
t(12;21) TEL-AML1 20% t(8;21) AML1-ETO 12%
11q23 MLL fusions 6% inv(16) CBFβ-MYH11 12%
t(1;19) E2A-PBX1 5% t(9;11) MLL-AF9 7%
14q11 TCRαδ 4% 17q21 RARα 7%
t(9;22) BCR-ABL 4% 3q26 EVI1 3%
7q35 TCRβ 3% t(3;5) NMP-MLF1 1%
8q24 MYC 2% t(6;9) DEK-CAN 1%
t(17;19) E2A-HLF 1% t(16;21) FUS-ERG 1%
normal karyotype 30% t(7;11) NUP98-HOXA9 1%
rare translocations 25% normal karyotype 19%
rare translocations 36%
Normal karyotype refers to leukemias that lack identi fiable gene abnormal ities. 
*This table is deduced from a figure that appeared in Look et al (1997)19
AML
Table 1. Chromosomal abnormalities found in acute leukemias in children and young adults*
ALL
 
 
MAJOR PLAYERS OF THE TRANSLOCATION NETWORK 
AML1 and CBFβ 
The t(12;21) is found in approximately 20% of all pediatric patients and it was shown to 
occur in most cases already before birth.30,31 The translocation generates the TEL-AML1 
fusion protein, also known as ETV6-RUNX1.32,33 AML1 is the DNA binding subunit of the 
heterodimeric transcription factor core-binding factor (CBF). The other regulatory subunit is 
CBFβ. The heterodimeric transcription factor complex controls important developmental 
decisions by regulating a number of hematopoietic-specific genes, including IL-3 and GM-
CSF. Disturbance of this complex by the fusion proteins deregulates the differentiation and 
proliferation of the hematopoietic cells.29,34 The TEL gene encodes a DNA binding 
transcriptional repressor that recruits corepressors and histone deacetylases (HDACs). The 
TEL gene is more extensively discussed at the end of this introduction. The N-terminal and 
central domains of TEL are fused to the C-terminal DNA binding domain of AML1, also 
called RUNT domain, that is also important for dimerization with CBFβ. Evidence is provided 
that TEL-AML1 can still bind to promoter and enhancer regions of AML1-target genes and 
that the TEL moiety of the fusion protein recruits co-repressors.35,36,37,38 The fusion protein, 
however, still needs the binding to the CBFβ subunit of CBF for leukemogenesis as has 
been shown in mice studies by generating point mutations in the RUNT domain of TEL-
AML1.39 The recruitment of corepressors by the TEL-AML1 fusion leads to repression of 
CBF-target genes that are normally activated by CBF. Expression of the non-translocated 
TEL allele is frequently absent in ALL cases that are diagnosed with a TEL-AML1 fusion.40 
This is caused either by 12p deletions or by other non-cytogenetically detectable 
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mutations.41,42,43 This latter phenomenon is not unique for TEL-AML1 cases: also one-third 
of AML patients have deficient TEL expression.44 The absence of TEL protein suggests that 
this is an important step and contributes to leukemogenesis.  
Another translocation in which the AML1 gene takes part is the t(8;21) frequently 
detected in AML patients. The translocation fuses AML1 to ETO, a gene encoding a 
transcription factor. Also this translocation may be of prenatal origin.45,46 In contrast to the 
TEL-AML1 fusion, the N-terminal part of AML1-ETO is provided by AML1 sequences. The 
breakpoint within the AML1 gene, however, is much further C-terminally compared to the 
t(12;21) and as a consequence, AML1 again contributes the RUNT domain of AML1 to the 
fusion protein. The ETO moiety of the fusion protein contributes, similar to the mechanisms 
described for TEL-AML1, the sequences that recruits corepressors to the promoters that are 
normally stimulated by the AML1-CBFβ heterodimer.47,48,49 One of the targets of AML1-ETO 
that was recently identified is the microRNA (miRNA) miR-233, the activity of which is linked 
to differentiation of myeloid precursors. The expression of this miRNA is silenced by the 
fusion protein, thereby inhibiting the differentiation of myeloid precursors as seen in AMLs.50 
CBFβ, the non-DNA binding regulatory subunit of CBF, is involved in a frequently 
occurring inv(16), which is also associated with AML. Molecular cloning has revealed that 
CBFβ is fused to the smooth muscle myosin heavy-chain gene, MYH11. The same fusion 
can occur as a result of translocation between two chromosomes 16. The exact mechanism 
by which the fusion protein CBFβ-SMMHC fusion protein (this nomenclature refers to the 
protein, whereas MYH11 refers to the gene) performs it leukemogenic activity is largely 
unknown. Molecular studies have shown that also this fusion recruits repressor proteins to 
the promoters that are regulated by the AML1-CBFβ heterodimer.51 Animal studies have 
shown that secondary mutations are obligatory. Expression profiling of leukemic cells from 
patients with an inv(16) have shown that the MN1 gene is frequently upregulated. Mice 
studies have confirmed that overexpression of MN1 is an important second hit for the 
leukemogenesis by the inv(16) fusion protein.52  
 
MLL fusions 
The MLL gene is localized on chromosome 11q23 and many translocation partners have 
been described for this gene. The multiplicity of the partner genes has raised questions 
about the role of these genes in the leukemic process. All fusion genes, however, create in-
frame fusions at the mRNA level, making it plausible that the fused parts contribute to 
leukemogenesis. The mere absence of C-terminal sequences of the MLL gene is likely not 
sufficient to obtain leukemogenic properties.24 The MLL gene is important for normal 
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hematopoiesis as has been shown in Mll-null mice. These mice have defects in yolk sac 
hematopoiesis.53 The MLL protein is a histone methyl transferase that regulates, amongst 
others, the expression of HOX genes. HOX genes were shown to be expressed in 
hematopoietic precursors, with preferential expression in self-renewing HSCs, and are 
downregulated following differentiation.54 The MLL fusion proteins upregulate HOX genes, 
resulting in a block in hematopoietic differentiation, especially in the myeloid lineage.34,55 
Recently it has been shown that MLL also indirectly influences expression of HOX genes by 
regulating the expression of miRNA mir-196b. This miRNA is located within the HoxA cluster 
and targets several HOX genes. Upon differentiation of hematopoietic cells, miRNA-196b is 
downregulated. MLL fusions were shown to upregulate this miRNA and this suggests an 
additional mechanism whereby the increased expression of this miRNA contributes to 
leukemia development by MLL fusions.56 
 
Retinoic acid receptor (RAR)α translocations 
The most frequent and well studied translocation from this subgroup is de t(15;17) that 
generates the PML-RARα fusion gene. RARα is a member of the nuclear receptor family 
and binds as a heterodimer with the retinoid x receptor (RXR) to DNA response elements. 
The heterodimer binds the ligand all-trans retinoic acid (RA) using its ligand binding domain 
and stimulates or represses transcription by the recruitment of cofactors when bound to its 
responsive elements in the DNA.57 RA, a derivative of vitamin A, is essential during 
vertebrate development58 and stimulates the differentiation of normal hematopoietic 
progenitors.59 The fusion protein PML-RARα retains the ligand binding domain of RARα but, 
in the presence of physiological levels of RA, co-repressors bind to the fusion protein that 
result in repression of target genes that are normally activated by RARα.60 Several classes 
of genes are targets of RARα, including differentiation regulators and chromatin modifiers61 
and miRNA genes.62 Repression of these miRNA genes results in increased expression of 
HOX genes that keeps cells in a non-differentiated state by promoting self-renewal and 
blockage of differentiation.62  
Molecular studies have shown that high levels of RA displaces the repressor 
complexes from the fusion protein and subsequently activates genes required for the 
differentiation of cells in myeloid lineage. These days, patients diagnosed with a PML-RARα 
fusion are successfully treated with pharmalogical levels of RA.63,64 Unfortunately, another 
RARα fusion, PLZF-RARα does not respond to RA treatment.65 Although this translocation 
also results in the recruitment of corepressor complexes to the RAR-responsive elements, 
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these complexes are not released by high doses of RA, because the PLZF moiety itself has 
the capacity to bind corepressors, whereas this is not the case for PML.66 
  
The TEL (ETV6) gene translocations 
About 20 partners for the TEL (ETV6) gene have been described so far. One of the 
translocations, the TEL-AML1 fusion gene, was described before. A large group of TEL 
partners including PDGFRβ, JAK2, ABL, FGFR3, TRKC and ARG encode tyrosine 
kinases.67,68,69,70,71,72 The fusion proteins all contain the HLH domain of TEL that provides 
the TEL protein the interface for dimerization with itself. The TEL moiety of the fusion protein 
enables dimerization and this constitutively activates the tyrosine kinases, leading to 
activation of downstream pathways. This finally results in loss of differentiation and 
stimulation of proliferation of hematopoietic progenitors. 
Another group of translocations involving the TEL gene are more diverse and a 
common mechanisms seems to be the induced ectopic expression or overexpression of 
either the translocated gene or genes in the vicinity of the translocations. The translocation 
with the BTL gene was shown to produce a small fusion protein, but rather the ectopic 
expression of the homeobox gene GSH2, which is located near the breakpoint on 
chromosome 4 is thought to be critical for leukemogenesis.73 Translocations with MDS2 and 
STL result in fusions that contain only 4 amino acids (aa) from the coding sequences of the 
genes. Overexpression of neighboring genes, such as E2F2 (near MDS2) and OSTL (on 
antisense strand of STL gene) are most likely the main pathogenic mechanisms in these 
translocations. Also the translocations with EVI1 and CDX2 are thought to rely on this 
mechanism. The EVI1 and CDX2 fusions with TEL only harbor a very small part of TEL and 
ectopic expression of EVI1 and CDX2 is thought to contribute to leukemogenesis rather than 
the properties of the fusion protein.74,75,76 
The last group of translocations is rather small and the mechanism has been detected 
in both the MN1-TEL and the PAX5-TEL fusion genes. Both fusion genes carry the C-
terminus of TEL that contains the DBD domain and it is conceivable that the PAX5-TEL 
fusion, like the MN1-TEL fusion, binds to ETV6-target genes and deregulates their 
expression.  
Altogether, the many different fusions detected with the TEL gene show that TEL is a 
major player in leukemogenesis. Translocations involving the TEL gene activate partner 
kinases, upregulate genes close to the translocation breakpoint, or create fusion genes with 
unique properties. Additionally to these translocations, the non-translocated TEL allele is 
frequently inactivated by deletions or pointmutations. This observation supports that TEL 
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also functions as a tumor suppressor gene. The inactivation of TEL in combination with the 
specific characteristics of the translocation defines the subtype of leukemia that is found in 
patients.  
Since the MN1 gene is the major topic of this thesis, the remainder of the introduction 
will focus on the MN1 gene and the leukemogenic fusion protein MN1-TEL. 
 
THE MN1 GENE 
Conservation, expression and regulation. 
The MN1 gene is located on chromosome 22q11.2 and is comprised of two large exons of 
4.7 kb (5’ end) and 2.8 kb (3’ end). Homologues of MN1 have been found in more than ten 
species, including mouse (Mus musculus), duck-billed platypus (Ornithorhynchus anatinus), 
puffer fish (Tetraodon nigroviridis) and horse (Equus caballus). On Northern blots, 
homologues in fruit fly (Drosophila melanogaster) and frog (Xenopus laevis) have been 
detected.77  
Northern blots from different tissues with MN1 probes showed the existence of two 
transcripts. The largest transcript (8 kb) has been detected in several tissues, including 
brain, heart, skeletal muscle and liver. In skeletal muscle, a smaller band of 4.5 kb has been 
detected, possibly representing alternative splicing of the transcript in this tissue.77 
Expression of MN1 has also been detected in the hematopoietic system 52 and in hair follicle 
cells.78 The majority of cell lines of different tissue origins have no detectable levels of MN1 
expression. Kuang and coworkers have performed promoter methylation studies in more 
than twenty AML and acute lymphoid leukemia (ALL)-derived cell lines and showed that the 
MN1 promoter is highly methylated in both types of cell lines.79 The only two cell lines in our 
laboratory to date exhibiting MN1 expression are two osteosarcoma-derived cell lines: U2-
osteosarcoma (U2OS) and MG63.  
The promoter of the MN1 gene is not well mapped and pathways that regulate MN1 
expression are largely unknown. The synergy between MN1 and the vitamin D3/RX receptor 
dimer (discussed below) led to the identification of vitamin D3 as a regulator of the MN1 
gene.80 Expression profiling of vitamin D-treated SCC25 cells (tong keratinocytes) has 
confirmed this finding.81 Upregulation of MN1 is reported in response to TGFβ in epithelial 
cells of different origin, including skin keratinocytes, long epithelial cells and breast cancer 
cells.82,83 The synthetic androgen R1881 induced MN1 in breast cancer cells (MDA-MB-453 
cells),84 but not in hair follicle cells.78 A genome-wide mapping of polycomb-target genes has 
revealed that MN1 is a target of both polycomb-repressive complex 1 (PRC1) and PRC2.85 
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The coding sequence of the MN1 gene harbors two CAG repeats encoding glutamines 
(Q). The largest glutamine stretch is 28Q and is encoded by CAG codons interspersed by 
four single CAA codons. CAG repeats of this size can be subjected to instability and repeats 
of extreme lengths are associated with neurodegenerative diseases, such as Huntington’s 
disease.86 The length of the largest glutamine repeat within the MN1 gene varies in the 
population, but only three alleles have been found, differing 3 CAG codons in length.77 The 
repeat is stable upon transmission to offspring and no expansions of the glutamine repeat 
have been reported in patients suffering from neurodegenerative disorders or other 
pathology (unpublished data).  
 
Translocations involving the MN1 gene 
A balanced translocation (4;22) present in a meningioma, a benign brain tumor, has led to 
the identification of the MN1 gene. The breakpoint within the gene is located in the first 
exon, thereby disrupting the MN1 open reading frame. No other meningiomas samples have 
been found with large deletions or translocations within the MN1 gene region. Also the 
lengths of the large CAG repeats within the coding region of the MN1 gene have been 
analyzed in meningioma samples and were of normal length. A causal relationship between 
MN1 expression and meningioma development has thus not been proven to date. Notably, 
MN1 expression in meningiomas varies greatly from tumor to tumor.77 
More than ten leukemia patients have been diagnosed with a t(12;22) within their 
leukemic cells.27,87,88,89,90,91,92 A majority of these patients have been shown to exhibit a 
fusion gene involving the MN1 and TEL (ETV6) genes. In addition, several patients display 
this translocation after chemo and radiation therapy directed against solid tumors elsewhere 
in the body.87,88 The amount of patients analyzed, however, is too small to conclude that the 
t(12;22) is therapy-induced. TEL is translocated to over 20 partners in hematological 
disorders as discussed before (see Figure 3). Two leukemia cell lines, MUTZ-3 and 
UCSD/AML1 are known to harbor a t(12;22), creating only in UCSD/AML1 the MN1-TEL 
fusion. The breakpoint within the TEL gene in MUTZ-3 lies in the 5’ untranslated region, 
ruling out the possibility of an MN1-TEL fusion. The translocation in MUTZ-3 inactivates one 
copy of the TEL gene and the haploinsufficiency of TEL expression is considered to have a 
pathogenetic role in AML. 
 
The MN1 protein is a transcriptional cofactor 
The gene encodes a protein of 1319 amino acids (aa) in which the second exon accounts 
for only 59 aa. The protein does not show any homology to other proteins and besides the 
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glutamine-rich regions that point to a function in transcription regulation, no obvious 
structural domains have been detected. Indeed the MN1 protein was found to be able to 
stimulate transcription. It has been extensively studied on a viral promoter and deletion 
mutants have shown that transcription stimulating activity is located in the N-terminal region 
of the MN1 protein.93 On this viral promoter, it functions as a cofactor for the nuclear 
receptor dimer of RAR and RXR. Retinoic acid (RA), as discussed above, is a regulator of 
differentiation in various stages of embryogenesis and hematopoiesis and MN1, as a 
cofactor, is thought to modulate RA pathways. Binding studies have shown that MN1 does 
not bind the receptors directly.93 It confers activation by synergizing with p300 and RAC3, 
both known coactivators of nuclear receptors (Figure 4A and chapter 4).94 p300 possesses 
histone acetyltransferase activity and the acetylation of histones is associated with a relaxed 
chromatin configuration. This is thought to facilitate transcription factor access to DNA, 
resulting in a higher transcription activity.95 RAC3 is a member of the SRC family of nuclear 
receptor coactivators and is also known as nuclear coactivator 3 (NCoA3).96 Expression 
profiling studies have uncovered that MN1 has a more widespread effect that is not limited 
to nuclear receptors. It can both stimulate and repress transcription with and without the 
involvement of RA (Figure 4A,B, and D; see chapter 5).97 Several of the genes identified in 
this study as MN1-target genes are known players in leukemogenesis, such as BMI1 and 
MEIS1. Another interesting target of MN1 is DHRS9, which is involved in the synthesis of 
retinoic acid. RA stimulated the expression of DHRS9 whereas MN1 blocks this stimulatory 
effect of RA. This interference of the RA-regulated expression of DHRS9 by MN1 might be 
involved in the differentiation block apparent in leukemias. 
Additionally, Sutton and coworkers have identified MN1 as a cofactor for the vitamin D 
receptor (VDR).80 This nuclear receptor, like RAR, forms a dimer with RXR and has a dual 
function; it both inhibits proliferation and stimulates differentiation. MN1 is able to stimulate 
VDR-driven transcription and combining MN1 with SRC-1 or SRC-2, two coactivators of 
VDR, results in a synergistic activation (Figure 4C).  
Transcription-stimulation of MN1 can also occur via CACCC-rich elements in 
promoters. We have studied this mechanism on a natural target of MN1, the insulin-like 
growth factor binding protein 5 (IGFBP5) gene (see chapter 3).98 MN1 does not bind directly 
to the CACCC element within the promoter and transcription factors linking MN1 to the 
CACCC sequence are currently unknown (Figure 4E). 
Post-translational modifications of proteins, such as phosphorylation and methylation 
are important mechanisms to modulate the activity or localization of proteins in cells. 
Phosphorylation is carried out by kinases and occurs at serine, threonine or at tyrosine 
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residues. Interestingly, Beausoleil and coworkers identified that MN1 is phosphorylated at 
the evolutionary conserved serine at aa position 1081.99 Another large-scale study, aimed at 
identifying proteins that are methylated at arginine residues, identified that MN1 is 
methylated around position 943.100 It is yet to be discovered whether these phosphorylated 
and methylated residues are important for controlling the activity of MN1. 
 
 
 
 
Figure 4. MN1 is a transcriptional cofactor. (A) MN1 is a cofactor that stimulates RAR/RXR-mediated transcription together 
with p300/CBP and RAC3. (B) MN1 can also inhibit RAR/RXR-mediated transcription. Co-acting proteins are unknown. (C) 
Together with SRC-1 and SRC-2, MN1 enhances VDR/RXR-mediated transcription. (D) MN1 can both stimulate and inhibit 
transcription. (E) Indirect binding of MN1 has been proven on the IGFBP5 promoter. The CACCC-binding transcription factor is 
unknown (indicated with Y). 
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Mn1’s role in embryogenesis 
Whole mount in situ hybridization on mice embryos of various developmental stages has 
shown that Mn1 is first detected at embryonic day (E) 9.5. Expression has been detected in 
the midbrain and hindbrain tissues and in craniofacial mesenchyme. At day E10.5 Mn1 was 
highly expressed in various structures of the developing face, the developing somites and 
limb buds. Strong Mn1 mRNA expression persisted in the brain, in particular in the 
ventricular zone.101 
Mn1 knockout mice display severe defects in the bone structures of the skull (see 
chapter 2) and, in addition, these mice developed a cleft palate, an abnormality that is not 
compatible with life for newborn mice.102 Nearly all bones within the skull arise by 
intramembranous bone formation (i.e. the formation of bone within the flat surface), showing 
an essential role for Mn1 in this process. In relation to the observations in Mn1 knockout 
mice, it is notable that MN1 expression is found in two osteosarcoma cell lines. The exact 
origin of these cell lines (from membranous or endochondral bones), however, is not clear.  
Liu and coworkers have extended these studies focussing on the function of Mn1 in 
the developing palate in the Mn1 knockout mice strain.101 During normal development, 
palatal shelves elevate and grow together to fuse and form the roof of the mouth cavity. Mn1 
displayed differential expression within distinct regions of the developing palate. In Mn1-/- 
mice the palatal shelves failed to elevate and fuse and increased apoptosis and reduced 
proliferation has been detected. Mice studies have identified a set about 10 genes with 
functions in palatal development. Of those, only Cyclin D2 and Tbx22 had greatly reduced 
expression levels in the palatal structures of the Mn1-/- mice and, in wildtype animals, the 
expression patterns of the genes resembled that of Mn1 in the developing palate. Both 
genes are putative downstream targets of Mn1 in the process of palatal outgrowth. Cyclin 
D2 is an important cell cycle regulator. Tbx22 is the murine homologue of the human X-
linked cleft palate gene. Reporter gene studies using the Tbx22 promoter have 
demonstrated that indeed Mn1 is capable of upregulating Tbx22 levels. Interestingly, various 
CACCC elements, similar to the ones that were identified as the MN1-target sequence 
within the IGFBP5 promoter, are present in the mouse and human TBX22 promoters. It 
remains to be investigated which other players are involved in this novel molecular pathway 
regulating murine palatal development.  
The group of MacDonald has investigated the role of Mn1 on osteoblast function using 
the Mn1 knockout mice. In 2005 they have described the upregulation of MN1 in osteoblasts 
by vitamin D.80 The Mn1 knockout mice provided this research group with a valuable tool to 
extend these studies. Recently an article was published describing that calvarial osteoblasts 
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derived from Mn1 knockout mice were shown to have reduced differentiation, impaired 
proliferation and produced less mineralized matrix.103 Normal bone growth is a continuous 
process of bone formation by osteoblasts and the resorbtion of bone by osteoclasts. 
Osteoblasts secrete essential factors, like RANKL, a member of the tumor necrosis factor 
cytokine family, and M-CSF to regulate osteoclasts. Expression of both RANKL and M-CSF 
was lower in Mn1 knockout osteoblasts and reporter gene constructs with the RANKL 
promoter were used to prove that Mn1 stimulates the RANKL promoter. Altogether, these 
results show that Mn1 is important for appropriate osteoblast proliferation and differentiation 
and regulates osteoclast function through stimulation of RANKL gene transcription. 
 
MN1 expression in primitive, undifferentiated cells of different origin 
Within the hematopoietic system many different lineages and progenitor cells have been 
characterized (Figure 1). Wagner et al has isolated the long-term hematopoietic stem cells 
(LT-HSC) by using surface marks CD34+/CD38- and cultured these for several days. 
Subsequently they have isolated the slow-dividing, more primitive fraction of this pool of 
cells. Expression profiling has showed that MN1 is expressed in hematopoietic stem cells 
and expression is higher in slow-dividing cells, primitive cell populations, which are 
characterized by asymmetric division and self-renewal.104  
Heuser et al isolated similar bone marrow fractions, although the additional step to 
isolate slow dividing cells was not included in the isolation procedure. Highest MN1 
expression was detected in the CD34+/CD38- fraction of cells, which represent a pool of 
cells with LT-HSCs. In vitro differentiation of early hematopoietic, stem cell-like cells show 
that MN1 was downregulated by day 4, whereas CD34, the marker for hematopoietic 
stem/progenitor cells, was only downregulated by day 8.105 Also culturing CD34+ cells in 
lineage-unspecific cytokines supporting proliferation of early-stage progenitors can not 
sustain the expression of MN1. MN1 function might therefore be most important for 
uncommitted progenitors. 
In addition to the HSC pool, distinct progenitor populations are recognized within the 
bone marrow that give rise to the different blood cell lineages (Figure 1). Carella et al has 
sorted mouse bone marrow in five different fractions, representing hematopoietic stem cell 
(HSC), common myeloid progenitor (CMP), common lymphoid progenitor (CLP), 
granulocyte/ monocyte progenitor (GMP) and megakarocytes-erythrocytes progenitor 
(MEP). MN1 expression has been detected in both HSC en GMP fractions, showing highest 
expression in the GMP fraction. No expression was detected in CLP and MEP and CMP 
fractions.52 The CMP is a cell type in between the HSCs and GMPs. There are two possible 
27 
 
Chapter 1 
 
explanations for the lack of expression in the CMP fraction. (1) MN1 expression is switched 
off by transition from HSC to CMPs and subsequently switched on in GMPs. (2) The signal 
obtained in the HSC pool is derived from ‘contaminating’ GMP cells within this fraction 
(personal communication, G. Grosveld, Memphis). This latter explanation could also be true 
for the two experiments described above. The expression of MN1 in the myeloid lineage, 
however, is evident and is in line with the fact that leukemias in which MN1 is overexpressed 
are all of myeloid origin. In conclusion, MN1 expression is found in progenitors of myeloid 
origin and possibly in early stem cells, suggesting that MN1 expression is important for 
maintaining the non-differentiated state and possibly involved in self-renewal of cells. 
Overexpression of MN1, as found in leukemias, contributes to maintain the primitive, 
undifferentiated state.  
Expression of MN1 is not restricted to the hematopoietic system and a similar role for 
MN1 in maintaining the primitive state of cells in other tissues is possible. This hypothesis is 
supported by the finding that MN1 is also enriched in neuronal stem cells106 and in Wilms' 
tumor.107 Wilms’ tumor arises from very primitive, embryonic cells that are arrested in 
differentiation and were originally destined to become kidney cells. 
A genome-wide mapping of polycomb-target genes has identified that the promoter of 
MN1 is occupied by polycomb-repressive complex 1 (PRC1) and PRC2.85 This observation 
seems to be in contrast to above results, since these complexes are usually considered as 
being transcriptional repressors that are required for the maintenance of stem cell 
populations. Additional research is necessary to understand the regulation of MN1 by 
polycomb complexes. 
 
MN1 expression in AML and ALL cases 
Over the last years, numerous expression profiling studies, aiming at classifying different 
subtypes of AML, have discovered that MN1 expression is altered in different leukemia 
subtypes. Most profound is the overexpression of MN1 detected in inv(16) AML.52,108,109,110 
All patients investigated in these studies display overexpression of MN1 and mice studies, 
discussed below, have shown this is an important independent step in the development of 
leukemia by the inv(16) fusion protein.52 
Response to chemotherapy in AML patients is difficult to predict and Heuser et al 
conducted a study to identify an expression profile that can discriminate good from poor 
responders.111 A profile of CD34+ bone marrow cells, representing the progenitor/stem cell 
population, was included for comparison. Blasts of poor response patients displayed a 
profile that was highly similar to that of the CD34+ cells, indicating that these leukemic cells 
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retained or regained properties of self-renewal. The smallest discriminating set of genes that 
was able to discriminate good from poor responders consisted of 11 genes and included 
MN1. MN1 expression was found to be higher in poor response patients.  
Later studies by Heuser et al focused on a subgroup of AML patients: cytogenetically 
normal acute myeloid leukemia (CN-AML). In this group of patients high MN1 expression 
was found to be an independent predictor for poor response to chemotherapy, relapse-free 
survival and overall survival.105 Langer et al have confirmed the prognostic value of MN1 
expression in an independent group of 119 CN-AML patients.112  
High BAALC expression is an independent predictor for poor outcome in CN-AML 
patients and expression profiling has shown that high BAALC expression is correlated to 
high MN1 expression.113 Consistent with this observation is that NPM1 mutations in AMLs, 
which are associated with a favorable prognosis, were shown to correlate with lower MN1 
expression.114  
Occasionally, AML patients are treated with RA in addition to standard chemotherapy. 
RA stimulates differentiation of hematopoietic cells and a substantial part of patients benefit 
from this treatment. Molecular studies have revealed that MN1 is a cofactor for RA-induced 
expression as discussed above. A retrospective study has been performed to evaluate 
whether MN1 expression levels and RA-related treatment outcome are associated. Indeed, 
high MN1 expression in patients with AML at diagnosis was associated with resistance to 
RA-related treatment. Only patients with low MN1 expression benefited from addition of RA 
to standard chemotherapy.115,116 
Haferlach and coworkers performed expression profiling on 937 AML and ALL patients 
in order to classify known leukemia subgroups like inv(16) and MLL rearrangements. The 
profiling enabled them to separate all subgroups from each other and sets of genes were 
identified that could discriminate these subgroups. The MN1 gene belongs to a set of genes 
that can identify AMLs that are characterised by MLL rearrangements (11q23).117 
Surprisingly, instead of being upregulated, MN1 is downregulated in this group of AMLs 
(personal communication, T. Haferlach). Downregulation of MN1 expression, by means of 
promoter methylation, was also detected in the majority of ALL samples and ALL-derived 
cell lines.79  
On the whole, the above observations emphasize MN1 as an important player in 
leukemogenesis and prove that MN1 expression levels are important. High MN1 expression 
levels are unfavorable for AML patients. Either MN1-upregulation in several myeloid 
leukemias or downregulation of MN1 expression levels in leukemias of lymphoid origin (and 
the 11q23 subgroup of AMLs) contributes to leukemogenesis.  
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In recent years, the interest in microRNAs (miRNAs) as an alternative way to regulate 
gene expression, has been increasing. It has become evident that specific miRNA 
signatures exist for different tumor types and that altered miRNA expression contributes to 
carcinogenesis. Several leukemia-related fusion proteins were shown to deregulate the 
expression of miRNA genes.56,62 Langer et al. has shown that high MN1 expression in CN-
AMLs is associated with a specific miRNA signature consisting of at least 15 miRNAs.112 
Interestingly, there is a negative correlation of miR-16 with high MN1 expression. This 
miRNA targets the BCL2 gene and in case of high MN1 expression, an indirect upregulation 
of BCL2 is thus expected. BCL2 has proven anti-apoptotic functions and is frequently 
overexpressed in leukemia.118 The indirect upregulation of BCL2 by means of 
downregulating miR-16 might be one of the leukemogenic pathways involved in the 
leukemias that overexpress MN1. This is strengthened by the observation of Garzon et al 
who has described the upregulation of miR-16 in response to retinoic acid-induced 
differentiation of human acute promyelocytic leukemia.119 
 
MN1 overexpression in mouse bone marrow 
Forced overexpression of MN1 in bone marrow (BM) stimulates the outgrowth of myeloid 
cells. Cells rapidly proliferate and acquire a growth advantage over the non-transduced 
cells. Mice receiving transplants of these MN1-overexpressing BM cell lines rapidly develop 
myeloproliferative disease (MPD). MPD is a condition slightly different from AML in which 
myeloid cells are highly proliferative but still differentiate into mature cells. Both the in vivo 
and in vitro experiments show that MN1 stimulates the proliferation of myeloid cells, but 
does not block their differentiation.52 The growth stimulatory effects of MN1 in bone marrow 
cells is opposite to the inhibition of proliferation in osteosarcoma cells, as described by 
Sutton et al,80 showing that MN1 can have opposite effects depending on the cell type in 
which it is expressed. Contradictory to this latter result is the decreased proliferation that is 
detected in calvarial osteoblasts derived from the Mn1 knockout mice.103 
Co-expression of the inv(16) fusion protein Cbfβ-SMMHC and MN1 in bone marrow 
causes AML in mice within 5 to 8 weeks after transplantation, whereas Cbfβ-SMMHC 
expression alone does not result in hematopoietic disease.52 Furthermore, MN1 is not 
upregulated by the fusion protein itself. Altogether, this shows that MN1 is an important 
independent step in the development of leukemia caused by inv(16).  
Heuser and coworkers have performed similar mouse experiments, but the outcome 
was slightly different. In contrast to the above described mouse models, mice transplanted 
with MN1-transduced BM did develop an AML phenotype. In vitro experiments have shown 
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that MN1 both stimulates proliferation and blocks differentiation. The blocking of 
differentiation depends on the transcriptional repressor activity of MN1, whereas the 
promotion of self-renewal and proliferation is carried out by the stimulatory properties of 
MN1.116 One of the differences between these two separate mouse experiments is the 
promoter that controls the expression of MN1 in the BM cell lines. Heuser et al have used 
the spleen focus forming virus promoter, whereas Carella et al have used the murine stem 
cell virus (MSCV) promoter to control expression of MN1. Possibly the timing or level of 
expression of MN1 differs in these experiments. Also a slight difference in the subset of cells 
that express MN1 might account for the differences observed.  
Other studies that have provided evidence for the involvement of Mn1 in the 
development of leukemias of different origin are based on retroviral insertional mutagenesis. 
CALM-AF10 and NUP98-HOXD13 are two fusion proteins that are formed by leukemia-
causing translocations (2;11) and (10;11). Transgenic mice expressing either one of the 
fusion proteins develop leukemia, although in both mouse models the penetrance is not 
100%.120,121 To identify genes that might collaborate with the fusion proteins, retroviral 
insertional mutagenesis has been performed. Integration of the retrovirus accelerated 
leukemogenesis in both mouse models and viruses were shown to be integrated adjacent to 
well known leukemia-associated genes, such as Meis1 and Evi1, proving the validity of this 
method. In both mouse models, insertions near the Mn1 locus have been found.122,123,124 In 
NUP98-HOXD13 mice, the level of Mn1 expression has been analyzed and all mice with 
integrations near the Mn1 gene showed upregulation.124  
 
THE LEUKEMOGENIC FUSION PROTEIN MN1-TEL 
t(12;22)(p13;q11) in leukemia 
The t(12;22)(p13;q11) is only found in a minority of AML patients. The translocation fuses 
the first exon of MN1 to exon 3 of the TEL (ETV6) gene, resulting in a fusion protein that 
consists of almost the entire MN1 coding region (aa 1 to 1260) and aa 56 to 452 of the TEL 
protein. The reciprocal product of this translocation, TEL-MN1, is only 113 aa long and has 
been detected in patient material.88 Biological relevance for this reciprocal product has not 
been shown, however. Another patient has been described in which the breakpoint in the 
TEL gene is located in intron 3. This translocation results in an in-frame fusion of the first 
exon of MN1 with aa 110 to 452 of TEL.87  
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Figure 5. TEL is a sequence-specific transcriptional repressor. (A) TEL represses transcription by the recruitment of 
complexes containing N-CoR , SMRT, and HDAC3. (B) Another route of repression is by a histonedeacetylase-independent 
mechanism and involves the recruitment of L3-MBT, a polycomb-group protein. TEL-responsive element is decuded from data 
that appeared in thesis of A.Buijs.143 
 
 
Figure 6. The fusion protein MN1-TEL influences the normal functions of TEL and MN1. (A) MN1-TEL has been shown to bind 
to TEL binding sequence. It interferes with the normal function of TEL by stimulating genes that are normally repressed by 
TEL. Normal function of TEL is shown on the right. (B) MN1-TEL is a dominant-negative mutant of MN1 and inhibits RAR/RXR-
mediated transcription. Normal function of MN1 as a cofactor for RAR/RXR is shown on the right. 
TEL is a sequence specific repressor 
TEL, also known as ETV6, is a transcriptional repressor that binds to sequence specific 
factors that consists of 26 members. Most of them are transcriptional activators instead of 
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repressors, like TEL.125 Other members of this family include the TEL2, ETS1 and PU.1 
proteins. ETS family members are important regulators in various biological processes, 
including cellular proliferation, differentiation, hematopoiesis, apoptosis, metastasis, 
angiogenesis and transformation.126 Many ETS family members were shown to be involved 
in different cancer types, including breast cancer and prostate cancer.127 An example is the 
ETS family member ERG; the TMPRSS2-ERG fusion has been detected in up to 70% of 
prostate cancer.128,129 TEL is expressed throughout the body including the hematopoietic 
system and is crucial for HSC maintenance, as has been shown in Tel knockout mice.130 
These mice have been shown to die due to yolk sac angiogenesis. Chimeras with Tel-/- ES 
cells have shown that Tel function is also essential for the establishment of hematopoiesis of 
all lineages in the bone marrow during normal transition of hematopoietic activity from fetal 
liver to bone marrow.131 Members of the ETS family are highly homologous in their helix-
loop-helix (HLH) and DNA binding domains (DBD). Most members of the family bind to a 
core DNA sequence consisting of GGAA. 126 The surrounding sequences define the binding 
specificity for the different members of the family.132 The most common identified TEL- 
responsive element is CCGGAAGT. The HLH domain provides the TEL protein an interface 
for homodimerisation with other TEL proteins and heterodimerisation with other members of 
the family.125,133 After binding to its responsive sequence, corepressors N-CoR and SMRT 
are recruited to TEL and bind to the region between the HLH and DBD domains. 
Subsequently, HDAC3, a histone deacetylase, is recruited.134 Removal of histone acetyl 
groups by HDAC3 will compact the DNA around the histones, making the DNA less 
accessible for transcription initiation complexes (Figure 5A). Another route of transcriptional 
repression for TEL is carried out by the binding to L(3)MBT polycomb group protein.135 This 
mechanism of repression has been shown to be independent of histone deacetylation and is 
thought to facilitate long-term repression of TEL-target genes (Figure 5B). Post-translational 
modicifations of TEL involve phosphorylation136,137,138,139 and sumoylation140,141 and regulate 
the activity of the protein. 
 
Leukemogenic mechanisms of MN1-TEL  
The MN1-TEL fusion encodes a protein that combines the transcription activating domains 
(TAD) of MN1 with the DBD of TEL. Although most of the HLH domain is present in the 
fusion protein, it is not functional.142 The presence of a TAD and DBD suggests that the 
MN1-TEL  protein  functions  as  an  altered transcription factor that will stimulate genes that 
are normally repressed by TEL. Expression profiling of MN1-TEL-overexpressing cells have 
shown  that  MN1-TEL  can  indeed  stimulate  genes   that  are  normally  regulated  by ETS 
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transcription factors (Figure 6A and chapter 5).97 The list of genes, however, is very small 
and the most noticeable activity of MN1-TEL that has been detected in this study is the 
inhibition of the stimulatory effects of RA on a large set of genes. Furthermore, MN1-TEL is 
unable to stimulate a large set of genes that are induced by MN1. The interplay between 
MN1 and MN1-TEL on RAR/RXR-mediated transcription has been studied in more detail 
using the MSV-LTR (see chapter 4).144 These studies have also shown that MN1-TEL 
represses RAR/RXR-mediated transcription and exhibits dominant-negative effects on both 
MN1 and RA (Figure 6B).  
 
MN1-TEL expression in mouse BM  
Kawagoe et al have inserted the MN1-TEL fusion protein in the Aml1 locus in mice.145 Aml1 
is expressed in primitive progenitors of both myeloid and lymphoid lineages. BM cell lines 
derived from these mice have shown that MN1-TEL, expressed in both lineages, stimulates 
the proliferation and blocks the differentiation of both myeloid progenitors and T 
lymphocytes. In humans, MN1-TEL is under control of the MN1 promoter. The MN1 
promoter is activated in the myeloid lineage and this determines that in t(12;22) patients the 
myeloid lineage and not the lymphoid lineage is affected by expression of MN1-TEL. 
Mice expressing MN1-TEL from the endogenous Aml1 promoter do not develop AML, 
but T-lymphoid tumors are found. In some mice expansion of myeloid progenitors has been 
detected.146 MN1-TEL thus requires secondary mutations to cause AML in these mice. 
HOXA9 is an important transcription factor for normal myeloid proliferation and 
differentiation and elevated expression is frequently observed in myeloid leukemia, including 
two MN1-TEL AML patients. Transduction of HOXA9 in BM of mice causes AML and the co-
expression of HOXA9 and MN1-TEL accelerated the onset. Expression profiling of tumor 
material of these mice have shown that N-Myc is highly upregulated and contributes to the 
AML pathogenesis in these mice. In contrast to MN1-TEL expression from the Aml1 locus, 
expression of MN1-TEL in mouse BM using a viral transduction system is sufficient to cause 
an AML phenotype.147 This might be explained by the much higher expression level of MN1-
TEL generated by viral transduction. 
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OUTLINE OF THIS THESIS 
In order to unravel the function of the MN1 oncogene and the molecular mechanisms 
involved in its normal function and its oncogenic activity, different research lines were 
conducted over the last years in our laboratory. The fusion gene MN1-TEL has also been 
studied within these research projects.  
An important tool to study the function of a gene is the generation of a knockout mice 
strain. By homologous recombination Mn1 null mice were created and in chapter 2 the 
phenotype of these mice has been described. We have performed Caesarean sections to 
obtain embryos of various embryonic stages, ranging from embryonic day 8.5 to 18.5. The 
embryos were extensively studied using macroscopy, microscopy and whole-embryo bone 
and cartilage stainings (alizarin red and alcian blue stainings). Perinatal death of the Mn1-/- 
mice has prevented us from studying the effect of omission of Mn1 in adult mice. Mn1 
heterozygotes were alive after birth and were followed for 30 months in order to obtain data 
about long-term effects of the presence of only one functional Mn1 gene.  
Additional molecular studies on the MN1 protein have focused on its ability to stimulate 
transcription. Although MN1’s involvement in transcription regulation had been recognized 
soon after cloning, the MN1-responsive elements remained largely unknown. An oligo 
selection assay was performed to identify these DNA sequences. As described in chapter 3 
several DNA elements were identified. The coordinated expression of MN1 and IGFBP5 in 
meningioma samples has prompted us to screen the regulatory sequences of the IGFBP5 
gene for MN1-responsive elements. We have cloned several regions of the IGFBP5 
promoter in luciferase reporter plasmids en have tested the ability of MN1 and MN1-TEL to 
activate the cloned promoter regions in transient transfections in two different cell lines. In 
similar assays we tested previously described stimulatory reagents of the IGFBP5 promoter 
is combination with MN1 and MN1-TEL. Electrophoretic mobility shift assays were 
performed to prove the binding of MN1 to distinct regions within the promoter.  
The fusion gene MN1-TEL harbors large sequences of both partner gene MN1 and 
TEL. The DNA binding ability of the TEL moiety strongly suggests that MN1-TEL functions 
as a deregulated transcription factor that binds to elements that are normally bound by TEL. 
Additionally, MN1-TEL could possibly influence the normal function of MN1, independent of 
its DNA binding capacity. Research described in chapter 4 has addressed this latter 
question. We have used a viral promoter that harbors many transcription factor-binding 
sites, including a RAR/RXR-responsive element that is highly activated by MN1. We have 
studied the activity of MN1-TEL on this element and the cooperation of MN1 and MN1-TEL 
with cofactors p300/CBP and RAC3. The TEL moiety of the MN1-TEL fusion protein 
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contains a strong DNA-binding domain that creates a complex situation in which MN1-TEL 
can influence the normal function of both TEL and MN1. The use of a point mutant of MN1-
TEL that can not bind to DNA has enabled us to investigate the function of MN1-TEL in 
relation to MN1 without interference of the DNA binding properties of the TEL moiety. 
The interest in the MN1 gene has increased over the last years because of 
expression-profiling studies showing that this gene is upregulated in several subtypes of 
leukemia. The most important are the (inv)16-diagnosed patients and the cytogenetically 
normal AML patients. In the latter group, upregulation of MN1 is associated with worse 
survival and poor response to treatment. Additionally, a study has described that a high MN1 
expression level in AML patients is a predictor for resistance to RA therapy and this is 
explained by the fact that MN1 functions as a cofactor, both inhibitory and stimulatory, for 
RAR. Identification of genes that are regulated by MN1 without or in combination with RA 
provides tools to further study the pathways underlying MN1-involved leukemic processes. 
In chapter 5 we have described the establishment of leukemic cell lines with inducible 
expression of MN1 or MN1-TEL. Expression profiling of these cell lines under various 
conditions, i.e. with and without expression of MN1 or MN1-TEL at various time points after 
induction in the presence or absence of RA, has allowed us to identify the genes that 
responded to any of the conditions tested. Quantitative reverse transcriptase PCRs were 
performed to verify the effects observed in the expression arrays. Several interesting 
candidates were identified that have shed light on the molecular pathways involved in 
leukemias in which MN1 and MN1-TEL are involved. 
In chapter 6 the papers presented in this thesis are discussed in relation to recent 
literature. Furthermore, it provides leads for future research on MN1 and MN1-TEL. 
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ABSTRACT 
Fusion of the MN1 gene to TEL (ETV6) results in myeloid leukemia. The fusion protein 
combines the transcription activating domain of MN1 and the DNA binding domain of TEL 
and is thought to act as a deranged transcription factor. In addition, disruption of the large 
first exon of the MN1 gene is thought to inactivate MN1 function in a meningioma. To further 
investigate the role of MN1 in cancer, we generated Mn1 knockout mice. Mn1+/- animals 
were followed for 30 months, but they had no higher incidence of tumor formation than wild 
type littermates. Mn1 null mice, however, were found to die at birth or shortly thereafter as 
the result of a cleft palate. Investigation of newborn or embryonic day 15.5 (E15.5) to E17.5 
null mice revealed that the development of several bones in the skull was abnormal. The 
affected bones are almost exclusively formed by intramembranous ossification. They are 
either completely agenic at birth (alisphenoid and squamosal bones and vomer), hypoplastic 
or deformed (basisphenoid, pterygoid, and presphenoid), or substantially thinner (frontal, 
parietal and interparietal bones). In heterozygous mice hypoplastic membranous bones and 
incomplete penetrance of the cleft palate were observed. We conclude that Mn1 is an 
important factor in development of membranous bones. 
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INTRODUCTION 
The MN1 gene, localized on human chromosome 22, was cloned by our research group in 
1995 as a candidate gene for sporadic meningioma, a benign brain tumor arising from the 
arachnoidal cap cells found on the surface coverings (called meninges) of the brain.1 In a 
meningioma, the MN1 gene was found disrupted by a balanced translocation 
(4,22)(p16;q11). The breakpoint of the translocation lies within the first exon of the MN1 
gene, and the (truncated) protein was not detected. However, no mutations or deletions of 
the MN1 gene were found in other meningiomas; thus the causative relationship between 
MN1 and meningiomas remains unclear. Subsequently, the MN1 gene was found to play a 
role in acute myeloid leukemia (AML).2 The translocation (12;22)(p13;q11) creates a fusion 
between the MN1 and TEL (or ETV6) genes, resulting in the MN1-TEL gene. The TEL 
protein is a member of the ETS family of transcription factors and contributes its C-terminal 
DNA binding domain (DBD) to the fusion protein MN1-TEL. The MN1 protein donates 1259 
amino acids, 95% of its entire length, to the fusion protein. The fusion protein MN1-TEL has 
transforming activity on NIH3T3 cells and most likely acts as a deregulated transcription 
factor. MN1-TEL may adhere to genes via the TEL moiety and activate these genes 
whereas they are normally controlled by the repressor TEL.3 
The MN1 protein comprises 2 exons and encodes a protein of 1319 amino acids. The 
amino acid sequence shows no homology to other proteins or with specific domains with 
known functions. However, several proline/glutamine-rich regions and a polyglutamine 
stretch are present and point to a function in transcription regulation. We have shown 
previously that MN1 activates the transcription activity of the Moloney sarcoma virus long 
terminal repeat (MSV-LTR) and comprises multiple transcription activating domains.3 We 
recently described that MN1 can act on the MSV-LTR (and other promoters)(unpublished 
results) as a transcription coactivator in retinoic acid receptor (RAR)-retinoid-X-receptor 
(RXR)-mediated transcription leading to a synergistic induction of expression when MN1 and 
the RAR-RXR ligand retinoic acid (RA) are combined. Furthermore, we have shown that 
there is an interplay between MN1 and p300 and RAC3, both known coactivators of retinoic 
acid receptors.4 
Hybridization of a cDNA probe to a blot containing DNA of a number of different 
species shows signals in species as evolutionarily distant as Xenopus laevis and Drosophila 
melanogaster, proving conservation of MN1 in evolution.1 The identity/similarity between 
human and murine MN1 proteins is 93%. Database searches reveal homologues of MN1 in 
mice (Mus musculus) and puffer fish (Tetraodon nigroviridis). The puffer fish MN1 homolog 
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shows an identity/similarity of 64% with the human gene; the structure of the gene however 
is different. The gene consists of at least four exons; two additional small introns of 16 and 
32 bp are present in the region covered by exon 1 in humans and mice. Surprisingly, in 
puffer fish, MN1 has less pronounced proline/glutamine-rich regions and lacks the large 
glutamine stretch (28Q) present in human and mice half way in the protein. The importance 
of the glutamine stretch is, however, underlined by the fact that the puffer fish MN1 protein 
contains a large glutamine stretch (15Q) at a more N-terminal position, which is completely 
absent in humans and mice.  
To determine the physiological significance of MN1 in vivo, we disrupted the Mn1 gene 
in mice. The majority of heterozygous mice (Mn1+/-) showed no obvious defects and 
appeared to have a normal lifespan and tumor incidence was not altered when compared to 
wild-type littermates. In Mn1 null mice (Mn1-/-) cranial bone development is severely affected 
with several bones being completely absent or hypoplastic. In addition, null mice have a cleft 
palate and, due to these defects, do not survive beyond day 1 after birth. A minor 
percentage of heterozygotes also die due to a cleft palate. Closer examination of Mn1+/- 
mice revealed that they have an intermediary deficiency in cranial bone formation. 
 
MATERIALS AND METHODS 
Construction of targeting vector 
A cosmid clone was isolated from C129 cosmid library5 containing the mouse Mn1 gene 
using a human MN1 cDNA probe C.1 A BamHI/EcoRI fragment containing exon 1 was 
cloned in a targeting vector pMC1neo poly(A).6 The neomycin resistance gene (neo) was 
inserted into exon 1 of the Mn1 gene using BamHI/XhoI sites. The neo gene is controlled by 
the herpes simplex virus promoter, and the transcriptional orientation is opposite to the 
orientation of the Mn1 gene (Figure 1A). 
 
Generation of Mn1+/- and Mn1-/- mice 
The targeting vector was electroporated into strain 129 embryonic stem (ES) cells and G418 
resistant clones were isolated. G418 resistant clones were checked for the presence of the 
neo gene at the correct location using Southern blot hybridisation on NcoI digested DNA and 
a genomic probe upstream of the targeting construct. Targeted ES cells with correct 
integration of the neo gene and with the normal number of chromosomes (40) were injected 
into blastocysts of C57BL/6 mice. The blastocysts were injected into (strain FVB) foster 
mothers, and chimeras were obtained. Chimeric, transmitting males were crossed with 
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normal FVB females for 10 generations to produce an inbred strain. Mice were genotyped 
by Southern blots or by PCR using three primers. Primer MuMn1-F (5’-
CTTTGGGGGCAACTTCGGTGG-3’ ) is a forward primer localized within exon 1 upstream 
of the inserted neo gene. Primer MuMn1-R (5’-CTCCAGACCCACAGGCATC-3’) is a 
reverse primer located in the part of exon 1 deleted by the integration of the neo gene and 
thus primes only on the wild-type Mn1 allele, creating a 627 bp product in combination with 
MuMn1-F. The third primer is Neo-R (5’-GATGCAATGCGGCGGCTGCA-3’) and in 
combination with primer MuMN1-F detects the mutant allele resulting in a PCR product of 
528 bp. 
 
Examination of embryos, and newborn and adult mice: macroscopy, microscopy and alizarin 
red/alcian blue staining 
To obtain embryos of different stages of development (embryonic day 8.5 (E8.5) to E18.5), 
cesareans were performed on pregnant females. The day when a vaginal plug appeared 
was designated as E0.5. Extensive macroscopic and microscopic analysis was performed 
on embryos and newborn mice. Embryos were weighed and lung, heart, pancreas, spleen, 
liver, stomach, intestine, bladder, sex organs, thymus, and glands were dissected and 
macroscopically examined. They were fixed by immersion in 4% buffered formalin and 
embedded in paraffin. In addition, complete embryos were weighed, fixed, decalcified using 
EDTA for 5 days and embedded in paraffin. Four-micrometer sections were deparaffinized in 
xylene, rehydrated and hematoxylin-eosin (HE) stained and microscopically examined. 
Alizarin red/alcian blue staining of complete embryos or newborn mice was performed using 
standard methods as described by Kaufman.7 Briefly, complete embryos were deskinned, 
and organs removed and fixed in 80% EtOH (2 days), dehydrated in 96% EtOH (2 days) 
followed by aceton (2 days), stained with alizarin red/alcian blue at 37°C for 2 days and 
subsequently cleared using 1% KOH for several days. Finally, the specimens were stored in 
glycerol. 
 
RESULTS 
Mn1+/- mice have a normal lifespan 
In order to generate Mn1 knockout mice, a targeting construct was generated (Figure 1A). 
Disruption of the Mn1 gene at the BamHI site results in a truncated protein of 121 amino 
acids, deleting over 90% of the protein, including the transcription activating domain and the 
glutamine stretch. Chimeras successfully transmitted the targeted allele to the germ line, 
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and after crossing, mice harboring only one functional Mn1 gene were obtained (Mn1+/-). 
Mice were genotyped using either Southern blot hybridisation of NcoI-digested tail DNA 
(Figure 1B) or by PCR using 3 primers simultaneously in one reaction (Figure 1C). Because 
of the involvement of the MN1 gene in AML and its putative role in sporadic meningiomas, 
we determined whether the Mn1+/- genotype resulted in excess tumor formation or other 
forms of pathology. To this end, heterozygous males (n=143) and females (n=95) and wild 
type siblings (127 males and 93 females) were followed for 30 months. No significant 
differences were observed in lifespan of Mn1+/- or Mn1+/+ animals. Autopsies were 
performed on 47 Mn1+/- and 37 Mn1+/+ animals that either died spontaneously or that were 
killed because of apparent lack of well-being. No significant differences in number of tumors 
between heterozygous or wild-type controls were observed. Macroscopic and microscopic 
examination of heart, lungs, kidney, spleen, liver and muscle also revealed no abnormalities. 
 
 
 
 
Figure 1. Targeted disruption of the mouse Mn1 gene. (A) Restriction enzyme map showing relevant sites (N, NcoI; B, BamHI; 
H, HindIII; E, EcoRI; X, XhoI) in the first exon of Mn1 (top), the structure of the targeting vector (middle), and the targeted gene 
(bottom). The transcriptional orientation of the neomycin resistance gene (neo) is indicated with an arrow. The probe used for 
Southern blot hybridisation, a 0.6 kb HindIII/BamHI fragment, is indicated as a hatched box. Primers are indicated with 
arrowheads. (B) Southern blot analysis of NcoI-digested genomic DNA of a mouse homozygous for the wild-type allele (+/+), a 
heterozygous mouse (+/-) and a mouse homozygous for the mutated allele (-/-). Wild-type (wt) and targeted alleles show 
bands of 19.8 and 10.5 kb, respectively, after hybridization with the indicated probe (hatched box). (C) PCR genotyping of mice 
using one forward primer and two reverse primers (sequences mentioned in Materials and Methods). The wt allele gives a 
band of 627 bp; the mutant product detected with the reverse primer located in the neomycin resistance gene is 528 bp. 
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Mn1 null mice and a minor percentage of Mn1 heterozygotes die shortly after birth due to a 
cleft secondary palate  
Crosses between Mn1+/- mice failed to produce viable Mn1-/- mice. However, examination of 
embryos at various developmental stages (E8.5 to E18.5) showed that Mn1-/- mice were 
present in numbers compatible with normal Mendelian inheritance (Table 1).  
 
  TABLE 1. Genotyping of embryos of different embryonic stages 
      
  No.(%) of embryos with genotype Embryonic   
stage 
  +/+ +/- -/- 
 E 8.5  0 3 4 
 E 10.5  4 11 1 
 E 12.5  4 11 11 
 E 14.5  4 8 4 
 E 15.5  1 6 1 
 E 16.5  4 2 3 
 E 17.5  2 5 3 
 E 18.5  3 5 8 
      
 Total  22 (20) 51 (47) 35 (32) 
            
 
The Mn1-/- or Mn1+/- embryos of various developmental stages did not differ from their wild-
type siblings in weight, length and external appearance. These mice were examined 
microscopically and no abnormalities were observed in any of the internal organs including 
lung, heart, thymus, liver, kidney, pancreas, adrenal glands and sex organs. Subsequently, 
a new series of breedings were closely monitored at the moment of delivery. A 10h 
observation of newborn pups showed that a subset of pups died immediately following birth 
because they failed to start breathing, apparently because of breathing difficulties. A second 
group of pups did not suckle (empty stomachs), were lethargic, became cyanotic and 
subsequently died. Genotyping of all dead pups showed that most of these pups (83%) are 
homozygous mutants. To our surprise, the remaining group of dead pups (17%) was 
genotyped as heterozygotes (Table 2). We first examined whether the lungs of the Mn1 null 
mice displayed any abnormalities. Lungs of Mn1 null mice and wild-type animals were 
examined by light and electron microscopy and were found to be normal (data not shown). 
Subsequently, total RNA was isolated from lungs of postnatal day 0 (P0) Mn1-/-, Mn1+/- and 
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wild-type animals. The mRNA levels of surfactant A, B and C, factors known to be crucial for 
proper lung function, were analysed using quantitative reverse transcription-PCR and again 
no differences were found (data not shown). Subsequently, a closer macroscopic 
examination of the head region of newborn mice revealed that all dead mice had a cleft 
secondary palate. In mice, this defect is not compatible with life. The cleft secondary palate 
was clearly visible on inferior views of the cranial base of the heads (Figure 2A). Wild-type 
pups showed normal fusion of the palatal shelves while mutant mice do not. Three out of 21 
(15%) heterozygotes also had a cleft secondary palate, but the defect was less severe when 
compared to null mice: the palatal shelves were closer to each other in transversal direction 
leaving a cleft of only about half the distance when compared to homozygous Mn1 
knockouts. The palatal shelves in affected heterozygotes did form small rugae and were 
fused with the primary palate. Figure 2B and C show coronal sections of heads of newborn 
embryos at different positions. In wild-type animals the palate (p) has been formed correctly 
(Figure 2B, left panel). In null mice (Mn1-/-) the palatal shelves (ps) had developed (right 
panel of Figure 2B) but were far apart and had not fused, resulting in a connection between 
the nasal and oral cavities. A cleft palate is frequently seen in mouse knockout models, and 
in some models this is accompanied by agenesis of molars.8,9 In Mn1-/- mice, however, 
molars of both upper and lower jaw were correctly formed (Figure 2C, left and right panels). 
 
 TABLE 2. Close examination of newborn pups 
        
  No (%) of pups of genotype   Status of 
newborn pups 
   +/+ +/-  -/-   
Total (%) 
        
  Total    8 (18)   21 (48)   15 (34)    44 (100) 
  Viable    8   18   0    26 
  Deada    0 (0)   3 (17)   15 (83)    18 (100) 
                
a pups either died directly after delivery or within the first 10 hours 
 
 
Skulls of mutant mice at E15.5 to E18.5 display many bone abnormalities 
The process of palate formation is complex and depends on the correct position and 
formation of bone and soft tissue structures within the skull.10,11 In order to visualize bone 
formation in the skull, wild-type, heterozygous and homozygous mice at different stages of 
development (E15.5 to E18.5) were deskinned and stained with alizarin red and alcian blue.  
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Figure 2. Inferior views and histological sections of heads of newborn pups. (A) Normal palate with rugae (r) in a wild-type 
(wt;+/+) animal (left panel), and cleft secondary palate in a Mn1+/- and Mn1-/- animals (middle and right panels). Small rugae on 
both sides of the cleft are seen in the heterozygote. pp, primary palate. (B and C) Coronal sections showing the correctly 
formed palate (p) in wt animals (left panels). Palatal shelves (ps) are not fused in Mn1-/- animals (right panels). Molars in 
maxilla and mandible are indicated with asterisks. e, eyes; o , olfactory lobe; n, nasal septum; t , tongue. 
Figure 3A shows inferior views of the skulls from which the mandibles were removed. At 
E15.5 the palatal shelves have just fused in wild-type mice (+/+) and bone formation took 
place from both maxillary and palatine shelves. The increase in bone size within the palate 
is clearly visible at stage E16.5 (top, middle panel), and at stage E17.5 the bone structures 
from both sides had formed sutures (top, right panel). The Mn1-/- embryos had a cleft 
secondary palate and the bone growth within the palatal shelves (both maxillary and 
palatine) is hypoplastic at all stages (Figure 3A, bottom panels). Many additional 
abnormalities were obvious in the skulls of Mn1-/- mice. Several bone structures were absent 
(agenic) or were severely hypoplastic. In the E17.5, Mn1+/+ skull, the alisphenoid (a) and 
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squamosal (s) bones and the vomer (v) in a wild-type sibling are indicated. These bones 
were completely absent in the Mn1-/- mouse (Figure 3A, bottom, -/-). Furthermore, the 
presphenoid (ps) and basisphenoid (bs) were hypoplastic and the pterygoid bones (pt) were 
not formed correctly. The heterozygous Mn1 mice (Figure 3A, middle panels) showed 
intermediate defects. In the palate, bone structures in both the maxillary and palatine 
shelves are hypoplastic. In addition, bones that were agenic or hypoplastic in null mice 
(basisphenoid, alisphenoid and squamosal bones, and vomer) were also clearly hypoplastic 
in Mn1+/- mice when compared to wild-type mice. The Mn1+/- mice of E15.5 and E16.5 had a 
closed palate; the Mn1+/- mouse of E17.5 had a cleft palate. These results show that the 
heterozygous Mn1 mice display an intermediate phenotype when compared to Mn1 null 
mice. This suggests that the extent of the defect may be related to dosage of the Mn1 
protein. 
We also stained heads of E18.5 mice to study the bone structures of the skull at the 
moment close to delivery. The dorsal view of the skull shows the normal development of the 
supraoccipital bone in a wild-type mouse (Figure 3B, top). Bone formation starts in two 
ossification centers at E17 and fusion takes place at around P0. The formation of this bone 
in the Mn1-/- mouse is delayed (Figure 3B, bottom). Heterozygous mice (+/-, middle panel) 
had a normally developing supraoccipital bone. Figure 3C shows a detail of the E18.5 skull 
in lateral view. The alisphenoid and squamosal bones were agenic in the Mn1-/- mouse 
(lower panel). The differences between wild-type (+/+) and heterozygotes (+/-) at this stage 
were less pronounced, compared to differences seen at E15.5 and E16.5. At E18.5 the 
squamosal and alisphenoid bone were hypoplastic in heterozygotes (+/-) and the suture 
formation between these bones is in a less advanced stage. The bone within these 
structures is less dense, and the foramen ovale (for the mandibular nerve) and the foramen 
rotundum (for the maxillary nerve) are clearly larger, altogether indicating a delayed 
development of both bone structures in the Mn1+/- mouse. A closer look at the skulls of Mn1 
knockout mice and wild-type mice gave us the impression that all flat bones forming the roof 
of  the   skull  (frontal bone,  parietal  and  interparietal  bone)  were  thinner  in  Mn1-/-   mice. 
 
Figure 3. Alizarin red/alcian blue staining of skulls. (A) Inferior views of skulls (mandibles removed) of E15.5, E16.5 and E17.5 
mouse embryos. Wild-type (+/+), heterozygote Mn1 (+/-) and homozygote Mn1 (-/-)mice are shown in upper, middle and lower 
panels, respectively. Within E17.5, the affected bones in Mn1-/- and Mn1+/- mice are indicated. In the E17.5 Mn1 null mouse 
skull bones are indicated for orientation purposes. (B) Dorsal view of skulls of E18.5 mice showing the exoccipital and 
supraoccipital bones. Arrows indicate the delay in formation of the supraoccipital bone in the Mn1-/- mouse. (C) Detail of lateral 
view of E18.5 mice. The frontal direction of the skull is on the right side of the photographs, cranial base is on the bottom side 
of the photographs. Note the agenesis of alisphenoid and squamosal bones in the Mn1-/- mice. All animals of equal 
developmental stage are littermates. bs, basisphenoid; ps, presphenoid; p, palatine shelf; m, maxillary shelf; a, alisphenoid 
bone; pt, pterygoid bone; s, squamosal bone; so, supraoccipital bone; pm, premaxilla; z, zygomatic bone; mx, maxilla; t, 
tympanic ring; b, basioccipital bone; e, exoccipital bone; fo, foramen ovale; fr, foramen rotundum; v, vomer. 
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Staining of these bones was clearly less pronounced, and after processing the heads, the 
skulls from null mice appeared extremely fragile and compressible when compared to wild-
type littermates. We performed micro-computerized tomography (CT) scans on skulls of 
wild-type and Mn1 null mice (E18.5) and these confirm this observation: CT scans on skulls 
of a wild-type animal were readily obtained, but scans of skulls of Mn1-/- mouse were of poor 
quality, because of very thin frontal, parietal and interparietal bones (data not shown). A 
summary of all skull bones affected and not affected in Mn1+/- and Mn1-/- mice is shown in 
Table 3. 
 
 
      TABLE 3. Overview of bones within the skull of E18.5 Mn1 mice 
    
Resulta for mice of genotype 
Bone(s) 
+/-   -/- 
    
Maxilla n  n 
Mandible n  n 
Hard palate, maxillary  hy  hy 
Hard palate, palatine  hy  hy 
Premaxilla n  n 
Zygomatic n  n 
Squamosal  hy  ag 
Tympanic ring n  n 
Frontal  n  hy 
Pterygoid  hy  hy 
Parietal  n  hy 
Vomer hy  ag 
Interparietal  n  hy 
Nasal bone n  n 
Supraoccipital n  hy 
Exoccipital n  n 
Alisphenoid hy  ag 
Basioccipital n  n 
Basisphenoid  hy  hy 
Presphenoid hy  hy 
Maleus, incus, stapes n  n 
        
a n, normal development; hy, hypoplastic; ag, agenic.  
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No abnormalities were observed in the appendicular skeleton, axial skeleton (below the 
skull), or internal organs of Mn1-/- and Mn1+/- mice  
Skeletons of mice of different stages of embryonic development (E15.5 to E18.5) were 
stained with alizarin red/alcian blue and close observation did not reveal any abnormalities 
besides the abnormalities in the skull. All limbs were formed correctly, and no delay of 
endochondral bone formation was observed in Mn1-/- or Mn1+/- compared to wild-type 
animals (data not shown). Analysis of MN1 expression in human tissues showed that MN1 is 
expressed in many tissues but at low levels with higher expression in skeletal muscle,1 
kidney and striatum (putamen and caudate nucleus, unpublished results). The extensive 
analysis of many organs in the P0 Mn1-/- mice, however, revealed no abnormalities in these 
tissues or organs, indicating that Mn1 plays no critical role in their development. Since Mn1 
null mice are not viable, the role of Mn1 in normally functioning skeletal muscle, kidney and 
striatum has not been investigated in this mouse model.  
 
DISCUSSION 
In this study we show that Mn1 plays a pivotal role in the development of membranous 
bones in the skull during embryogenesis. In null mice, agenesis is observed for the 
alisphenoid and squamosal bones, and vomer. Pterygoid, presphenoid, and basisphenoid 
bones are hypoplastic and the supraoccipital bone is delayed in formation. Furthermore, the 
parietal, frontal, and interparietal bones forming the roof of the skull are thinner and less 
mineralized. Bones not affected include the mandible, maxilla, and the nasal bones. In 
heterozygous Mn1+/- mice these developmental defects are less pronounced with normal 
mineralization of frontal, parietal and interparietal bones of the skull and formation of the 
supraoccipital bone and the vomer. The squamosal and alisphenoid bones are formed but 
are hypoplastic and less mineralized and contain larger foramina. This suggests that there is 
a dosage effect of the Mn1 protein on cranial bone development. Incomplete penetrance is 
found for cleft secondary palate, a phenomenon seen in many mouse models with cleft 
secondary palate. Loss of one functional copy of the Mn1 gene is compatible with a normal 
lifespan and does not lead to excess tumor formation or other pathologies.  
Mineralization by osteoblasts occurs by two mechanisms: endochondral and 
intramembranous ossification.7 During endochondral ossification, precursor cells condense 
in areas destined to become bone, forming cartilage that will be replaced by bone material at 
a later stage. This mechanism is used for most of the vertebrate skeleton, including limbs, 
ribs, and part of the base of the skull. In the skull the parietal, interparietal, and frontal bones 
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as well as the alisphenoid, pterygoid, squamosal, and palatal bones (from maxillary and 
palatine shelves) are formed by intramembranous ossification, which involves the 
condensation of precursors cells and the direct transition to differentiated bone cells, without 
an intermediate cartilage template formed. In mice, the remainder of the skull, including 
maxilla and mandible, is formed by a combination of the two processes. Thus nearly all 
bones affected in Mn1-/- mice are formed by the process of intramembranous ossification, 
and consequently it appears that Mn1 plays a pivotal role in the formation of membranous 
bones during embryogenesis. The supraoccipital bone, which is delayed in its formation in 
Mn1 null mice, is formed by endochondral ossification. The supraoccipital bone is formed 
late during embryonic development (E17.5) and processes involving the onset of bone 
formation are unknown. Possibly, the formation of bone structures in the vicinity of the 
supraoccipital bone, known to be affected in the Mn1 knockout mice, influences the onset of 
ossification. The question remains whether all bone structures formed by intramembranous 
ossification are affected in Mn1 null mice. The mandible and maxilla are formed by a 
combination of the two processes, and an impaired mineralization is difficult to detect in 
these structures by alizarin red/alcian blue stainings.  
Since MN1 is able to function as a transcriptional coactivator, an interplay between 
MN1 and other transcription factors regulating intramembranous ossification is plausible. 
Many transcription factors known to have a function in bone formation, like Cbf-β, Osx, and 
Runx2,12,13,14 are controlling osteoblast differentiation in both intramembranous and 
endochondral ossification. Cleidocranial dysplasia, an autosomal dominant skeletal disease 
in humans, is caused by mutations in the RUNX2 gene.15 Haploinsufficiency of the 
transcription factor causes skeletal abnormalities of both membranous en endochondral 
bones in patients, including enlarged calvaria with open fontanelles and short stature. Two 
isoforms of Runx2, I and II, have been found.16 Separate promoters control the expression 
of the two isoforms, resulting in two proteins with only minor differences in the N-terminus. 
By generating selective Runx2-II-deficient mice, the separate functions of the two isoforms 
were studied. In Runx2-II null mice, intramembranous ossification was not affected, 
suggesting that it is the Runx2-I isoform that is responsible for proper development of 
membranous bones. Runx2-I and II are subunits of the heterodimeric transcription factor 
PEBP2/CBF.17 The C-terminal region of Runx2 is involved in interaction with various 
transcription factors, coactivators, and corepressors. Since Mn1 is known to act as a 
transcriptional coactivator in RA-mediated transcription, it is possible that Mn1 acts as a 
coactivator in Runx2-I-related transcriptional regulation. 
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In humans no syndromes are known that resemble the abnormalities seen in Mn1 
knockout mice. Defects in membranous bones are rare; only 2 papers describe families with 
delayed intramembranous ossification.18,19 During infancy, these patients show a complete 
lack of ossification of the calvarial bones forming the roof of the skull resulting in a soft skull. 
In adults, the cranial vault is ossified but is deformed because of delayed ossification. The 
temporalis (squamosal) and sphenoid bones are not severely affected and no cleft palate is 
observed in these patients. One of the families had a translocation (2;3)(p15;q12). The 
translocation breakpoints and the localization of MN1 in the human genome (chromosome 
22), together with the differences in defects observed, rule out the possibility that MN1 is the 
mutated gene in these families. The gene mutated in these families may only be involved in 
intramembranous ossification of a subset of the calvarial bones forming the roof of the skull.  
A short administration of RA to pregnant mice carrying embryos of E10, results in 
abnormalities showing similarities to the ones observed in Mn1 knockout mice. At birth these 
mice show a failure of ossification at P0 of the parietal and interparietal bones and reduction 
in size of the alisphenoid and squamosal bones.20 Biochemical experiments in our group 
have shown that MN1 can act as a transcription coactivator in RAR-RXR-mediated 
transcription.4 Thus, since MN1 enhances RAR function, one would expect that obliteration 
of Mn1 has the opposite effect from a high, non physiological, dose of the RAR ligand RA. 
However, it is known that both long-term excess but also deficiency of vitamin A in the diet 
of a pregnant mouse causes a broad range of abnormalities in the offspring21,22 and that the 
abnormalities in both diet conditions show great similarities. This shows that a shift in the 
balance of RAR-RXR-related processes results in similar defects. A more subtle short-term 
administration of RA at E10 or the lack of Mn1 also results in similar defects, indicative of an 
interplay between Mn1 and RA in the processes involving the correct formation of the 
affected bones. 
Another mouse model showing striking similarities to the bone abnormalities observed 
in Mn1-/- mice is the Dlx2-/- mouse.9 Dlx2 is a homeobox gene controlling the patterning of 
cells within the first and second proximal branchial arches starting around E8.5. Bones 
absent in the Mn1 knockout mice are also agenic in the Dlx2-/-mice (squamosal and 
alisphenoid bones). Furthermore, both mouse models show abnormalities of basisphenoid 
and pterygoid bones, and a cleft of secondary palate is observed in 80% of Dlx2 knockout 
mice. However, there are also notable differences. The vomer is not affected in Dlx2 
knockout mice, and the supraoccipital bone is not delayed in formation. In addition, there is 
no evidence for impaired mineralization of parietal, frontal and interparietal bones of the 
skull. In Dlx2-/- mice abnormalities in the inner ear, forebrain, and enteric nervous system are 
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observed, but we have no evidence that any of these structures is affected in Mn1-/- mice. In 
conclusion, defects in Mn1-/- and Dlx2-/- mice overlap but there are also deficiencies 
associated with the lack of each gene separately. 
The most obvious external abnormality observed in the Mn1-/- and in a minor 
percentage of Mn1+/- mice is the cleft secondary palate. The formation of the palate is a 
complex process, and a cleft secondary palate has been observed in a number of transgenic 
mice8,9,22,23,24,25,26 and in a spontaneous mutant mice strain, the Twirler mice.27 Cleft 
secondary palate in these mice is caused by a variety of defects, including a deformed 
tongue (Ryk-/- mice),23 shortened mandibles (Msx1-/- mice),8 a wider midface (Twirler 
mice),27 malformation of the inner ear region (Hoxa-2-/- mice),26 agenesis of numerous bones 
of the lateral skull (Dlx2-/- mice),9 and a failure to fuse the patatal shelves (TGF-β3 -/- 
mice).24,25 Besides the TGF-β3 knockout model, the palatal defects in these mice can be 
attributed, at least partially, to the malformations in the vicinity of the palatal shelves that 
cause mechanical hindrance in positioning, elevation, and fusion of the shelves. The cleft 
palate observed in Mn1-/- mice is most likely a secondary effect of missing bones in the 
vicinity of the palatal shelves, although we can not rule out the possibility that Mn1 plays an 
intrinsic role in palatal development.  
We conclude that loss of the Mn1 gene is not compatible with life, that Mn1 plays an 
essential role in intramembranous bone formation and that the lack of proper development 
of these parts of the cranial skeleton results in a cleft secondary palate. The Mn1 knockout 
mouse is the first mouse model that selectively affects membranous bones and therefore 
presents an excellent model to study this complex process of bone formation. 
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ABSTRACT 
The IGF-binding protein (IGFBP) family consists of six proteins that are expressed and 
secreted in different tissues. The proteins are regulators of physiological processes 
throughout the body by modulating the activity of IGF-I and IGF-II. In this article, we describe 
the coordinated expression of IGFBP5 and MN1 in meningiomas. MN1 is a transcriptional 
coactivator and we show that MN1 stimulates the IGFBP5 promoter in Hep3B cells. A 
CACCC-containing sequence, located 140 bp upstream of the transcription start site of the 
promoter, is required for MN1 action. This sequence matches with the CACCCAC 
consensus sequence that was selected in an oligonucleotide selection assay performed for 
MN1. The CACCC element has also been shown to be important for induction of the 
IGFBP5 promoter by retinoic acid (RA) and progesterone (Pg). We were unable to confirm 
the effect of Pg on the promoter in Hep3B and U2-osteosarcoma cells regardless of the 
presence of MN1. On the other hand, we show that induction of the promoter by RA 
depends on co-expressed MN1 in Hep3B cells. MN1-TEL, a leukemia-related fusion protein 
containing parts of the MN1 and TEL (ETV6) genes, is capable of stimulating the IGFBP5 
promoter but is unable to cooperate with RA in Hep3B cells. This suggests that the effects of 
RA can be negatively affected in leukemias caused by MN1-TEL.  
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INTRODUCTION 
The insulin-like growth factor-binding proteins (IGFBPs) belong to a protein family with six 
members and are expressed and secreted in a tissue and developmental stage specific 
manner. The proteins bind the small effector molecules IGF-I and IGF-II, and act as carrier 
proteins. IGFs are the most important regulators of mammalian growth and development 
and mediate the effects of growth hormone. The six IGFBP members are highly 
homologous, but each has distinct functions and biochemical properties. Dependent on the 
particular IGFBP and the type of tissue, the effect on IGF action can be inhibitory or 
stimulatory. IGFBPs can also have IGF-independent effects on cell growth. These effects 
are exerted by binding of IGFBPs to non-IGF molecules, that are either present outside or 
inside the cell.1,2,3 IGFBP5 is the most conserved member of the protein family and plays an 
important role in mediating IGF effects, particularly in bone. IGFBP5 binds IGF-I and is 
regulated by proteolysis, glycosylation and phosphorylation. It binds extracellular matrix 
components in osteoblast cell cultures and potentiates IGF function by positioning it in the 
vicinity of the cell membrane.4,5 In cultured osteoblasts and muscle cells both inhibitory and 
stimulatory effects of IGFBP5 on IGF function have been described. Transgenic mice 
overexpressing IGFBP5 have osteopenia, lower body weight, retarded muscle development 
and lower female fertility.6,7 Within different tissues, there is a tight balance of IGFBP5 
expression and disregulation of this equilibrium is thought to be a cause of disorders such as 
osteoporosis and renal osteodystrophy.8,9 Other physiological processes in which IGFBP5 is 
involved are mammary gland involution, follicular development in the ovary and kidney 
physiology.3  
Expression of IGFBP5 is stimulated by IGF-1 through the phosphatidylinositol-3 kinase 
pathway.10 Transcription factors that have been shown to affect the IGFBP5 promoter are 
the progesterone receptor (PR),11 the retinoic acid receptor (RAR),12,13 the glucocorticoid 
receptor,14 activator protein-2 (AP-2)15 and Myb.16 Furthermore, prostaglandin E2, 
parathyroid hormone, and osteogenic protein-1 have been described to regulate the 
expression of IGFBP5.17,18,19 
Several studies have associated IGFBP5 expression with cancer. IGFBP5 was shown 
to be able to stimulate growth of prostate cancer cells in vitro and tumor growth in vivo.20,21 
Both inhibition and induction of apoptosis have been described in breast cancer cells in 
vitro.22,23,24 Furthermore, IGFBP5 was shown to inhibit the proliferation of cervical carcinoma 
cells and osteosarcoma cells.25,26 This study is, among others, based on our unpublished 
findings that IGFBP5 and the transcriptional coactivator MN1 are co-expressed in 
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meningiomas, a benign brain tumor arising from the arachnoidal cap cells. This suggests 
that expression of the two proteins is related.  
The MN1 oncogene was cloned and described by our group in 1995 on the basis of its 
involvement in a t(4;22) found in a meningioma.27 The protein consists of 1319 amino acids 
and has a nuclear localization. The primary protein sequence shows no homology to other 
proteins, but homologues of MN1 are found in mice (Mus musculus) and puffer fish 
(Tetraodon nigroviridus), proving conservation of MN1 in evolution.28 Extensive searches in 
domain databases did not reveal any specific domain within the protein. The 
proline/glutamine-rich regions in the sequence suggested a function in transcription and 
indeed, we have shown that MN1 activates the transcription activity of the Moloney sarcoma 
virus long terminal repeat (MSV-LTR)29 MN1 can synergize on this promoter with 
transcription mediated by the RAR - retinoid X receptor (RXR) heterodimer in the presence 
of the RAR-RXR ligand RA. We have also shown that MN1 binds p300 and RAC3, both 
known coactivators of RARs.30 MN1 is fused to the TEL (ETV6) gene as a result of the 
t(12;22) in acute myeloid leukemia. The MN1-TEL fusion protein is able to transform NIH3T3 
cells in vitro and causes leukemia and lymphoid tumors in mice.29,31,32  
Since Mn1 null mice die shortly after birth as the result of a cleft secondary palate, 
MN1 is an essential gene.28 Interestingly, the development of several bones in the skull of 
these mice is abnormal. The affected bones are almost exclusively formed by 
intramembranous ossification. They are either completely agenic at birth or substantially 
thinner. Endochondral bone formation is normal. Thus, Mn1 plays a crucial role in the 
formation of the membranous bones in the skull during mammalian development. This is 
further supported by Sutton et al. They have described the inhibition of osteoblastic cell 
proliferation by MN1.33 
In this report we further investigated the role of MN1 in regulating transcription. 
Because MN1 has transcription-activating domains, we were prompted to investigate 
whether it can bind DNA and function as a transcription factor. We show that MN1 activates 
the IGFBP5 promoter, that this effect is exerted through CA-rich elements present in the 
proximal promoter, and that the activation of the promoter by RA is dependent on the 
presence of MN1 in the cells used in this study. These findings also explain the coordinated 
expression of MN1 and IGFBP5 in meningiomas. 
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MATERIALS AND METHODS 
Oligonucleotide-binding selection 
The method used has been described previously30 and is a modified version of that 
described by Blackwell and Weintraub.34 Oligonucleotides for selection contained a central 
15-nucleotide random sequence flanked by two constant regions of 20 bp. Cellular extracts 
from MN1-expressing HtTA cells (cells stably transfected with a tetracyclin-conrolled 
activator),30 were incubated with the oligonucleotides, and a monoclonal antibody against 
MN1 called 2F2,29,30 was used to precipitate protein-DNA complexes. Bound DNA was 
amplified using the constant flanking sequences and used for further selection/enrichment. 
After five rounds of selection, PCR fragments were cloned and sequenced. 
 
Northern blot hybridisation 
Total RNA was isolated from primary meningioma tumors using guanidinium thiocyanate 
method.35 Electrophoresis, blotting and hybridisation were carried out using standard 
procedures as described previously.27 For detection of the MN1 transcript, a 0.6 kb BamHI 
cDNA fragment was used. For IGFBP5 we used a 0.9 kb murine cDNA covering the entire 
coding region.36 The coding regions of murine and human IGFBP5 are 91% identical. As a 
control for RNA loading we used a 0.8 kb EcoRI-PstI fragment derived from the coding 
region of the human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA. 
Hybridisation signals were quantified using a phosphorImager (GE Healthcare, Uppsala, 
Sweden). Hybridisation signals for MN1 and IGFBP5 were corrected for background and 
GAPDH expression, and the resulting values were plotted against each other. 
 
Cloning of IGFBP5 promoter and generation of deletion/mutation constructs 
PCR was performed on bacterial artificial chromosomes (BAC) clone PR11-506C837 
containing the IGFBP5 promoter. The forward primers are localized at position -1111 (5’- 
CAGGTACC-CTAGTGGCATGATTCGGTTC-3’) and -204 (5’-CGGGTACCGGAGGAGGGC-
GCTGTTCAGG-3’) of the promoter with respect to the transcription start site and each 
contains a KpnI site for cloning purposes. The reverse primer at position +1645 contains a 
BamHI site (5’-GCGGATCC-CAGGAGAGCGAGAGTGCAGG-3’). The resulting PCR 
products were cloned in pGL2basic and sequenced. A KpnI-XmaI fragment (-204 to + 119) 
from pGL2 BP5 –204 +738 was subcloned in pGL3basic, resulting in pGL3BP5 –204 +119. 
The mutants mPR, dCA, dGT and dCAdGT were generated using the QuikChange Site-
Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA). The mPR mutant is as described 
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by Boonyaratanakornkit et al..11 The CA-rich element at positions –147 to –133 
(CCCCACCCCCACCCC) is mutated in CCCCACCaaaACCCC. The dCA mutant lacks the 
entire CA-rich element (from positions –147 to –133), and the dGT mutant lacks the 
complete GT-rich element localized at positions –87 to –78 (GGGTGTTGGG). The dCAdGT 
mutant lacks both elements. All plasmids were sequenced to confirm the different 
deletions/mutations. 
 
Cell culture and transfections 
Hela-derived HtTA cell lines and 3T3 Gene-Switch cell lines were generated and cultured as 
described previously.30 In 3T3 Gene-Switch cell lines expression of HA-tagged-MN1 and 
HA-tag (as control) were induced overnight with mifepristone (10-8M) and used to generate 
cell lysates for electrophoretic mobility shift assays (EMSAs). Transient transfections were 
performed using hepatocarcinoma cell line 3B (Hep3B)38 or U2-Osteosarcoma cells (U2OS). 
U2OS cells were obtained from the American Type Culture Collection (ATCC, Manassas, 
VA, USA) and are known as HTB-96 in this collection. Hep3B was maintained in α-minimum 
essential medium (α-MEM) supplemented with 5% fetal calf serum (FCS), 2 mM L-
glutamine, 1000U/l penicillin and 1mg/l streptomycin at 37°C with 5% CO2 and U2OS cells 
were cultured in Dulbecco's Modified Eagle's medium (DMEM) supplemented with 10% 
FCS, 1000U/l penicillin and 1mg/l streptomycin at 37°C with 5% CO2. The day before 
transient transfections cells were seeded in 24-well plates (0.7x105 cells/well). On the day of 
transfection, medium was changed and, if indicated in figure legends, progesteron (Pg 
(Q2600), Steraloids, Newport, RI, USA) or all-trans RA (R2625, Sigma-Aldrich, St.Louis, 
MO, USA) was added at the desired concentration (Pg, 10-7M; RA, 10-9M). Transfections 
were carried out using FuGENE 6 Transfection Reagent (Roche Applied Science, Basel, 
Switzerland) according to the manufacturer's recommendations. The MN1 expression 
plasmid, pMN50, has been described previously,30 the expression plasmid for PR (pCMV3.1 
PR-β) and the PR-responsive luc (PRE2-luc) reporter were obtained from G.Jenster 
(Department of Urology, Erasmus MC, Rotterdam, The Netherlands).39 Expression plasmid 
pcDNA3 TEL was generated by cloning the insert of pSCTOP TEL29 (HindIII-NotI digestion) 
into pcDNA3.1. pcDNA3 MN1-TEL was made by cloning the C-terminal region of MN1-TEL 
(pSCTOP MN1-TEL, SfiI-NotI digestion29) into pMN50. For a transfection experiment, 375ng 
of expression plasmid and 25ng of reporter plasmid were used. For each experiment, the 
total amount of transfected DNA and the molar ratio of CMV promoter were kept constant by 
the addition of puc6 plasmid DNA. After incubation for 48 h, cells were lysed and luciferase 
activity was measured on a Fluoroscan Ascent FL luminometer (Thermo Electron 
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Corporation, Waltham, MA, USA). Transfection efficiency was monitored regularly by adding 
a Renilla luciferase construct or a LacZ internal control plasmid (pcDNA3.1 HisLacZ). 
Transfection efficiency was shown not to vary within an experiment (data not shown). Each 
experiment was done at least thrice in triplicate.  
 
Real-time PCR (Taqman analysis) 
RNA was isolated from 3x105 cells using the Rneasy mini kit (Qiagen, Venlo, the 
Netherlands) according to manufacturer's recommendations. RNA (3μg) was reverse 
transcribed using 300 U Moloney Murine Leukemia Virus (M-MLV) reverse transcriptase 
(Invitrogen, Carlsbad, CA, USA) and 750ng random hexamers. cDNA (12.5 ng) was 
analysed for the expression of RNA polymerase II, subunit A (PolR2A), MN1 and IGFBP5 by 
real-time PCR using SYBR green PCR assay (Applied Biosystems, Foster City, CA, USA) 
and an ABI Prism 7700. Levels of expression for MN1 and IGFBP5 were calculated relative 
to PolR2A level in the sample using the observed threshold cycle. Two separate RNA 
samples of cell lines were analysed. Primers (7.5pmol used for each PCR): PolR2A-F: 5’-
CGGATGAACTGAAGCGAATG-3’; PolR2A-R: 5’-GAGTCCACAAGCAGTTTGG-3’; MN1-F: 
5’-TCGCTGATGGCAGAGCACAG-3; MN1-R: 5’-GTCATTCAAGTTAGGGCAG-3’; IGFBP5-
F: 5’-CGGGGGAGCCGAGAACAC-3’; IGFBP5-R: 5’-GGCGCTGGCTGGAGTCGG-3’.  
 
Electrophoretic mobility shift assay (EMSA) 
Lysates were made of mifepristone (10-8M)-induced 3T3 cell lines (expressing hemaglutinin 
(HA)-tagged MN1 and the HA-tag alone as a control) using EMSA lysis buffer (20 mM 
HEPES pH 7.9, 10 mM KCl, 1 mM MgCl2, 300 mM NaCl, 0.1% Triton X-100, 20% glycerol, 
0.5mM dithiotreitol (DTT) and protease inhibitor cocktail Complete (Roche, Germany)). Cells 
were disrupted in a cuphorn sonifier. Protein concentration was measured and 20ug of 
protein was used for each EMSA experiment. Protein lysates were incubated with 10,000 
cpm 32P-labeled double-stranded oligo in 10 mM Hepes pH 7.9, 60 mM KCl, 4 % Ficoll 400, 
1 mM DTT, and 1 mM EDTA at room temperature for 30 min. Double-stranded oligos used 
for EMSA: IGFBP5-CA: 5’-CCTCTCCCCACCCCCACCCCGTGTG-3’; IGFBP5-GT: 5’-
GAGTTGGGTGTTGGGAAGCT-3’; Selex-78: 5’-GACCACCCACGTTGGCTCC-3’. Samples 
were analysed on a 4% acrylamide gel (37,5 : 1; acrylamide: bisacrylamide) in 0.5x Tris-
boric acid-EDTA (TBE) at 15mA. After electrophoresis, the gel was transferred to paper and 
dried. Bands were quantified using a Typhoon 9200 scanner (GE Healthcare, Uppsala, 
Sweden). 
 
69 
 
Chapter 3 
 
RESULTS 
Oligonucleotide selection experiments reveal that MN1 recognizes a CACCC-rich sequence 
We have shown previously that MN1 can activate transcription from the MSV-LTR, and that 
MN1 contains a transcription-activating domain near its N-terminus.30,40 In order to 
investigate whether the MN1 protein can bind to DNA and whether it recognises a specific 
DNA  element,  we   performed   an   oligonucleotide   selection   assay.   To   this   end,   an  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Oligonucleotide selection assay. To establish the consensus sequence CACCCAC, 34 oligonucleotides from the 
selection assay were used. The numbers indicate the percentage of oligonucleotides containing each nucleotide. The 
oligonucleotide indicated with an asterisk was used for the bandshift assay (figure 4). 
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oligonucleotide pool was synthesized with a random core of 15 residues with 20 residues of 
known flanking sequence on both sides. The pool was incubated with a lysate obtained from 
an HtTA HeLa cell line in which MN1 expression was induced by omitting tetracycline from 
the medium.30 Oligonucleotides binding to MN1 were precipitated from the mixture using the 
MN1 monoclonal antibody 2F2. These oligonucleotides were amplified using primers 
annealing to the sequences flanking the random core. This selection procedure was 
repeated five times. The resulting oligonucleotides enriched for MN1-binding were cloned 
and the insert sequence of 54 different plasmids was determined. A CACCC-rich sequence 
was found in 34 plasmid inserts from which a consensus-binding sequence CACCCAC was 
deduced (Figure 1). In seven plasmids, a sequence AGGTCAaAGGTCA resembling a RAR-
RXR DR1-binding site was observed. The RAR/RXR-responsive elements were shown to be 
responsible for a synergistic induction of expression by RA and MN1 in an earlier paper.30 
The remaining 13 inserts contained random sequences.  
We have shown previously that MN1 and RAR-RXR can synergistically induce 
expression from the MSV-LTR, a viral promoter that contains a RA-responsive element.30 To 
investigate the effect of the CACCC element on expression, an oligonucleotide containing 
two of the CACCC consensus sequences was inserted into a reporter vector in front of a 
TATA box. However, when MN1 cDNA was co-transfected with the reporter, we were unable 
to establish an effect on expression of this synthetic promoter.  
 
Coordinated expression of MN1 and IGFBP5 in meningiomas 
In a previous study we showed that MN1 expression varies considerably between 
meningiomas.27 We also investigated a putative role for the IGF pathway in these benign 
tumors. These experiments showed that there was a correlation between the expression of 
MN1 and IGFBP5. Figure 2A shows a representative northern blot containing RNA from ten 
meningiomas hybridized with probes against IGFBP5 (top panel), MN1 (middle panel) and 
control GAPDH (bottom panel). Quantification of expression of MN1, IGFBP5 and GAPDH 
using a phosphorImager revealed that expression of the MN1 gene correlated with 
expression of the IGFBP5 gene in 18 out of the 20 meningiomas tested, with high 
expression of MN1 occurring in the same tumors that showed high expression of IGFBP5. 
Figure 2B is a graphical representation of all the meningiomas tested; the Pearson 
correlation coefficient (r) calculated is 0.765 (P value <0.0001 at significance level 0.01). 
These results suggest a functional relationship between the expression of these genes. 
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Figure 2. Coordinated expression of MN1 and IGFBP5 in meningiomas. (A) The northern blot, containing 20 ug of each RNA 
sample, was hybridised to probes for IGFBP5 (top panel), MN1 (middle panel) and GAPDH (lower panel). (B) Correlation of 
MN1 and IGFBP5 expression in 20 meningiomas. Expression of IGFBP5 and MN1 was calculated in relation to GAPDH using 
phosphorImager data. r, Pearson correlation. 
 
MN1 stimulates expression of the IGFBP5 gene through CA- and GT-rich elements 
Inspection of the promoter of the IGFBP5 gene showed that it contains a CA-rich element 
that may present a possible natural target for regulation of expression by MN1. Another 
element is GT-rich, and is nearly the reverse sequence of the consensus sequence picked 
up by the oligonucleotide selection assay. Both the elements are located just upstream of 
the transcription start site: (-146) CCCCACCCCACCC (-132) and (-86) GGTGTTGGG (-77). 
In order to establish whether MN1 induces expression of IGFBP5, we cloned the 
promoter in front of a luciferase reporter (outline of the constructs is shown in Figure 3A). 
Transient transfections were carried out using an MN1 expression construct. For these 
experiments, we used the Hep3B hepatocarcinoma cell line, in which there is no expression 
of the endogenous MN1 gene. Figure 3B shows that MN1 induces the IGFBP5 promoter 
about sixfold, and that the smaller promoter construct spanning nucleotide (nt) -204 to nt 
738 is sufficient for induction by MN1. Deletion of nucleotide +119 to +738 did not influence 
the induction of MN1 (data not shown). 
To investigate the role of the CA-rich and/or GT-rich elements in MN1-induced 
expression, the sequences were deleted from the shortest IGFBP5 promoter construct. Both 
single and double mutants (lacking both CA en GT-rich elements) were generated. The 
effect of the mutations is shown in Figure 3C. MN1 was able to induce the IGFBP5 promoter 
in  a   dose-dependent   manner,  and   deletion  of   both  elements  negatively  affected  the 
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Figure 3. MN1 stimulates the IGFBP5 promoter through CA-rich elements. (A) Schematic representation of luciferase reporter 
constructs of the IGFBP5 promoter. Numbers indicate nucleotide positions relative to the transcription start site (+1, indicated 
with an arrow). The constructs of the IGFBP5 promoter contain +738 or + 119 basepairs of untranslated exon 1. The 
constructs used for Figure 3B are cloned in pGL2basic. The constructs used for Figure 3C are cloned in pGL3basic. This 
vector contains a modified coding region in the luciferase gene, resulting in an enhanced luciferase activity. (B) In Hep3B cells, 
25 ng of reporter plasmids and 120 ng of MN1 expression plasmid or pcDNA3 was transfected. MN1 stimulates the IGFBP5 
promoter and -204 bp of the promoter is sufficient for induction by MN1. (C) In Hep3B cells, 25 ng of reporter plasmid and 
increasing amounts of MN1 expression plasmid were transfected. The promoter is stimulated in a dose-dependent manner and 
the mutated promoters are stimulated less efficiently. Values shown are the mean of triplicate wells ± S.E., except for Figure 
3C (mean of two separate RNA samples analysed ± S.E.). P values are shown for significant changes (two-tailed Student's t-
test). rlu, relative light units. 
 
induction of the IGFBP5 promoter by MN1. When both elements were deleted, promoter 
activity was almost completely abolished. In the literature, the CA-rich element is described 
as a PR-sensitive element.11 A mutant used by the authors of this article in which 3 C’s were 
exchanged with A’s was no longer able to confer PR activity to the IGFBP5 promoter. We 
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used this mutant to investigate a possible interplay between MN1 and PR. Figure 3C shows 
that the Pr mutation construct (mPr) is also stimulated less efficiently by MN1. On the basis 
of these experiments, we conclude that MN1 is able to efficiently induce the IGFBP5 
promoter and that the CA-rich and GT-rich elements are involved in MN1-induced 
expression.  
 
MN1 binds indirectly to CA-containing oligonucleotides 
The finding that MN1 recognizes a CACCC sequence in the oligonucleotide selection 
experiments and is able to activate the IGFBP5 promoter containing similar elements 
prompted us to investigate whether MN1 binds to the CA and GT-rich DNA elements in a 
bandshift assay. To this end, an NIH3T3 cell line was used in which expression of HA-
tagged MN1 can be induced by addition of mifepristone. Lysates of HA and HA-MN1 cell 
lines were incubated with 32P-labeled double-stranded oligonucleotides containing the CA 
consensus sequence (as shown in figure 4A; selex 78) and CA and GT containing 
oligonucleotides derived from the IGFBP5 promoter sequence (see Materials and methods 
section and Figure 4B for specific sequences). The results of the mobility shift assays are 
shown in Figure 4. The CA-containing selex oligonucleotide (selex 78) was found to bind to 
four separate protein complexes (lane 4, complexes numbered I-IV). Figure 4B is a 
graphical representation of the binding. The four complexes are distinguishable as four 
peaks. The CA oligonucleotide derived from the IGFBP5 promoter (IGFBP5-CA) binds two 
complexes, similar to complexes I and II detected with selex 78 oligonucleotide (lane 1). 
Although the sequence of the GT oligonucleotide is not exactly complementary to the 
CCACCC consensus sequence, the IGFBP5-GT oligonucleotide binds two complexes 
similar to complexes III and IV. Close examination of the sequences of the selex 78 and the 
IGFBP5-GT oligonucleotide reveals that the oligonucleotides share the GTTGG sequence: 
most likely, this represents the sequence responsible for the complexes binding to both 
oligonucleotides. 
Binding specificity was established by competition with cold oligonucleotides (lane 3, 6 
and 9). In the presence of HA-MN1, the relative intensities of complexes I and II change and 
complex II is now the major complex for bandshifts with both selex 78 and IGFBP5–CA 
oligonucleotides experiments (lane 2 and 5; indicated with arrows in Figure 4A and B). 
Possible explanations are that the newly formed complex with HA-MN1 migrates at the 
same position as the complex II that is seen in the absence of MN1, or alternatively, that 
MN1 stimulates the formation of complex II, for instance by increasing the recruitment of 
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proteins, such as p160 and p300 that bind to MN1. No influence of HA-MN1 was detectable 
on the complexes binding the IGFBP5-GT oligonucleotide. 
In order to establish whether binding of MN1 was direct or indirect, mobility shift 
assays were performed with MN1 produced through in-vitro transcription-translation. No 
binding of MN1 to the oligonucleotides was found (data not shown). Thus, we conclude that 
MN1 recognizes CACCC-rich sequences indirectly, presumably by binding to a CACCC-
specific transcription factor.  
 
 
 
 
Figure 4. Bandshift assay using the selected CACCCAC sequence and IGFBP5-derived oligonucleotides. (A) Autoradiograms 
of bandshift assays using three different oligonucleotides incubated with total lysates of cell lines expressing HA-tagged MN1 
and the HA-tag alone as a control. Four protein complexes binding the selex78 oligonucleotide are indicated with roman 
numbers I-IV. Lanes 1, 4, and 7: shifts observed with control lysate of HA-expressing 3T3 cell line. Lanes 2, 5 and 6: shifts 
observed with lysate of HAMN1 expressing cell line. Arrows indicated the more intense band appearing in lanes 2 and 5. 
Lanes 3, 6 and 9: competition experiment using cold oligonucleotides (100 x molar excess). (B) Graphic representation of 
bandshift assays. Peaks are indicated for protein complexes I, II, III and IV. More intense bands are indicated with an arrow. 
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The progesterone receptor (PR) does not stimulate the IGFBP5 promoter in Hep3B cells 
and U2 Osteosarcoma cells, and the effect of MN1 is not affected by PR 
 It has previously been shown by Boonyaratanakornkit et al.11 that the PR can stimulate the 
IGFBP5 promoter in the presence of its ligand, progesterone. Although no canonical PR-
responsive elements are present in the IGFBP5 promoter, Boonyaratanakornkit et al. 
showed that induction by PR is mediated by the CACCC element in the promoter. Since 
MN1 also uses this element to induce to IGFBP5 promoter, and can collaborate with another 
nuclear receptor, the RAR-RXR heterodimer,30 we sought to investigate the effect of a 
combination of PR and MN1 on this promoter. To this end, we co-transfected MN1 and PR 
expression constructs and the IGFBP5 reporter into Hep3B cells. The result of this 
experiment is shown in Figure 5A. Whereas MN1 efficiently induced the IGFBP5 promoter 
as shown before, we were unable to find induction of the promoter by PR. Neither did 
different concentrations of PR result in induction of the IGFBP5 promoter in Hep3B cells 
(data not shown). Co-transfection of MN1 and PR did not increase the induction of the 
IGFBP5 promoter by MN1. 
Since the experiments described by Boonyaratanakornkit et al. had been carried out in 
human U2OS cells, we repeated the experiments in this cell line. U2OS cells express MN1 
endogenously as is shown in Figure 5C and, as a consequence, no effect of transfection of 
MN1 is obvious (Figure 5B). Figure 5C also shows that MN1 and IGFBP5 are both 
expressed in U2OS cells but not in Hep3B cells. In contrast to Boonyaratanakornkit et al., 
we found inhibition of the IGFBP5 promoter by the PR in U2OS cells rather than stimulation 
(Figure 5B). As a control for PR activity we established that PR in the presence of ligand but 
not in its absence could induce a luciferase reporter driven by two copies of the canonical 
progesteron-responsive element (PRE, Figure 5D). The results are shown for U2OS cells 
and were similar in Hep3B cells. 
 
The IGFBP5 promoter can also be induced by MN1-TEL, and induction by MN1 can be 
enhanced by RA in Hep3B cells 
Because of the effect of IGFBP5 in various forms of cancer, we next sought to investigate 
whether the leukemia-associated MN1-TEL fusion protein is also capable of induction of the 
IGFBP5 promoter. Figure 5E shows that MN1TEL is indeed able to induce the IGFBP5 
promoter. It has also been described that RA can induce IGFBP5 in neuroblastoma cells 
and other cell types.12,13 Since MN1 is known to collaborate with the receptors of this ligand, 
RAR-RXR, by inducing expression from the MSV-LTR,30 we investigated the effect of RA on 
the IGFBP5 promoter in the presence or absence of MN1. In Hep3B cells, that express all 
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RARs and RXRs,41 we observed that addition of RA alone is insufficient to stimulate the 
promoter. In the presence of MN1, however, a clear induction was found (Figure 5E). Thus, 
in Hep3B cells, induction of the IGFBP5 promoter with RA requires expression of MN1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. The PR does not stimulate the IGFBP5 promoter; RA induction of the IGFBP5 promoter depends on the presence of 
MN1. (A) Expression plasmids for MN1 (125 ng) and PR (250 ng) were transfected together with pGL3 BP5 -204 +119 in 
Hep3B cells in the presence of progesterone (Pg; 10-7M).The PR has no effect on the transfected promoter. (B) Transfection 
performed in U2OS cells (as described for 5A). The PR does not stimulate transcription from the transfected IFGBP5 promoter 
in U2OS cells. (C) Endogenous expression of MN1 and IGFBP5 in Hep3B and U2OS cells as determined by real-time PCR. 
Expression of MN1 and IGFBP5 was observed in U2OS cells, whereas Hep3B had no expression of either of the genes. (D) 
Control for the effect of progesterone. pPRE-luc contains two copies of the canonical PR responsive element and, when co-
transfected with PR, is efficiently induced in the presence of Pg. (E) In Hep3B cells, 25 ng reporter plasmid (pGL3 BP5 -204 + 
119) and 375 ng of expression plasmid for MN1, MN1-TEL and TEL were transfected in the presence or absence of retinoic 
acid (RA; 10-9M). RA can stimulate the IGFBP5 promoter only in the presence of MN1. MN1-TEL cannot replace MN1 in this 
process. TEL does not have any effect on the IGFBP5 promoter. Values shown are the mean of triplicate wells ± S.E. P values 
are shown for significant changes (two-tailed Student's t-test). rlu, relative light units; RA, retinoic acid; Pg, progesterone; PR, 
progesterone receptor. 
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Since we previously found that the fusion protein MN1-TEL can induce expression, but 
is not capable of synergising with RA in the case of the MSV-LTR (van Wely et al., 
submitted), we investigated whether the same was true for the IGFBP5 promoter. In analogy 
to our results with the MSV-LTR, the effect of MN1-TEL was not enhanced in the presence 
of RA. We also found that the fusion partner TEL had no effect on the IGFBP5 promoter 
(Figure 5E). If induction of the IGFBP5 promoter by RA was always dependent on co-
expressed MN1, the sole addition of RA to U2OS cells would be sufficient to induce the 
IGFBP5 promoter, since these cells express MN1 endogenously. Transfection of the 
IGFBP5 reporter construct in U2OS cells and incubation with RA, however, did not result in 
increased expression from the promoter. We conclude that there was no induction of the 
IGFBP5 promoter by RA alone either in Hep3B or in U2OS cells and that expression of MN1 
in Hep3B cells is required for RA to have an effect on the IGFBP5 promoter. 
 
DISCUSSION 
The oligonucleotide selection experiments revealed a consensus sequence CACCCAC that 
was recognized by protein complexes containing MN1. Our data suggest that this binding is 
presumably indirect and through another, as yet unknown, protein or proteins. The 
CACCCAC sequence is present in the list of regulatory motifs in human promoters 
generated by the study of Xie et al.,42 in which over 17,000 well-annotated genes were 
studied by aligning promoters and 3’UTRs of different mammalian species. The motif 
CACCCAC was found in reverse (GTGGGTGK) together with about 150 other short 
regulatory sequences. Searching the Transfac database with the motif in both orientations 
shows that many transcription factors, such as AP2-1, Egr-1, paired box protein (PAX)1, 5 
and 9, Sp1, AP1, human T-cell leukemia virus enhancer factor (HLTF) and Dopamine 
receptor regulating factor (DRRF) bind to this motif (http://www.gene-
regulation.com/pub/databases.html#transfac). In addition, there is an intriguing correlation 
between the CACCCAC-MN1 binding motif and the GACCACCCAC elements to which 
Glioma-associated oncogene (GLI) 1, 2 and 3 and the family members GLIS1, 2 and 3 
bind.43,44 In the sequences that were determined on the basis of the oligonucleotide 
selection assay, the same flanking sequence was present upstream of the conserved motif 
in all cases. If the motif is then extended at its 5’ end with 3 nucleotides of flanking 
sequence, it reads GACCACCCAC. The sequence of the other flanking sequence is 
different for all selected sequences, suggesting that a selection has occurred for one of the 
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two flanking sequences in conjunction with the core motif CACCCAC, and thus that it is also 
possible that it a GLI family member is a target protein for MN1. 
MN1 and IGFBP5 are co-expressed in meningiomas, a benign tumor of the meninges. 
Considering the results presented in this work, the most likely explanation for this finding 
would be that MN1 induces IGFBP5 expression in these tumors. Expression of MN1 and 
IGFBP5 between the different meningiomas differs considerably, some tumors having hardly 
detectable expression levels, and others having high expression. Our comparison of 
expression levels of MN1 and IGFBP5 with other characteristics of these meningiomas 
produced no correlation with the position of the tumor, histological subtype or grade, nor any 
or evidence for involvement of the NF2 tumor suppressor gene.27,45 Sandberg Nordqvist and 
Mathiesen46 studied the expression of IGFBP5 in three groups of meningiomas (classified 
on the basis of invasiveness) and concluded that higher expression of IGFBP5 is observed 
predominantly in tumors that do not invade the brain. This would correlate with our finding, 
since, in meningiomas, invasion of surrounding structures is extremely rare, and was 
certainly not seen in the meningiomas in our study. Thus, both studies suggest that 
expression of IGFBP5 is high in some meningiomas and low in others. Whether expression 
is higher than normal is not known at present. Persistent, but low-level expression of 
IGFBP5 mRNA and protein has been observed in the mouse meninges,47 but there is no 
data on the IGFBP5 expression level in normal human meninges. 
Boonyaratanakornkit et al.11 reported previously that PR efficiently stimulated the 
IGFBP5 promoter, and that the CA-rich region was responsible for this, although the 
sequence does not resemble a canonical PRE. They also showed that the PR does not bind 
the CA element directly. We investigated the relationship between MN1 and PR in the 
presence of Pg and we were not able to reproduce the effect of PR on the IGFBP5 promoter 
either in Hep3B or in U2OS cells. In both cell lines, the control PRE-driven reporter was 
efficiently induced by co-transfected PR after the addition of Pg. Explanations for these 
discrepancies are difficult to give, but may result from differences in cell lines after prolonged 
culturing or in culture conditions. 
In the neuroblastoma cell line LAN-5, cervical carcinoma cells, human breast 
carcinoma cells and rat osteoblastic cells, RA was shown to stimulate the expression of 
IGFBP5.12,13,26,48 Mutagenesis of the CACCC element decreased, but did not completely 
abolish induction by RA in LAN-5. This suggests that other sites for RA induction are present 
in the promoter.12,13 In contrast, RA decreased IGFBP5 levels in the prostate 
adenocarcinoma cell line PC-3 and in the human breast carcinoma cell line T47D.49,50 In the 
Hep3B and U2OS cells studied in this work, RA had no effect on its own. We showed that 
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RA can cooperate with exogenously added MN1 in Hep3B cells, leading to stimulation of the 
promoter, but cannot do this in U2OS cells that express the protein endogenously. These 
results suggest that regulation of the IGFBP5 promoter by RA occurs, but that unknown cell-
dependent factors determine the outcome. 
Interestingly, MN1-TEL was as efficient in activating the IGFBP5 promoter as MN1, but 
this activity could not be enhanced by addition of RA. TEL on its own had no effect on the 
promoter. Since MN1-TEL is under control of the MN1 promoter, its expression is probably 
similar to expression of MN1, which makes it possible that the fusion protein competes for 
MN1-binding partners. Its inertness in collaborating with RA is not unique for the IGFBP5 
promoter. The Moloney sarcoma virus long terminal repeat (MSV-LTR) is stimulated by both 
MN1 and MN1TEL; on this promoter too, MN1 can collaborate with RA, whereas MN1 TEL 
cannot. This property of MN1-TEL could play a role in leukemia caused by MN1-TEL. 
 
 
 
 
Figure 6. Alignment of the IGFBP5 promoter in human, chimp, mouse and rat. The promoter is aligned for bp -200 to +20 
relative to the transcription start site (indicated with an arrow). The CA-rich and GT-rich elements, CAAT box and TATA box 
are boxed. Known binding sites are indicated under the sequence with a line. a, E-box, CCAAT/enhances binding protein 
(C/EBP)-responsive element (RE); b, cortisol and osteogenic protein 1 RE; c, Myb-binding site; d, AP2-binding site; e, nuclear 
factor-1 (NF1)-binding site; f, MN1-RE / progesterone-RE. 
No other transcription factors have been described that regulate the transcription of the 
IGFBP5 gene through the regions identified as being important for MN1. The CACCCAC 
motif overlaps with two putative AP-2 sites but they were shown not to be used by this 
transcription factor. Instead, a more proximal GCCNNNGGC sequence within the promoter 
was shown to be the target of AP-2. Both the CA-rich and GT-rich motifs are highly 
conserved between species. Figure 6 shows the alignment of the IGFBP5 promoter, which 
ranges from nt -200 to +20 for human, chimp, mouse and rat. Proven consensus sequences 
for several factors are indicated. Most of them cluster in the region between the CAAT box 
and the TATA box. The sequences identified here to be important for proper MN1 function 
are completely conserved, indicative of an important role for these regions of the promoter. 
Future experiments should reveal whether transcription factors known to bind CA-rich 
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regions, such as Sp1, GLI etc., regulate the transcription of the IGFBP5 promoter and how 
MN1 is involved in this regulation. 
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ABSTRACT 
The translocation t(12;22)(p13;q11) creates an MN1-TEL fusion gene leading to acute 
myeloid leukemia. MN1 is a transcription coactivator of the retinoic acid and vitamin D 
receptors, and TEL (ETV6) is a member of the E26-transformation-specific family of 
transcription factors. In MN1-TEL, the transactivating domains of MN1 are combined with 
the DNA-binding domain of TEL. We show that MN1-TEL inhibits RAR-mediated 
transcription, counteracts coactivators such as p160 and p300, and acts as a dominant-
negative mutant of MN1. Compared to MN1, the same transactivation domains in MN1-TEL 
are poorly stimulated by p160, p300 or histone deacetylase inhibitors, indicating that the 
block of RAR-mediated transcription by MN1-TEL is caused by dysfunctional transactivation 
domains rather than by recruitment of corepressors. The mechanism leading to myeloid 
leukemia in t(12;22) thus differs from the translocations that involve RAR itself. 
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INTRODUCTION 
The translocation t(12;22)(p13;q11) leads to the formation of an MN1-TEL fusion gene in 
acute myeloid leukemia (AML).1 The encoded fusion protein comprises nearly all of MN1 
fused to the central part and DNA-binding domain of TEL. MN1, a protein of 1319 amino 
acids, is a transcription coactivator of the nuclear hormone receptors for all-trans retinoic 
acid (ATRA) and vitamin D.2,3 Targeted disruption of the Mn1 gene causes a defect in the 
development of cranial membranous bones and death just after birth.4 The TEL gene, also 
termed ETV6, codes for a member of the E26-transformation-specific (ETS) family of 
transcription factors, and is the target of many different translocations leading to leukemia.5 
Whereas TEL confers its oligomerization domain in some translocations, it contributes the 
ETS-like DNA-binding domain in others, thus creating chimeric transcription factors with 
altered properties.6,7
The retinoic acid receptor (RAR) is a key regulator of proliferation and differentiation of 
blood cell lineages. RAR forms a dimer with RXR, and recruits p160 coactivators upon 
binding of ATRA to its ligand-binding domain.8 In turn, the members of the p160 family bind 
other factors, for example. p300/CBP. This complex of coactivators contacts the basal 
transcription machinery and causes histone acetylation, which is thought to facilitate access 
of RNA polymerase.9 In the absence of ATRA, RAR-RXR recruits corepressors like NCoR 
and SMRT, which in turn recruit histone deacetylase complexes containing SIN3 and 
HDAC.10 Inhibition of RAR function, for example by its fusion to promyelocytic leukemia 
(PML) protein, leads to downregulation of RAR-responsive genes, which results in a block in 
differentiation and an increase in the number of progenitor cells.11 The transcription-
repressing effect of PML-RARα relative to RARα is at least partially caused by a 
comparatively tight binding of corepressors.12 It is now widely believed that fusion 
transcription factors can cause leukemia by altering the balance between activation and 
inhibition of critical target genes. 
The transforming activity of MN1-TEL in fibroblasts depends on the transactivation 
domains of MN1 and the DNA binding domain of TEL,13 but the fusion protein also 
immortalizes myeloid cells and causes AML in mice.14,15 Although these studies have 
established the capacity of MN1-TEL to promote leukemia, they did not provide a molecular 
basis for its malignant effects. We therefore studied the fusion protein in a model system 
with established MN1 activity.2 MN1-TEL acts as an altered transcription factor compared to 
TEL, as it stimulates transcription from a reporter carrying responsive elements normally 
repressed by TEL.13 We now show that fusion to TEL also alters the properties of MN1. 
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Rather than stimulating RAR-mediated transcription, as does MN1, MN1-TEL inhibits RAR-
mediated transcription. Moreover, MN1-TEL acts as a dominant-negative mutant, as it 
efficiently represses RAR-RXR- mediated transcription even in the presence of MN1. Thus, 
repression of RAR-responsive genes may be an important aspect of the leukemogenic 
activity of MN1-TEL.  
 
MATERIALS AND METHODS 
Plasmids and detection of fusion proteins 
Dr. A. Zantema and Dr. G. Jenster provided expression constructs for p300 and RAC3, 
respectively. For expression purposes, MN1-TEL cDNA1 was cloned into vector pcDNA3 
(Invitrogen, Carlsbad, CA, USA), resulting in plasmid pcDNA3MN1-TEL. An MN1 expression 
construct and reporter constructs bearing the MSV-LTR and GAL4 upstream activator 
sequences,2 and expression constructs for TEL and MN1-TELDBDm1 have been described. 
The pGL-MSV4 construct comprises a reporter containing the 360 basepair MSV-LTR 
excluding all sequences upstream of the first direct repeat. In pGL-MSV45, the 5´ direct 
repeat of pGL-MSV4 has been replaced by the canonical DR5 sequence of the RARβ 
promoter.16 Fusions to the GAL4 DNA binding domain (DBD) were constructed in plasmid 
pGBT9 (Clontech, Palo Alto, CA, USA) and subsequently transferred to pcDNA3 for 
expression in mammalian cells. Fusions to green fluorescent protein (GFP) were made by 
cloning the MN1 cDNA sequence into pEGFP-C3 or pEGFP-N3 (Clontech) using internal 
BamHI or XhoI sites corresponding to MN1 aminoacids 48 and 1292, respectively. Correct 
expression was confirmed by Western blotting. The antibody to MN1 (2F2) has been 
described.13 Antibodies to GAL4 (SC-510) and TEL (H-214) were from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA), and the antibody to GFP (no. 11814460) was from 
Roche, Basel, Switserland.  
 
Transient transfections 
Hep3B cells were cultured in α-MEM supplemented with 5% fetal calf serum and antibiotics. 
For transient transfections, 8x104 cells were seeded per well of a 24-wells tissue culture 
plate. After 24h, transfections were performed using 1.0 μl FuGENE 6 (Roche) per 0.5 μg of 
total plasmid DNA, as recommended by the manufacturer. Where indicated, ATRA (Sigma, 
St. Louis, MO, USA) was added to a concentration of 1 μM, and TSA (Sigma) to the 
specified concentration, both from ethanol stocks. Cells were harvested 24h after 
transfection, lysed, and luciferase expression was assayed on a Fluoroscan Ascent FL 
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luminometer (Labsystems, Helsinki, Finland). In all experiments, the total amount of 
transfected DNA and the molar ratio of cytomegalovirus (CMV) promoter were kept 
constant. All transfections were performed at least three times and in triplicate, and the 
results proved highly reproducible. Protein expression by various fusion constructs was 
assayed by Western blotting of lysates of the transfected cells, and their expression level 
was found to be similar, confirming that transfection efficiencies were reproducible within an 
experiment. 
 
Inducible cell lines and real-time quantitative PCR 
U937-derived17 stable cell lines expressing MN1 or MN1-TEL under control of the tet-off 
system were generated essentially as described, by selecting cells transfected with 
pUHD10S plasmid bearing the cDNA of the gene of interest.18 Empty vector was used as a 
control. U937-derived cell lines were grown in RPMI 1640 supplemented with 10% fetal calf 
serum, antibiotics, 1 μg/ml tetracyclin, 0.5 μg/ml puromycin, and 100 μg/ml hygromycin. 
Gene expression (3 x 106 cells per sample) was induced by three washes in phosphate-
buffered saline (PBS) and resuspension in 15 ml tetracyclin-free medium either without 
ATRA or containing 1 μM ATRA. Total RNA was extracted 24h after induction with TRIzol 
reagent (Life Technologies, Gaithersburg, MD, USA) and further purified using RNeasy 
columns with on-column DNase treatment (Qiagen, Valencia, CA, USA). Total RNA (3 μg) 
was converted into cDNA with the M-MLV reverse transcriptase system (Invitrogen). Real-
time qPCR was performed using the cDNA equivalent of 25 ng total RNA, 330 nM of each 
primer, and 12.5 μl SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, 
USA) in a total volume of 25 μl. MEIS1 (ID3185) primer sequences were taken from the 
RTprimerDB,19 POLR2A primers were provided by E. Korpershoek, and S100A8 primer 
sequences were 5'-ATGTTGACCGAGCTGGAGAA-3' and 5'-CAGAATGAGGAACTCCTG 
GAAG-3'. Standards were prepared by fourfold serial dilutions of a pooled sample, 
consisting of equal amounts of cDNA from each of the MN1 and MN1-TEL inducible cell 
lines. Quantitative RT-PCR was performed in duplicate for each biological duplicate, on an 
ABI 7700 (Applied Biosystems), annealing at 60°C and measuring at 72°C. 
 
RESULTS 
MN1-TEL does not synergize with RAR-RXR 
Both MN1 and MN1-TEL stimulate transcription from the murine sarcoma virus long terminal 
repeat (MSV-LTR), and MN1 synergizes with RAR-RXR, p160, and p300 in the activation of 
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this promoter.2,13 The MSV-LTR comprises multiple transcription factor binding sites 
including a direct repeat 5 (DR5) ATRA-responsive element2 and several binding sites for 
ETS transcription factors.20 To determine whether MN1-TEL synergizes with RAR-RXR 
when stimulating the MSV promoter, we co-transfected human Hep3B cells with the MSV1 
reporter and an MN1-TEL expression construct. Co-transfections were carried out either in 
the absence or presence of ATRA, thus activating the endogenous RAR-RXR.21 MN1 and 
TEL cDNA expression constructs were used as controls, and expression was verified by 
Western blot analysis (Figure 1A and B). MN1 stimulated transcription of the MSV-LTR and 
synergized with RAR-RXR after addition of ATRA (Figure 1C). The transcriptional repressor 
TEL22 inhibited transcription from the MSV-LTR (Figure 1D). MN1-TEL also stimulated 
transcription,  albeit  less  efficiently  than MN1 (Figure 1E). Addition of ATRA  independently 
 
Figure 1. MN1-TEL does not synergize with RAR-RXR when stimulating the MSV-LTR. Expression constructs were 
transfected into Hep3B cells, and Western blot analysis using antibodies to MN1 (A) or TEL (B) showed comparable levels of 
MN1, MN1-TEL and TEL. The MSV1 reporter was co-transfected with the indicated amounts of MN1 (C), TEL (D), or MN1-TEL 
(E) expression construct in the absence (open symbols) or presence (closed symbols) of ATRA. Whereas MN1 synergizes with 
RAR-RXR in activation of the MSV-LTR, MN1-TEL activates transcription but does not synergize with RAR-RXR. TEL 
suppresses the MSV-LTR.  
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stimulated transcription, but the stimulation by ATRA was progressively lost in the presence 
of higher concentrations of MN1-TEL. Thus, in contrast to MN1, MN1-TEL does not 
synergize with RAR-RXR. 
To analyse whether MN1-TEL exerts a similar effect on endogenous genes as it does 
on the MSV-LTR, we determined whether MN1 and MN1-TEL differentially regulate MEIS1 
and S100A8 (MRP8), two RAR target genes involved in differentiation of hematopoietic 
cells.23,24,25 MEIS1 and S100A8 mRNA levels in U937 cells expressing MN1 or MN1-TEL 
under the control of the tet-off system were determined by real-time quantitative reverse 
transcription-polymerase chain reaction (RT-PCR) (Figure 2). The results were normalized 
using the mRNA levels of RNA polymerase 2 and presented relative to those in the 
presence of the tet-repressor. Compared to basal expression levels, both ATRA and MN1 
individually induced MEIS1 and S100A8. MN1 expression in the presence of ATRA resulted 
in a synergistic induction. U937 cells expressing MN1-TEL failed to induce MEIS1 and 
S100A8, and did not synergize with ATRA. MN1-TEL behaved similar to the control, 
showing a slight reduction of MEIS1 and S100A8 stimulation by ATRA upon tetracyclin 
release. The failure of MN1-TEL to synergize with RAR-RXR is thus a more general 
phenomenon and not restricted to the MSV-LTR. 
Figure 2. MN1-TEL does not synergize with RAR-RXR-mediated induction of MEIS1 and S100A8. Expression of MN1 or MN1-
TEL was induced by withdrawing tetracyclin (-tet) from stably transfected U937 cells in the absence or presence of ATRA. 
Subsequently, MEIS1 (A) and S100A8 (B) mRNA levels were determined by quantitative RT-PCR. ATRA and MN1 each 
induce MEIS1 and S100A8, and together work synergistically. MN1-TEL, however, does not induce these RAR target genes 
and shows no synergy with ATRA. 
MN1-TEL does not synergize with typical RAR-RXR coactivators 
Stimulation of the MSV-LTR by MN1 is enhanced in a synergistic manner by p160 and p300, 
indicating that these coactivators mediate the synergy of MN1 and RAR-RXR.2 To determine 
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whether MN1-TEL synergizes with p160 and p300, increasing amounts of RAC3 or p300 
were co-transfected with either MN1 or MN1-TEL. MN1 stimulated transcription of the MSV-
LTR, and a combination of MN1, ATRA and the p160 family member RAC3 markedly 
boosted the induction level (Figure 3A). An even stronger effect was observed when a 
combination of MN1, ATRA and p300 was used (Figure 3B). These effects were not 
recapitulated by a combination of MN1-TEL, ATRA and RAC3 (Figure 3C) or p300 (Figure 
3D), and MN1-TEL had a repressing effect on the final induction level in the presence of 
RAC3 or p300. These results demonstrated synergy when RAC3 or p300 and MN1 were 
transfected, but a clear absence thereof when combinations of RAC3 or p300 and MN1-TEL 
were used. 
Figure 3. MN1-TEL does not synergize with RAC3 or p300. The MSV1 reporter and 125 ng of MN1 (A and B) or MN1-TEL (C 
and D) expression constructs were co-transfected with the indicated amounts of RAC3 or p300 expression constructs in the 
absence (open symbols) or presence (closed symbols) of ATRA. Triangles (U) represent the effects of RAC3 or p300 in the 
absence of MN1 or MN1-TEL, and circles ({) represent the effect in the presence of MN1 or MN1-TEL. MN1 shows clear 
synergy with RAC3 and p300. Under the same conditions, MN1-TEL does not show synergy with either coactivator. 
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The activation domains in MN1-TEL do not function properly 
The MN1-TEL fusion protein contains nearly the complete MN1 sequence, including its 
transactivating domains that stimulate transcription through an interaction with p160 and 
p300.2 Deletion of the MN1 transactivating domains from MN1-TEL abolishes activation of a 
TEL-responsive reporter.13 Given that MN1-TEL does not synergize with p160 and p300, its 
transactivating domains may not function properly. We thus examined the functionality of the 
transactivating  domains (TADs) in MN1-TEL with GAL4 DNA-binding  domain (DBD)  fusion  
 
 
 
Figure 4. The transactivating domains in MN1-TEL do not respond to coactivators or histone deacetylase inhibitors. 
Expression constructs were transfected into Hep3B cells, and Western blot analysis using an antibody to MN1 showed 
comparable protein levels (A). Similar results were obtained using an antibody to GAL4 DBD (not shown). Luciferase reporters 
were co-transfected with fixed amounts of GAL4 fusion constructs and the indicated amounts of RAC3 or p300 constructs. 
GAL4-MN1 activates transcription in the presence of endogenous levels of coactivators. Whereas RAC3 (B) and p300 (C) 
enhance expression driven by GAL4-MN1 in a synergistic way (). They stimulate MN1-GAL4 to a lesser degree (), and do 
not productively stimulate GAL4-MN1-TEL ({) hybrid protein or GAL4 (U) control. Luciferase reporters were co-transfected 
with 125 ng GAL4 fusion constructs and treated with increasing concentrations of TSA (D). Addition of histone deacetylase 
inhibitors restored GAL4-MN1-TEL ({) driven transcription only to levels well below those of GAL4-MN1 (), and also below 
those of MN1-GAL4 (). The GAL4 (U) control plasmid did not activate transcription.  
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constructs and a reporter containing GAL4 upstream activator sequences. The nuclear 
localization of fusion proteins was verified using antibodies to GAL4 (not shown), and 
Western blots of lysates of transfected cells showed similar expression of the fusion proteins 
(Figure 4A). Fusions of MN1 and the GAL4-DBD showed a strong transactivation of the 
reporter, both when GAL4 was fused to the amino-terminus (GAL4-MN1) or the carboxy-
terminus (MN1-GAL4). The transcription activation by GAL4-MN1, and to a lesser extent 
MN1-GAL4, could be further stimulated by RAC3 (Figure 4B) or p300 (Figure 4C). The 
fusion of MN1-TEL and the GAL4-DBD, however, activated transcription far less efficiently 
than GAL4-MN1 and MN1-GAL4. Additionally, GAL4-MN1-TEL driven transcription was 
stimulated ineffectively by RAC3 or p300. This indicates that, in contrast to MN1, MN1-TEL 
does not interact productively with p160 or p300.  
Given that TEL represses transcription by recruiting a histone deacetylase complex,22 
it is conceivable that these deacetylases counteract coactivators bound to MN1-TEL. To test 
this hypothesis, GAL4-MN1-TEL and the reporter were transfected in the absence or 
presence of trichostatin A (TSA), a potent inhibitor of histone deacetylases.26 Addition of 
TSA further stimulated activation by GAL4-MN1, and to a lesser degree by MN1-GAL4 
(Figure 4D). Although GAL4-MN1-TEL was stimulated somewhat by TSA, its final activity 
was only one fifth of that of GAL4-MN1, and was lower than that of MN1-GAL4. TSA 
concentrations above 0.6 μM did not result in further activation of the reporter. These results 
show that histone deacetylases may inhibit MN1-TEL to some extent, but its inability to 
transactivate efficiently is the major reason for its modest transcription activation. 
  
The MN1 carboxy-terminus contributes to the transcription activity of the protein 
TEL fusion to the carboxy-terminus of MN1 eliminates its capacity to synergize with p160 
and p300. Because GAL4 fusion to the MN1 carboxy-terminus also reduced the 
responsiveness towards coactivators, this may be a general phenomenon. To determine 
whether fusion of an unrelated protein domain could recapitulate this effect, we compared 
the transcription stimulation of the MSV-LTR by amino-terminal (GFP-MN1) and carboxy-
terminal (MN1-GFP) fusions of MN1 with green fluorescent protein (GFP) (Figure 5). GFP 
alone was transfected as control. Western blots of lysates of transfected cells revealed that 
the fusions were expressed at a similar level (Figure 5A). Although both GFP-MN1 and 
MN1-GFP were able to stimulate the MSV-LTR and synergized with RAR-RXR, the carboxy-
terminal fusion was far less active than the amino-terminal fusion (Figure 5B). Given that the 
carboxy-terminal fusion of GFP, GAL4 or TEL moieties all reduced MN1 performance, the 
carboxy-terminus contributes to its transcription activity. TEL fusion nonetheless appears to 
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have a more severe effect than the fusion of GAL4, as GAL4-MN1-TEL was less active than 
GAL4-MN1 and MN1-GAL4. 
Figure 5. The MN1 carboxy-terminus contributes to its transcription-activating function. The MSV4 reporter was co-transfected 
with GFP alone or with GFP fused to the MN1 amino-terminus (GFP-MN1) or carboxy-terminus (MN1-GFP). Fusion constructs 
were transfected into Hep3B cells, and Western blot analysis of cell lysates with a GFP antibody showed comparable protein 
levels (A). Whereas GFP-MN1 efficiently stimulated transcription from the MSV-LTR, MN1-GFP was a markedly less potent 
activator (B). GFP alone (GFP-C3 and GFP-N3) did not stimulate transcription from the MSV-LTR. 
MN1-TEL has a dual effect on transcription and acts as a dominant-negative mutant of MN1 
Mutation of the TEL DBD abolishes the ability of MN1-TEL to activate the MSV-LTR, 
showing that this domain enables MN1-TEL to activate transcription through TEL-responsive 
elements.13 On the other hand, MN1, RAR-RXR, p160 and p300 synergistically stimulate the 
MSV-LTR, whereas MN1-TEL does not. Therefore, the weak transactivation of the MSV-
LTR by MN1-TEL compared to MN1 may be a combination of activation through TEL-
responsive elements and repression through ATRA-responsive elements. To discriminate 
between these different modes of action, fully functional MN1-TEL was compared with a 
point mutant (MN1-TELDBDm) unable to bind TEL-responsive elements.13 Whereas MN1-
TEL may affect both TEL and RAR-responsive elements, MN1-TELDBDm is predicted to act 
only on RAR-responsive elements. The MSV-LTR was stimulated strongly by MN1, 
moderately by MN1-TEL, but was repressed by MN1-TELDBDm (Figure 6A). Hence, MN1-
TEL has both a stimulatory and a repressing effect on transcription. TEL strongly repressed 
transcription. Because the DBD mutant of TEL locates to the cytoplasm instead of the 
nucleus,13 it was not included in these experiments.
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Figure 6. MN1-TEL has a dual effect on transcription from the MSV-LTR (A), and acts as a dominant-negative mutant (B). The 
MSV1 reporter was co-transfected with various expression constructs in the absence or presence of ATRA (A). Whereas MN1 
and MN1-TEL stimulate reporter activity, MN1-TELDBDm and TEL inhibit transcription compared to the control. The MSV45 
reporter was co-transfected with the indicated amounts of MN1-TELDBDm expression construct in the absence ({) or 
presence () of 125 ng MN1 expression construct and in the absence (open symbols) or presence (closed symbols) of ATRA 
(B). MN1-TELDBDm inhibits reporter activity in a dose-dependent manner under all conditions tested. 
Several leukemia-associated fusion proteins affect the function of both partner proteins 
encoded by the remaining normal alleles.6,7 To determine whether MN1-TEL interferes with 
MN1 function, a constant amount of MN1 construct was co-transfected with increasing 
amounts of MN1-TELDBDm, thus avoiding the stimulatory effect of MN1-TEL on TEL-
responsive elements. In the absence of MN1, MN1-TELDBDm caused a dose-dependent 
repression of reporter activity (Figure 6B). MN1 and ATRA activated the MSV-LTR alone 
and in combination, but co-transfection of small amounts of MN1-TELDBDm efficiently 
repressed this activation. An equimolar ratio of MN1-TELDBDm and MN1 (125 ng), the 
situation that most likely mimics their expression in t(12;22)(p13;q11), activated the reporter 
only slightly above basal level and significantly diminished the stimulatory effect of ATRA. 
Higher amounts of MN1-TELDBDm did not further decrease activity. These results show 
that MN1-TELDBDm inhibits the normal activation of the MSV-LTR by MN1 and RAR-RXR, 
and indicate that MN1-TEL acts as a dominant-negative inhibitor of MN1 on promoters 
without TEL-responsive elements.  
 
DISCUSSION 
We have studied the properties of the MN1-TEL fusion protein, the product of 
t(12;22,p13;q11) associated with AML. This fusion protein was shown to activate TEL-
responsive transcription, whereas TEL itself is a repressor.13,22 Now, we have compared the 
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properties of the MN1 and MN1-TEL with respect to RAR-RXR-mediated transcription, 
crucial for the proliferation and differentiation of blood cell lineages. Whereas MN1 functions 
as a coactivator for RAR-RXR, MN1-TEL inhibits RAR-RXR-mediated transcription. 
Furthermore, MN1-TEL seemed to act as a dominant-negative inhibitor of MN1, as it 
severely hampered the activation of RAR-RXR by MN1.  
Using MN1-TELDBDm, a mutant that cannot bind DNA by itself, we have been able to 
distinguish between direct and indirect effects of MN1-TEL on promoters. MN1-TEL 
enhances transcription from TEL-responsive elements, by directly stimulating transcription, 
by competing with endogenous repressors such as TEL itself, or both. MN1-TEL may thus 
activate transcription of genes that are normally repressed by TEL. In our transfection 
experiments too, MN1-TEL stimulated transcription from the MSV-LTR. Unlike MN1, 
however, MN1-TEL did not synergize with RAR-RXR, p160 or p300, nor did it stimulate 
expression of the endogenous RAR-RXR target genes MEIS1 and S100A8. MN1-
TELDBDm, which only affects RAR-RXR function, strongly repressed transcription. These 
results show that MN1-TEL has at least two distinct and opposing effects on the MSV-LTR, 
a stimulatory activity dependent on direct recognition of responsive elements, and a 
repressive activity independent of direct DNA binding. MN1-TELDBDm not only repressed 
RAR-mediated transcription in the absence of MN1, but also diminished the stimulatory 
effect of ATRA when expressed at a concentration equimolar to that of MN1. This shows 
that MN1-TEL acts as a dominant-negative inhibitor of RAR and MN1 when eliminating the 
contribution of TEL-responsive elements. 
ATRA did not prevent MN1-TEL from repressing RAR-RXR-mediated transcription. 
This suggests that MN1-TEL functions differently from the classical corepressor complexes 
containing NCoR and SMRT, which bind only in the absence of ATRA.27 In t(15;17) acute 
promyelocytic leukemia, the PML-RARα fusion protein binds corepressor complexes more 
tightly than RAR alone. Corepressor complexes can be released from PML-RARα with 
pharmacological doses of ATRA, or can be counteracted by histone deacetylase inhibitors in 
the case of the PLZF-RAR fusion.12 Because TEL is a transcriptional repressor that recruits 
corepressors and histone deacetylases,22 MN1-TEL could recruit such corepressor 
complexes to RAR-RXR. Nonetheless, even pharmacological doses of ATRA only 
marginally relieved the repression in our transfection assays and experiments with histone 
deacetylase inhibitors showed that tight or irreversible binding of corepressor complexes is 
not the cause of MN1-TEL´s inhibitory activity. Instead, MN1-TEL appears to block RAR-
RXR-mediated transcription by preventing the productive recruitment of coactivator 
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complexes. Accordingly, MN1-TEL inhibited the capacity of p160 and p300 to stimulate the 
MSV-LTR. 
The fusion of amino-terminal TADs to the DBD of ETS family members is not 
restricted to leukemias. The EWS-FLI fusion protein that causes Ewing sarcoma bears 
very similar characteristics.28 This fusion, too, may have both transcription-stimulating and 
transcription-repressing effects.29 Future studies may thus reveal the importance of the 
disruption of gene expression by this type of fusions in a wide variety of tumors. Whereas 
MN1-TEL was shown to activate TEL-responsive elements,13 we now reveal that the fusion 
protein is also a dominant-negative suppressor of MN1 and RAR-RXR. ATRA or histone 
deacetylase inhibitors are unable to relieve this effect. Thus, a possible treatment of t(12;22) 
leukemia will likely require a novel combined strategy, aiming to reduce the stimulation of 
TEL-responsive promoters and simultaneously overcome the inhibition of RAR-RXR.  
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ABSTRACT 
The oncoprotein meningioma 1 (MN1) is overexpressed in several subtypes of acute 
myeloid leukemia (AML) and overexpression was associated with a poor reponse to 
chemotherapy. MN1 is a cofactor of retinoic acid receptor/retinoid-x-receptor (RAR/RXR)-
mediated transcription and this study identified genes in the promonocytic cell line U937 that 
were regulated by MN1. We found that MN1 can both stimulate and inhibit transcription. 
Combining MN1 expression with all-trans retinoic acid (ATRA), the ligand of the RAR/RXR 
dimer, showed that MN1 could both enhance and repress ATRA effects. Many of the 
identified genes are key players in hematopoiesis and leukemogenesis (e.g. MEIS1 and 
BMI1). Another interesting target is DHRS9. DHRS9 is involved in the synthesis of ATRA 
from vitamin A. MN1 inhibited DHRS9 expression and completely abolished its induction by 
ATRA. MN1 is also the target of a rare AML-causing translocation encoding the MN1-TEL 
protein. MN1-TEL induces expression of only a few genes and its most pronounced effect is 
inhibition of a large group of ATRA-induced genes including DHRS9. In conclusion, both 
MN1 and MN1TEL interfere with the ATRA pathway and this might explain the differentiation 
block in leukemias in which these genes are involved.  
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INTRODUCTION 
Recently, meningioma 1 (MN1) was identified as an important player in myeloid 
leukemogenesis. Overexpression of MN1 is observed in AML specified by the chromosomal 
aberration inv (16),1,2 in some AMLs overexpressing the transcription factor ecotropic viral 
integration (EVI1),2 and in some adult AMLs with normal karyotype.3 A high level of MN1 
expression is a predictor of poor prognosis in these latter patients and recently it has been 
shown that low MN1 expression can be used as a marker to predict sensitivity to all-trans 
retinoic acid (ATRA) treatment.4 By retroviral insertional mutagenesis Slape et al have 
identified Mn1 as an second hit that co-operates with the NUP98-HOXD13 fusion in causing 
myelodysplastic syndrome (MDS) or AML in mice.5 
However, the involvement of MN1 in AML has already been known much longer. In 
1995, we cloned the MN1 gene6 and soon thereafter it was identified as a target gene of the 
recurrent t (12;22) found in AML patients.7 As a result, almost all of the coding sequence of 
MN1 is fused to two-thirds of the coding sequence of TEL (ETV6). MN1 appeared to act as a 
transcriptional coactivator of retinoic acid receptor/retinoid-x-receptor (RAR/RXR),8 but 
recent research4 and also this paper show that MN1 has a dual function. Depending on the 
type of RAR/RXR target gene, MN1 can either stimulate or repress transcription, with or 
without collaboration with ATRA. TEL, the other fusion partner of the MN1-TEL fusion, is a 
member of the E26 transformation-specific (ETS) family of transcription factors and 
represses transcription by binding to ETS elements in promoters.9,10 MN1-TEL is thought to 
act as a novel transcription factor causing transcription deregulation of genes normally 
repressed by TEL.11 Recently, we have shown that MN1-TEL has an additional 
characteristic important for its pathogenic properties. By the use of a point mutant that 
cannot bind to ETS elements, we have shown that MN1-TEL represses RAR/RXR-mediated 
transcription.12 
Bone marrow (BM) transduction/transplantation experiments in mice have shown that 
both MN1-TEL and MN1 are hematopoietic oncogenes. MN1-TEL induces AML within three 
months after BM transplantation.13 MN1 overexpression in mouse BM causes 
myeloproliferative disease, a condition slightly different from AML. Mice died within 5-8 
weeks after receiving transplants. Combined expression in mouse BM of MN1 and CBFb-
MYH11, the product of inv (16), resulted in rapid development of AML strongly suggesting 
that overexpression of MN1 is indeed an important step in the development of inv (16) 
AML.14 Heuser et al have also shown that MN1 is a powerful oncogene in mouse BM and 
based on the rapid development of disease suggested that overexpression of MN1 alone 
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might be sufficient to cause AML in mice.4 In agreement with the results of the in vivo 
studies, Mn1 expression is found in the granulocytes-monocytes progenitor (GMP) fraction 
of hematopoietic cells in mice.14 Wagner et al detected MN1 in the slow dividing, primitive 
fraction of hematopoietic stem cells obtained from human umbilical cord blood .15 
Although all these reports document the importance of MN1 in different forms of 
leukemia, little is known about the downstream targets of MN1 expression, which severely 
hampers our understanding of its involvement in leukemogenic transformation. This study 
aimed to identify genes regulated by MN1 and MN1-TEL by expression profiling in the 
promonocytic cell line U93716 and the effect of expression of these genes in absence or 
presence of ATRA. The U937 cell line has a progenitor phenotype with features close to the 
granulocytes-monocytes progenitor (GMP) stage of hematopoiesis. The cell line has 
extensively been employed to study myeloid differentiation induced by agents such as ATRA 
and DMSO. We show that MN1, directly or indirectly, affects expression of many genes that 
play a role in hematopoiesis. Moreover, MN1 can both inhibit and stimulate expression of 
genes induced by RAR/RXR. MN1-TEL inhibits some genes that are also inhibited by MN1 
but its greatest effect is in inhibiting RAR/RXR-induced genes. 
 
MATERIALS AND METHODS 
Origin of cell lines, cell culture, induction of gene expression and Western blotting 
The cell lines were based on U937T17 (derived from cell line U93718) and inducibly express 
MN1 or MN1-TEL using the tet-off system. They were generated as described previously,17 
by selecting cells transfected with pUHD10S plasmid, containing complementary DNA 
(cDNA) of the gene of interest. The cell lines will be referred to as the MN1, MN1-TEL, and 
UHD cell line. The UHD cell line is transfected with empty expression plasmid. The cell lines 
were cultured in RPMI 1640 medium supplemented with 10% fetal calf serum, 1000 U/ml 
penicillin, 1 mg/l streptomycin, 1 ug/ml tetracyclin, 0.5 μg/ml puromycin, and 100 μg/ml 
hygromycin. Gene expression was induced by withdrawal of tetracyclin. Two separate 
induction experiments were performed a few weeks apart, to serve as biological duplicates. 
For each time point (0, 16, 20, 24, 48, 72h) 3x106 cells of each cell line were exposed to four 
different medium conditions: absence of tetracyclin (-tet: induction of target gene); presence 
of tetracyclin (+tet: no induction of target gene); both in absence or presence of 1 μM all-
trans retinoic acid (ATRA, Sigma-Aldrich, Zwijdrecht, The Netherlands). The cells were 
harvested and washed in PBS. Dry cell pellets were stored at -80°C corresponding to a 1-ml 
portion (to be used later for RNA extraction) and two 100-µl portions of resuspended cells 
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(each to be used for Western blot analysis; enough for loading of 4 gels). The antibody 
against the N-terminal part of MN1 (2F2) has been described.11 The antibody against BMI1 
was F6 (Upstate, USA), for YES1 #610375 (BD Biosciences, Breda, the Netherlands) and 
ID1 SC-488 (Santa Cruz, CA, USA). The Western blots were incubated with horseradish 
peroxidase-labeled secondary antibodies (P044701, DAKO, Glostrup, Denmark) and IRDye 
680 conjugated anti-mouse (LI-COR, Lincoln, NE, USA). The latter was used to scan and 
quantify the protein signals on an Odyssey infrared imaging system (LI-COR). Protein levels 
were calculated relative to the amount of β-tubulin present in the sample. The β-tubulin 
antibody was from hybridoma E7. 
 
RNA extraction and amplification of RNA 
Total RNA was extracted from the frozen cell pellets by TRIzol reagent (Invitrogen, 
Carlsbad, CA, USA) and further purified using RNeasy columns with on-column DNase 
treatment (Qiagen, Hilden, Germany). The concentration and purity of the RNA was 
measured on a NanoDrop ND-1000 UV-VIS spectrophotometer and the quality of the RNA 
was checked using the Agilent 2100 BioAnalyzer with an RNA 6000 Nano LabChip. Three 
microgram of total RNA was used for linear amplification using the Superscript III RNA 
Amplification kit (Invitrogen). The concentration and purity of the amplified RNA were 
measured on a NanoDrop instrument and the quality of the amplified RNA was checked by 
agarose gel electrophoresis.  
 
Gene expression profiling with microarrays 
Spotted oligo microarrays with the Operon V3.0 library (35K Human, 
http://omad.operon.com/humanV3) were obtained from the Netherlands Cancer Institute 
Central Microarray Facility (NKI-CMF). Protocols for sample preparation were taken from the 
NKI-CMF website (http://microarrays.nki.nl). In short, 1 µg of amplified RNA was labeled 
using the ULSTM-Cy3/5 aRNA fluorescent labeling kit (Kreatech, Amsterdam, The 
Netherlands), and was used for hybridization on the same day. The labeling efficiency was 
checked on a NanoDrop instrument. The labeled aRNA was fragmented (RNA 
Fragmentation Reagents, Ambion, Austen, TX, USA) and mixed with blocking solution 
containing Poly d(A), Cot-1 DNA, and yeast t-RNA (GE Healthcare, Zeist, the Netherlands 
and Roche, Basel, Switserland). The arrays were hybridized overnight at 42°C on a Tecan 
HS4800 hybridization station, according to the M016 protocol developed by the Erasmus 
Center for Biomics (http://www.biomics.nl). Samples were co-hybridized according to a 
multifactorial design scheme as shown in supplementary Figure 1, with each combination of 
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samples in a straight and dye-swap fashion for each biological duplicate. The hybridized 
arrays were scanned on a Perkin Elmer ScanArray Express HT instrument. The measured 
fluorescence intensities were determined using ImaGene software version 6.0 
(Biodiscovery, El Segundo, CA, USA).  
 
Microarray data analysis 
The ImaGene data were uploaded into the CMF database (CMFdb, http://cmfdb.nki.nl) and 
normalized using the lowess subarray method (default settings, except for background 
correction). No background correction was applied, as overall background was very low and 
even (mean background 311±75 for Cy5 and 446±173 for Cy3, averaged over all arrays, 
versus a mean signal of 2376±592 for Cy5 and 2927±650 for Cy3, corresponding to 15%). 
Background correction would result in negative intensities for low-intensity spots, indicating 
that any background signal was not superimposed on the spots but rather present next to 
the spots. This was also indicated by the appearance of the blank spotting controls, which 
showed up as holes in the background. The normalized data were downloaded from the 
CMF database and further analyzed in R using limmaGUI.19,20,21 The data were analyzed 
with each time point separately as well as combined for each condition. Linear 
parametrizations were created including each of the comparisons of interest. Each separate 
comparison at each time point is composed of four arrays (supplementary Figure 1). In 
addition, each biological duplicate was analyzed separately to assess the biological 
variability. Gene lists were ranked based on the B-statistic (log odds of differential 
expression); P values are also reported. Unsupervised hierarchical clustering was performed 
using Spotfire DecisionSite 9.0 (Tibco, Somerville, MA, USA) with default settings. In the 
cluster analysis, log2 ratios at the individual time points with B values <1 were set to 0 when 
the accompanying B value of the combined time points of a certain reporter was also <1. 
 
Reverse transcription-polymerase chain reaction and real-time quantitative polymerase 
chain reaction 
Total RNA was converted into cDNA with the M-MLV reverse transcriptase system 
(Invitrogen), using 3 µg of total RNA and 750 ng of random primer (Invitrogen). Real-time 
quantitative polymerase chain reaction (qPCR) was performed using the amount of cDNA 
equivalent to 25 ng total RNA in a total volume of 25 µl containing 330 nM of primers each 
and 12.5 µl Power SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, 
USA). The primers used for qPCR for MEIS1 and YES1 were taken from the RTprimerDB 
database (http://medgen.ugent.be/rtprimerdb/)22 (IDs indicated). The primer sets for NDRG1 
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and POLR2A were obtained from fellow researchers. Whenever possible, intron-spanning 
primers were used. The sequences are shown in supplementary Table 1. Expression levels 
were determined relative to a standard curve for which standards were prepared by making 
4-fold serial dilutions of a pooled sample. For each biological duplicate, qPCR was 
performed in duplicate and thus the results are represented as the average and standard 
deviation of four measurements. PCR reactions and real-time fluorescence measurements 
were done on an ABI 7700 Sequence Detection System (Applied Biosystems; annealing: 
60°C, measurement: 72°C). The qPCR results were normalized using the messenger RNA 
levels of RNA polymerase 2A (POLR2A). The results are presented relative to the 
expression levels in the presence of tetracyclin for each cell line. 
 
Fluorescent in situ hybridization 
The U937 cell line cultures were treated for 30 min with colcemid and fixed with 
ethanol/acetic acid (3:1). Nuclei were spotted onto slides and incubated with the 
nicktranslation-labelled plasmids (Bio-nicktranslation kit, Invitrogen) or BAC probes 
(Random Prime labellings system, Invitrogen). The amount of plasmid probes was 5 ng per 
slide and that of BAC probes 50-75 ng per slide. BAC clones were selected from the UCSC 
genome browser (UC Santa Cruz) and purchased from BACPAC Resources (Oakland, 
USA). FISH slides were analysed with an Axioplan 2 Imaging microscope (Zeiss, Göttingen, 
Germany) and images were captured using Isis software (MetaSystems, Altlussheim, 
Germany).  
 
RESULTS 
Induction of expression of MN1 and MN1-TEL in U937T cells 
Expression of MN1 and MN1-TEL was induced in U937T cells by tetracyclin (tet) withdrawal 
for 16, 20, 24, 40, 48 and 72h. A Western blot visualizing the induction of MN1 or MN1-TEL 
protein is shown in Figure 1A. In the presence of tetracyclin (0h) there was no detectable 
expression of either protein but expression gradually increased from 16h onward, as 
indicated by the appearance of single bands of the correct molecular weight. At induction 
times exceeding 24h, additional bands appeared, possibly representing breakdown products 
of MN1 and MN1-TEL. The blots were stained with Coomassie blue to verify equal loading 
of the lanes (not shown). In parallel, the messenger RNA expression levels were examined 
by qPCR analysis as shown in Figure 1B. Both cell lines contained a low, but clearly 
detectable level of MN1 or MN1-TEL transcripts even in the presence of tetracyclin, whereas 
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these products were not detected in the other inducible cell lines or the control cell line UHD. 
Tetracyclin release resulted in a 10-fold increase in transcript levels within 16-24h, 
increasing further with longer induction times. Interestingly, the presence of ATRA during 
tetracyclin release led to elevated expression levels in both cases (25-30 fold for MN1 and 
30-40 fold for MN1-TEL at 16-24h). In pilot experiments, a similar effect of ATRA on 
induction of MN1 and MN1-TEL protein was observed (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Induction of MN1 and MN1-TEL expression in U937T cells. The expression of MN1 and MN1-TEL was induced by 
withdrawal of tetracyclin for 16, 20, 24, 40, 48, and 72h, after which samples were collected for Western blotting and real-time 
qPCR. The cells collected at 0h were grown in the presence of tetracyclin and without the addition of ATRA. (A) Assessment of 
the expression of MN1 or MN1-TEL by Western blot, using an antibody raised against the N-terminal part of MN1 (2F2). (B) 
Assessment of the levels of MN1 and MN1-TEL messenger RNA expression by qPCR. The qPCR results were normalized, 
using the messenger RNA levels of POLR2A, and are presented relative to those in the presence of only the tet-repressor. 
(white squares (□): +tet and +ATRA; black circles (●): -tet, no ATRA; grey triangles (▲): -tet and +ATRA). 
Alterations in gene expression mediated by MN1 and MN1-TEL and ATRA in U937 cells 
To examine the effects of MN1 and MN1-TEL on the expression of genes and the influence 
of ATRA on these effects, oligonucleotide microarray analysis was performed following the 
scheme presented in supplementary Figure 1. Only samples taken after 16, 20, and 24h of 
induction were used for microarray analysis because there is a clear expression of the 
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genes at these time points and we want to detect early effects and not focus on possible 
secondary effects of expression of MN1 and MN1-TEL. For assessment of the effect of 
ATRA, only samples induced for 16 and 20h were used. Each combination of samples was 
hybridized in a straight and dye-swap fashion for two biological duplicates, adding up to four 
arrays per combination. Both raw and normalized data have been deposited in NCBI's Gene 
Expression Omnibus23 and are accessible through GEO Series accession number 
GSE11441 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE11441). 
On average, 29129±2699 unflagged spots were quantified per array (out of 37632 on 
each of the 100 arrays in total). We identified 4468 spots showing statistically significant 
differences (B values of 1 or higher when all the time points (16, 20, 24h) were combined for 
analysis) in mean expression levels under the conditions selected for supplementary Figure 
3. The unsupervised hierarchical clustering (supplementary Figure 3) of these signals shows 
that time points of each different treatment cluster together, and that all the ATRA effects 
cluster together. It is obvious that addition of ATRA results in higher expression levels than 
those observed with MN1 or MN1-TEL expression alone. When analyzing the expression 
data, we realized that MN1, although present on the array, did not show up as one of the 
differentially expressed genes. A closer inspection of the signal showed that it was 
consistently low for both Cy5 and Cy3 in all arrays (514±114 and 516±115, respectively), 
suggesting that the oligo for MN1 most probably did not hybridize very well with the labeled 
amplified RNA. 
To assess the reproducibility between biological duplicates for the genes affected by 
MN1, MN1-TEL and ATRA, correlation plots for the resulting reporter sets are shown in 
supplementary Figure 2. For these, the microarrays were analyzed for each biological 
replicate separately. Correlation coefficients (R2) were obtained by linear regression of the 
log2 ratios in each biological duplicate plotted against each other. This resulted in correlation 
coefficients between the log2 ratios in each biological duplicate of 0.900 for genes affected 
by MN1, 0.843 for genes affected by MN1-TEL and 0.938 for genes affected by ATRA alone 
(all time points combined), indicating very similar behavior in both experiments. Even though 
most of the log2 ratios found were relatively low, just above 0.2 (absolute value), with 
maximal values up to 1.0 for MN1 and up to 0.6 for MN1-TEL, these high correlation 
coefficients give us confidence that even low log2 ratios are meaningful. 
 
Genes affected by MN1, MN1-TEL and ATRA 
A list was assembled consisting of all genes influenced by MN1 or MN1-TEL expression with 
a cutoff of log2 ratios >0.2 or <-0.2 (n=85) supplemented with 60 genes whose expression 
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Figure 2. A selected set of 165 reporters cluster together for subsequent time points of MN1 or MN1-TEL expression and/or 
ATRA treatment in U937 cells. The log2 ratios of changes in expression between the conditions indicated were subjected to 
unsupervised hierarchical clustering. The conditions tested on the different arrays are indicated at the bottom with numbers 
(16, 20 or 24) and letter codes A-F. Numbers correspond to hours after induction of MN1 or MN1-TEL. The table underneath 
the figure explains the letter codes (+: presence of MN1 or MN1-TEL or ATRA; -: absence of MN1 or MN1-TEL or ATRA). For 
instance, A ↔ B means that a sample with induced MN1-TEL expression is hybridized against a sample without MN1-TEL 
expression. Blue color represents stimulation and yellow repression. 
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Figure 3. Genes regulated by MN1 and MN1-TEL. The clustering analysis was performed with expression data from the three 
different time points (16, 20 and 24 hours after induction of MN1 or MN1-TEL). All genes listed show a significant change in 
expression (log2 ratio ≤0.2 or ≥0.2) for all three separate time points. The listed log2 ratios together with the P value are 
calculated from combined time points. Genes indicated in bold are used for qPCR analyses (Fig 5 and 6 and supplementary 
Figure 5). Blue represents stimulation and yellow repression. 
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was most significantly affected by ATRA treatment. A cutoff value of 0.2 corresponds to a 
15% difference in expression between conditions. The list was supplemented with a set of 
genes that do not meet the above criteria, but of which the expression is influenced by 
ATRA treatment in combination with MN1 or MN1-TEL (n=28). Genes were removed from 
the lists if a similar significant change in expression was observed by tetracyclin release of 
the control cell line as that invoked by MN1 or MN1-TEL expression. The final list, consisting 
of 165 reporters comprising 155 different genes, was used for cluster analysis. The results 
are visualized in Figure 2 and it is clear that there is clustering of the different time points of 
each different treatment and all the ATRA effects. Supplementary Table 2 contains all data 
including the extended gene names, Genbank accession numbers, combined log2 ratios, B 
values and P values. Figure 3 displays the genes that are regulated by MN1 or MN1-TEL 
(n=85). The different time points are represented by cluster analysis and accompanied by 
the combined log2 ratios and P values. It is obvious that MN1 expression affects many more 
genes than MN1-TEL expression. About 50% of the genes that are repressed by MN1 are 
also repressed by MN1-TEL (yellow), whereas MN1-TEL has no effect on most genes that 
are induced by MN1 (blue). This suggests that the transcription-stimulating properties of 
MN1 are lost in the MN1-TEL protein. In addition, we identified a small set of genes that is 
influenced by MN1-TEL and that does not respond to MN1. 
Figure 4 summarizes those genes that are differentially affected in the combination of MN1 
or MN1-TEL with ATRA when compared with either treatment alone. Clearly the differentials 
in expression in the presence of ATRA are in general larger than those of MN1 and MN1-
TEL. An explanation for this striking difference might be that, in contrast to the effect of 
ATRA, which impacts all cells, only part of the cells are effectively expressing the gene of 
interest when released from tetracyclin inhibition. Limitation of expression to a sub 
population of the culture is not uncommon in the expression system used in this study (Dr. 
Judith Boer, Leiden University Medical Center, personal communication, 2006). Synergistic 
induction or repression of transcription is indicated in Figure 4 with a black or grey 
background, respectively. We concluded there was synergy when the observed effect of 
ATRA in combination with MN1 or MN1-TEL was higher or lower than that expected from 
the sum of the observed separate effects (cutoff value log2 > 0.2). Figure 4A lists genes 
induced by ATRA. A small subset of ATRA-stimulated genes is synergistically stimulated by 
MN1 (indicated with a black box). These include the leukemogenic oncogene MEIS1. MN1-
TEL either has no effect on these genes or inhibits the ATRA effect. Figure 4A also shows 
that expression of MN1 results in a synergistic inhibition of gene expression of about half of 
the ATRA-stimulated genes (indicated by the grey background) and an even larger  group of 
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genes is repressed by MN1-TEL. For instance, the induction of DHRS9, an enzyme involved 
in ATRA synthesis,24 by ATRA is completely annulled by both MN1 and MN1-TEL. The 
integrin family member ITGAM is the only gene whose expression is synergistically induced 
by MN1-TEL and ATRA. Figure 4B shows that MN1 or MN1-TEL can sometimes revert gene 
inhibition by ATRA. Most notable is the high induction of BMI1 by MN1, which is even further 
stimulated in the presence of ATRA. Figure 4C shows a selection of genes of which 
expression is not affected by ATRA alone, but that are affected by the combination of MN1 
or MN1-TEL and ATRA. Of special interest are the genes SPAG6, DNAJC1 and COMMD3 
that, together with BMI1 (Figure 4B), are similarly regulated by ATRA and MN1. These 
genes are all located on chromosome 10p12.31. None of these genes is upregulated in the 
control cell line or in the MN1-TEL cell line. BMI1 is a known common viral integration site in 
for B-cell lymphomas in mice25 and the possibility existed that integration of the MN1 
expression plasmid in this region of the genome might have caused an artificial upregulation 
of the entire group of genes. We therefore performed fluorescent insitu hybridisation on 
metaphase chromosomes using a plasmid containing the MN1 cDNA and a 10p12.31 
specific BAC clone as probes. No integrations of the plasmid were detected in the 10p12.31 
region of the genome (Supplementary Figure 4). Thus, we conclude that the stimulation of 
these genes by MN1 is genuine. In conclusion, Figure 4 shows that both MN1 and MN1-TEL 
have considerable effects on RAR/RXR-mediated transcription.  
 
Validation and extension of microarray results by qPCR analysis 
To validate the microarray results, we selected a number of genes for qPCR evaluation. 
Included were genes exhibiting interesting expression differences between MN1 and MN1-
TEL or upon ATRA addition. The results were compared to the corresponding microarray 
data. This comparison is visually represented by heat maps in Figure 5. This shows that the 
qPCR results are very similar to those obtained by the microarray analysis, as indicated by 
the overall similarity in patterning of the heat maps. Notably, there is a 2-fold difference in 
magnitude in the color scale, which runs from –0.8 to 0.8 for the microarray data and from –
1.5 to 1.5 for the qPCR data. This indicates that the microarray data give an ~2-fold 
underestimation of the change in gene expression. RNA samples were not only collected for 
the time points used for microarray analysis, but also at 0h and at longer induction times of 
40, 48, and 72h. Therefore, we were able to follow the behavior of interesting candidate 
genes beyond the limited 24 hour interval of the microarray analysis, and generally, the 
magnitude of the observed effects continued to increase. Some of the results for S100A8, 
NDRG1, DHRS9, BMI1, YES1 and ID1 are highlighted in Figure 6, and the  full  data  set  for  
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Figure 4. ATRA-regulated genes and the influence of MN1 and MN1-TEL on their expression. Log2 ratios of changes in 
expression are indicated for ATRA treatment, MN1 or MN1-TEL induction, and the combination of MN1 or MN1-TEL induction 
and ATRA treatment. Black or grey background represents a synergistic induction or repression of ATRA effects (cut off value 
log2 ratio 0.2). (A) ATRA-stimulated genes. (B) ATRA-repressed genes. (C) Genes not influenced by ATRA treatment alone, 
but affected by the combination of ATRA and MN1 or MN1-TEL. Gene names and Genbank number are shown in 
supplementary Table 2 (available at http://carcin.oxfordjournals.org). Genes indicated in bold are used for qPCR analyses 
(Figures 5 and 6 and supplementary Figure 5). 
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Figure 5. Comparison of microarray and qPCR results. The RNA samples used for microarray analysis were also used for 
qPCR analysis. Expression levels were determined relative to a standard curve and used without further normalization. The 
results were compared to the corresponding microarray data by expressing the qPCR data as mean log2 ratios. (A) 
Unsupervised hierarchical clustering of the microarray data (log2 ratios) for the genes selected for qPCR validation. The 
conditions tested on the different arrays are indicated at the bottom with numbers (16, 20 or 24) and letter codes A-F. A 
detailed explanation is given in legend of Figure 2. (B) Heat map of the qPCR data in the order corresponding to the 
unsupervised hierarchical clustering of the microarray data. Blue color represents stimulation and yellow repression. 
these genes and for MEIS1, CDKN2C, ITGAM, ID1, and IGFBP6 is shown in supplementary 
Figure 5. Figure 6A shows that S100A8 expression after 72h is 100-fold increased by ATRA, 
600-fold by MN1 and 1800-fold by the combination of the two. On the contrary, MN1-TEL 
expression seems to negatively influence the ATRA effect (supplementary Figure 5B). ATRA 
also stimulates NDRG1 expression that is completely abolished by MN1-TEL (Figure 6B). 
Both MN1 and MN1-TEL abolish the 8 to 10-fold induction by ATRA of DHRS9 expression 
(Figures 6C and 6D). Figure 6E shows that MN1 expression causes a considerable increase 
in BMI1 levels, regardless of the presence of ATRA. YES1 is a gene that is repressed by the 
addition of ATRA (supplementary Figure 5I). Upon MN1 and MN1-TEL expression there is 
an increase in YES1 expression that is similar in absence or presence of ATRA. The 
increase is most pronounced upon MN1-TEL expression at time points beyond 24h (Figure 
6F). ID1 expression is decreased upon MN1 induction, whereas the presence of ATRA 
stimulates (Figure 6G). Figure 6H shows the validation of the observed effects on the protein 
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level for BMI1, ID1 and YES1. Together, the qPCR data and Western blots confirm our 
microarray observations and show that many of the effects continue after the 24h time point 
that was the end point for the microarray experiments. 
 
 
 
Figure 6. Time dependence of effects of MN1 and MN1-TEL on expression levels and validation of qPCR results by Western 
blot. MN1 and MN1-TEL expression were induced by tetracyclin release in the presence or absence of ATRA. In parallel with 
the RNA samples used for the microarray hybridizations (16, 20, and 24h), samples were also collected and analyzed with 
qPCR for time point 0h and longer incubation times of 40, 48, and 72h. The qPCR results were normalized, using the 
messengerRNA levels of POLR2A, and are presented relative to those in the presence of only the tet-repressor: white squares 
(□): +tet & +ATRA; black circles (●): -tet, no ATRA; grey triangles (▲): -tet and +ATRA. The results are shown only for the cell 
line indicated in the upper left corner of each graph. (A) S100A8 (MN1 cell line). (B) NDRG1 (MN1-TEL cell line). (C) DHRS9 
(MN1 cell line). (D) DHRS9 (MN1-TEL cell line). (E) BMI1 (MN1 cell line). (F) YES1 (MN1-TEL cell line). Three of the target 
genes (BMI1, ID1 and YES1) were analysed on the protein level. Time points after induction of MN1 or MN1-TEL expression 
and treatments were chosen (BMI1, 24 h; YES1, 48 h and ID1 72 h) and protein levels detected and quantified. Protein 
expression levels (indicated with a ratio above the signal) were calculated relative to the amount of β-tubulin present in the 
sample and the not-induced sample. tub, tubulin. 
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DISCUSSION 
In this study, we have identified genes regulated by the oncoprotein MN1 and the fusion 
protein MN1-TEL in U937T cells. During the past year, MN1 and MN1-TEL have been 
identified as potent leukemogenic oncogenes in mice. In humans, MN1 is overexpressed in 
different subgroups of AML, especially in inv (16) AML, while its overexpression in AML with 
a normal karyotype has been associated with a poor response to ATRA treatment. In the 
past we and others showed that MN1 influences RAR/RXR-regulated gene expression and 
therefore we also studied the effect of MN1 expression on the activation of endogenously 
expressed retinoid receptors in the presence of ATRA. 
The expression profiling resulted in a list of genes up or downregulated by ATRA, MN1 
or by the combination of MN1 and ATRA. We focussed on direct effects by choosing the 
time points following induction of MN1 expression when, and shortly after, expression was 
visible. We, however, cannot rule out the possibility that some genes are indirectly affected 
by MN1 expression. For some genes such as MEIS1, CDKN2C, S100A8 and 9, the 
combination of MN1 and ATRA synergistically induced expression (Figure 4A). This 
regulation pattern is identical to the one we observed in transient transfection experiments 
using a mouse sarcoma virus long terminal repeat-driven reporter gene.8 In previous 
studies, we showed that the transactivating N-terminal domain of MN1, that binds 
coactivators such as p300 and RAC3, is responsible for this type of regulation. Here, we 
also show that MN1 can inhibit gene expression induced by ATRA, which is concordant with 
the data presented by Heuser et al4 who described that MN1 opposes the effects of ATRA 
and even conferred ATRA resistance to cells. At present, we do not know how MN1 exerts 
these effects. Besides the transactivating domain, not much is known about functional 
domains in the rest of this large protein. Finally, there are genes whose expression is 
minimally affected by ATRA alone but whose expression is induced to a higher level by the 
combination of MN1 and ATRA than by MN1 alone. Among these are BMI1, SPAG6, 
DNAJC1 and COMMD3, four genes that are located within 0.5 Mb of each other on 
chromsome 10p12. The joint regulation of these genes suggests that MN1 might be able to 
extend its influence over a larger genomic area. Interestingly, BMI1 and SPAG6 are also 
coordinately and highly expressed in inv (16) leukemias in which high expression of MN1 is 
thought to be obligatory.2 
It is obvious that many of the genes affected by MN1 play a role in hematopoiesis and 
leukemia. BMI1 is a member of the polycomb repression complex 1 and is required for the 
maintenance of adult hematopoietic stem cells. It functions by repressing genes that 
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promote lineage specification and cell-cycle arrest, such as p16/Arf.26,27,28 SPAG6 was 
recently identified as a marker for minimal residual disease in AML patients29 in cases where 
expression of SPAG6 is high. In case of a remission, the expression of SPAG6 drops, 
whereas a relapse is characterized by rising SPAG6 expression levels. The same is true for 
S100A8 and S100A9. The expression of these two calcium-binding proteins is upregulated 
by MN1 and they were recently described as genes upregulated in AML.30 The genes are 
downregulated in response to treatment with methotrexate. The Meis1 locus is a common 
retroviral integration site and was shown to be important for the pathogenesis of AML in 
mice.31,32 
Overexpression of MN1 in mouse BM produces highly proliferating immortalized cell 
lines and mice receiving transplants with MN1 retrovirus-transduced cells rapidly develop a 
lethal myeloproliferative disease/myeloid leukaemia.4,14 Heuser et al4 showed that p21, p27 
and PU.1 were repressed in these cells. We see no effect of MN1 and/or ATRA on p21 and 
PU.1 expression in U937 cells. However, we do see upregulation of the cyclin dependent 
kinase inhibitors CDKN1B (p27) and CDKN2C (p18). A counterintuitive effect is that 
upregulation of these genes is expected to lead to cell cycle arrest. On the other hand, it has 
been shown that CDKN2C is abundantly expressed in hematopoietic progenitors, AML, and 
cell lines and its expression is downregulated along with myeloid differentiation.33,34 
The MN1-TEL fusion gene contains most of the coding sequence of MN1 and TEL 
(ETV6), thereby combining the transcription-activating domains of MN1 with the DNA-
binding domain of TEL. The fusion protein is thought to act as a deregulated transcription 
factor possibly disturbing the function of both MN1 and TEL. We therefore expected a much 
more extensive list of genes whose expression would be affected by MN1-TEL. However, 
only few genes are induced or inhibited by MN1-TEL. Perhaps its most profound effects 
reside in the fact that it is unable to stimulate a large set of genes that are induced by MN1 
(Figure 3). The other most noticeable activity of the fusion protein is its inhibition of the 
stimulatory effects of ATRA on a large set of genes (Figure 4A). Disturbing the function of 
TEL is most likely caused by the binding of MN1-TEL to ETS regulatory sequences using 
TEL’s DNA-binding domain. Further scrutiny of genes that are induced by MN1-TEL 
identified two genes, ITGAM and HPSE, that are indeed regulated by the ETS factors PU.1 
and GABP.35,36,37 It is not known whether TEL also regulates these genes, but it has been 
described that ETS family members can bind to different ETS elements making it possible 
that MN1-TEL binds the ETS responsive elements in these genes. In agreement with our q-
PCR and array data there are retinoic acid-responsive elements in the promoter region of 
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the ITGAM gene,37 explaining the increase in ITGAM expression in response to ATRA 
treatment. 
The most interesting tumorigenesis-related genes that are influenced by MN1-TEL are 
NDRG1, ITGAM and DHRS9. The expression of NDRG1 is not directly influenced by the 
presence of MN1-TEL, but in combination with ATRA treatment it inhibits the ATRA effects 
on NDRG1 expression. NDRG1 is a metastasis suppressor, frequently downregulated in 
more advanced and poorly differentiated tumors.38 ITGAM, also known as CD11b or MAC-1, 
belongs to the family of integrins. CD11b/MAC-1 is expressed on mature monocytes and 
macrophages and is present on AML cells with a myelomonocytic differentiation. In fact, 
antibodies against CD11b/MAC-1 are widely used to sort and define the differentiation 
status of leukemic cells. High CD11b/MAC-1 expression was also seen in leukemias 
induced by expression of MN1-TEL in mouse bone marrow cells.14 Overexpression of 
CD11b/MAC-1 has also been associated with a unfavorable prognosis in AML.39,40 
Finally, the effect of MN1 and MN1-TEL on DHRS9 is interesting in relation to the 
differentiation block observed in most leukemias. The gene encodes an enzyme that is 
essential for the synthesis of ATRA from vitamin A. We show that ATRA stimulates 
expression of this gene and may thus enhance its own synthesis in mammals. Both MN1 
and MN1-TEL inhibit DHRS9 expression and completely abolish its induction by ATRA. 
Thus, this might inhibit the ATRA-induced differentiation in AML in humans and of MN1 and 
MN1-TEL-induced leukemia in mice. One could hypothesize that AML with high MN1 
expression would perhaps benefit from adjuvant treatment with ATRA. However, the 
contrary appears to be the case. AML patients that were treated with ATRA only benefited 
from this treatment when MN1 expression was low. High MN1 expression apparently 
conferred ATRA resistance to the leukemic cells.4 These findings suggest that perhaps other 
MN1 target genes play a more important role in defining the leukemia phenotype. 
In conclusion, we have shown that MN1 and MN1-TEL, directly or indirectly, regulate 
expression of many genes that have been implicated in leukemogenesis. Both proteins are 
able to enhance or to inhibit ATRA effects on gene expression. Further research is 
necessary to fully understand the pleiotropic effects executed by MN1 and MN1-TEL on 
gene expression. 
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SUPPLEMENTARY MATERIALS 
 
 
Supplementary Table 1. Primersets used for qPCR 
 
      
gene forward primer reverse primer 
BMI1 5'-ACTTCATTGATGCCACAACC-3' 5'-CAGAAGGATGAGCTGCATAA-3' 
CDKN2C 5'-ATGGATTTGGAAGGACTGC-3' 5'-GTGTGCTTCACCAGGAACTC-3' 
DHRS9 5'-TCAGAGAGACTTCGTACTGTGC-3' 5'-TGTAGTCCTCTAGTGTCAGCCA-3' 
ID1 5'-TCCAGCACGTCATCGACTAC-3' 5'-TCAGCGACACAAGATGCG-3' 
IGFBP6 5'-CATGCCGTAGACATCTGGAC-3' 5'-AGGAGCTTCCATTGCCATC-3' 
ITGAM 5'-GTGAAGCCAATAACGCAGC-3' 5'-TCTCCATCCGTGATGACAAC-3' 
MEIS1 (ID 3185) 5'-ATGTGACAATTTCTGCCACCG-3' 5'-CCTGAACGAGTAGATGCCGTG-3' 
MN1 5'-TCGCTGATGGCAGAGCACAG-3' 5'-GTCATTCAAGTTAGGGCAG-3' 
MN1TEL 5'-TCGCTGATGGCAGAGCACAG-3' 5'-CTCCGGCTGTGTGTGTATAG-3' 
NDRG1 5'-GACCCAACAAAGACCACTCTC-3' 5'-TGCCATCCAGAGAAGTGACG-3' 
POLR2A 5'-CGGATGAACTGAAGCGAATG-3' 5'-GAGTCCACAAGCAGTTTGG-3' 
S100A8 5'-ATGTTGACCGAGCTGGAGAA-3' 5'-CAGAATGAGGAACTCCTGGAAG-3' 
YES1 (ID 441). 5'-CAGCAAGACAAGGTGCAAAA-3' 5'-TGCAGAATTCCAAATGACCA-3' 
All newly designed primersets are deposited in the primer database.  
 
 
 
Supplementary Table 2  is available at http://carcin.oxfordjournals.org 
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Supplementary Figure 1. Experimental design of the microarray study. Expression of MN1 or MN1-TEL using the tet-off 
system was induced by withdrawal of tetracyclin from stably transfected U937T cells, in presence or absence of ATRA. Each 
dot represents the samples of the corresponding cell line (U937T-MN1, U937T-MN1-TEL, or U937T-UHD as control) after 
incubation for the indicated time under the condition indicated, that were used for hybridization.  The presence (+)  or absence 
(-) of tetracyclin or ATRA is indicated. Each double-headed arrow represents 4 arrays, consisting of two biological duplicates 
that were each hybridized in a straight and dye-swap fashion. A total of 100 arrays were performed. Conditions with ATRA 
were compared to their untreated counterparts at time points 16 and 20h only. The cell lines without expression of the target 
gene (+tet, no tet release) were compared to each other at time point 16h only. 
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Supplementary Figure 2. Reproducibility of microarray results between biological duplicates. The microarrays were analyzed 
according to the design in Fig S1, but now for each biological experiment separately, with each arrow in Fig S1 representing 
only two arrays for one biological replicate, hybridized in a straight and dye-swap fashion. Correlation plots included only 
reporters with a B value ≥1 in the combined analysis of all time points and both biological replicates together. The mean log2 
ratios obtained for biological experiment 2 were plotted against the mean log2 ratios obtained for biological experiment 1. The 
correlation coefficients (R2) indicated in the graphs were obtained by linear regression analysis. (A) Correlation plot of the 297 
reporters affected upon MN1 expression. (B) Correlation plot of the 420 reporters affected upon MN1-TEL expression. (C) 
Correlation plot of the 3162 reporters affected upon ATRA treatment. 
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Supplementary Figure 3. Unsupervised hierarchical clustering of 4468 spots that showed statistically significant differences in 
mean expression levels under any of the conditions shown. The conditions tested on the different arrays are indicated at the 
bottom with numbers (16, 20 or 24) and letter codes A to F. Numbers correspond to hours after induction of MN1 or MN1-TEL. 
The table underneath the figure explains the letter codes (+: presence of MN1 or MN1-TEL or ATRA; -: absence of MN1 or 
MN1-TEL or ATRA). For instance:  A ↔ B means that a sample with induced MN1-TEL expression is hybridized against a 
sample without MN1-TEL expression. Blue color represents stimulation and yellow repression.  
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Supplementary Figure 4. Fluorescent in-situ hybridisation in cell line U937 MN1. Metaphase chromosomes were hybridized 
with plasmid pMN50, containing the cDNA of MN1 (red), and the BAC clone RP11-293I13 (green). Note that the pMN50 
plasmid will detect all integrated plasmids because of homologous vector sequences. Signal of the RP11-293I13 BAC is 
observed on the two chromosome 10 derivatives (arrowhead/green) and plasmid pMN50 detects 3 plasmid integration sites 
(red) in this cell line. The big dot on the M5 marker chromosome,41,42 indicated by the asterisk, was present in all three different 
cell lines and thus derived from the tetracyclin-repressor plasmid. The other signals, indicated by arrows, located on two 
smaller marker chromosomes, are derived from the pUDH10S plasmid containing the MN1 cDNA or the co-transfected 
hygromycin selection plasmid. 
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Supplementary Figure 5. Effects of MN1 and MN1-TEL on expression levels of several genes. MN1 and MN1-TEL 
expression were induced by tetracyclin release in the presence and absence of ATRA. Time points used for the qPCR 
analyses are 0, 16, 20, 24, 40, 48, and 72h. The qPCR results were normalized, using the mRNA levels of POLR2A, and are 
presented relative to those in the presence of only the tet-repressor (white squares (□): +tet & +ATRA; black circles (●): -tet, 
no ATRA; grey triangles (▲): -tet & +ATRA). Left graphs: effects in MN1 cell line; middle graphs: effects in MN1-TEL cell line; 
right graphs: effects in UHD cell line. (A) MEIS1. (B) S100A8. (C) CDKN2C. (D) NDRG. (E) ITGAM. (F) ID1. (G) DHRS9. (H) 
BMI1. (I) YES1. (J) IGFBP6. Please note the different ranges between y-axis of the different cell lines for MEIS1, S100A8, 
ITGAM, ID1 and DHRS9.  
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GENERAL DISCUSSION 
Since the MN1 gene was cloned in 1995, subsequent research has shown that the MN1 
protein is implicated in the development of various tissues within the body, both during early 
development and in adult life. In the developing mouse embryo, expression of Mn1 has been 
detected mainly in the developing facial structures and in the brain. Mn1 knockout mice have 
shown that Mn1 is crucial for proper craniofacial bone development during embryogenesis. 
In adult mice, analysis of the bone marrow has detected high Mn1 levels in progenitors of 
the granulocyte and macrophage lineage and possibly in more primitive hematopoietic stem 
cells. In humans, overexpression of MN1 has been detected in bone marrow derived from 
patients with distinct subtypes of leukemia. Moreover, MN1 has been shown to present an 
independent marker for poor treatment outcome and shorter overall survival. Studies in mice 
have confirmed that induced MN1 expression in the bone marrow contributes to a leukemic 
phenotype. In vitro studies using cell lines that overexpress MN1 have shown that MN1 
promotes proliferation. Based on these observations in humans, mice and in cell lines, MN1 
is thought to maintain an undifferentiated state of cells and possibly promote self-renewal. 
Although MN1 expression has been detected in other tissues, for example in skeletal 
muscle, these areas have not been investigated yet. In vitro studies have provided a basis to 
unravel the molecular mechanisms involved: MN1 has been shown to be a transcriptional 
cofactor for the vitamin A and D nuclear receptors. Expression profiling of the MN1-inducible 
leukemic cell line U937 has shown that MN1’s activity is not restricted to nuclear receptors, 
because MN1 also inhibits and induces transcription without the involvement of vitamin A. 
For example, expression of IGFBP5 is regulated by MN1 through activation of the IGFBP5 
promoter and a transcription factor that cooperates with MN1 has been shown to bind a 
CACCC-rich element within this promoter. The role of MN1 in leukemia is reviewed by G. 
Grosveld.1 
This chapter will discuss recent papers in relation to the chapters presented in this 
thesis. Furthermore, some important issues and leads for future research on MN1 are 
discussed. 
 
THE CRUCIAL ROLE OF MN1 IN EARLY MAMMALIAN DEVELOPMENT 
Defects detected in Mn1 knockout mice clearly point to an important role for Mn1 in the 
development of cranial bone structures. In addition to the observed cranial bone defects, 
these mice suffer from a cleft palate, causing the mice to die shortly after birth. We 
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hypothesized that the palatal defects are most likely an additional effect to the malformations 
in the bone structures of the head, although an intrinsic role of Mn1 in palatal development 
was not ruled out. As mentioned in the introduction, Liu et al have investigated Mn1’s role in 
palatal development in more detail. Mn1 expresssion was detected within distinct regions of  
the developing palate. In palatal structures of Mn1 knockout mice Tbx22 expression was 
greatly reduced. Reporter studies using the Tbx22 promoter have demonstrated that indeed 
Mn1 is capable of upregulating Tbx22 levels. Altogether, this showed that Mn1 and Tbx22, 
function in a novel molecular pathway regulating mammalian palatal development.2 The 
palatal defect as detected in the Mn1 knockout mice is thus, at least partially, accounted for 
by a primary defect in palatal growth.  
MacDonald et al have investigated the Mn1 knockout mice and have focused on the 
role of Mn1 in bone formation. Calvarial osteoblasts derived from Mn1 knockout mice 
displayed reduced differentiation, impaired proliferation and produced less mineralized 
matrix.3 Additionally, it was shown that Mn1 is able to stimulate RANKL, an important 
osteoclast-inhiting factor. Altogether, these results show that Mn1 is important for 
appropriate osteoblast proliferation and differentiation and regulates osteoclast function 
through stimulation of RANKL gene transcription. However, it does not explain why the lack 
of Mn1 only creates cranial bone malformation; osteoblasts and osteoclasts are involved in 
bone formation throughout the skeleton and thus a more widespread effect would be 
expected. Most of the bones affected in the Mn1 knockout mice are formed by 
intramembranous bone formation. However, as mentioned before, also several bones that 
are formed by endochondral ossification processes are affected. Another point of view 
towards this issue focusses on the embryonic origin of the cells that form the skeleton. Cells 
that form the vertebrate skeleton are derived from three distinct embryonic regions. The 
craniofacial bone structures originate from cranial neural crest cells, a layer of cells located 
between the neural tube and the epidermis whereas the remainder of the skeleton is formed 
from paraxial and lateral plate mesoderm. The agenesis or improper development of 
craniofacial bones could therefore also be caused by defects in neural crest cell migration 
and/or differentiation.  
MN1’s role in leukemias, either by overexpression or by a translocation, indicates 
additional functions for MN1 in the adult hematopoietic system. The perinatal death of the 
Mn1 knockout newborns prevents us to study the role of MN1 in adult hematopoiesis 
directly, but transplantation of hematopoietic cells derived from livers of Mn1 newborn 
knockout mice into irradiated adult recipients is possible. Hematopoietic cells from the Mn1 
knockout mice will home in the bone marrow of recipient mice and this enables studies on 
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aberrant hematopoiesis caused by Mn1 deficiency. These experiments are currently being 
performed and will hopefully shed light on Mn1’s role in murine hematopoiesis (personal 
communication G. Grosveld). Whether Mn1 also plays an important role during embryonic 
hematopoesis is unknown and has not been investigated yet. 
The role of Mn1 in postnatal skeletal dynamics and other physiological processes in, 
for instance, the brain where Mn1 expression is detected in normal mice, is impossible 
because of the perinatal death of Mn1 knockout mice. To address these questions, 
conditional knockout models that survive postnatally need to be created.  
 
MN1 STIMULATES AND INHIBITS GENE TRANSCRIPTION 
We have shown that MN1 stimulates the Insulin Like Growth Factor Binding Protein 5 
(IGFBP5) gene through a CACCC-rich element in its proximal promoter. IGFBP5 belongs to 
a protein family with six members, which are expressed and secreted in a tissue and 
developmental stage-specific manner throughout the body. The proteins bind the most 
important regulators of mammalian growth and development, IGF-I and IGF-II. IGFBP5 
expression has also been observed in bone. IGFBP5’s specific role in bone is interesting in 
relation to Mn1’s effect on bone formation: does a disturbed regulation of IGFBP5 by Mn1 
contribute to the observed bone defects? The role of IGFBP5 in bone formation, however, is 
highly contradictory. Knocking out IGFBP5 in mice had minimal impact on bone4 and 
overexpression caused impaired mineralization.5,6 In contrast, administration of IGFBP5 and 
IGF-I led to increased bone formation and enhanced bone mineral density, both in cortical 
and calvarial bones.7 Studies in cultured osteoblasts and bone cell lines have also shown 
these opposing results.8,9,10 
 Expression profiling of our MN1-inducible cell line U937 has revealed a large list of 
genes that are regulated by MN1. The data have also shown that the effects of MN1 are 
more widespread: MN1 not only functions as a cofactor for retinoic acid (RA)-mediated 
transcription, but it can also stimulate and inhibit transcription independent of RA. 
Interestingly, within the list of genes that are upregulated by MN1 are four genes that are 
localized in a small region of chromosome 10. This combined upregulation of neighboring 
genes might possibly point to a long distance effect of MN1 on transcription. Also two closely 
related genes, namely S100A8 and S100A9, both localized close to each other on 
chromosome 1, are regulated in a similar way by MN1. Within the genome several clusters 
of genes are shown to be upregulated simultaneously. Enhancer sequences can be 
separated from the genes often by thousands of base pairs or can even be located on 
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separate chromosomes.11 Simultaneously upregulated, clustered genes are usually closely 
related with regard to their function. An well studied example is the β-globin locus.12 
Functional relations between the genes that are simultaneously upregulated by MN1 on 
chromosome 10 is however not recognized. 
Expression profiling of MN1-inducible cell lines has provides important data about 
which genes are switched on of off after induction of MN1 expression, but it does not give 
clues on which sequences within promoters of genes are crucial for MN1. Earlier studies 
have identified different DNA response elements that are important for MN1 function. These 
include CACCC sequences, DR1 and DR5 repeats and vitamin D responsive elements. We 
have searched for these response elements in promoters of identified genes, but they were 
not recognizable. Chromatin immune precipitations (ChIPs) enable the identification of the 
exact regions within a promoter where a transcription factor or cofactor binds. Activation or 
downregulation of a gene is accompanied by specific histone modifications and the 
recruitment of specific protein complexes. Combining the MN1-inducible cell lines with ChIP 
technology enables to monitor these changes in histone modifications and protein 
complexes in response to MN1 induction. A combination of ChIP with high-throughput 
sequencing technology, so called ChIP-seq, enables the analysis of protein-DNA interaction 
sites on a genome-wide scale. We are currently setting up these techniques in order to 
perform conventional ChIPs and ChIP-seq analyses on MN1-induced cell lines in the near 
future. A more direct approach is achieved by cloning the upstream regions of genes 
regulated by MN1. Subsequent transient transfection assays and deletion of these promoter 
regions will most likely help us to gain insight into transcription regulation by MN1.  
 
OVEREXPRESSION OF MN1 IN LEUKEMIA 
The overexpression of MN1 in various leukemia subgroups has been detected by the use of 
microarray platforms. In a subset of patients, these data have been verified by reverse 
transcriptase (RT)-PCRs. Comparison of microarray and RT-PCR results has shown that 
microarray results greatly underestimate the level of MN1 overexpression in inv(16) 
patients.13 Presumably, small increases in MN1 expression levels are present in other 
subclasses of leukemia that are undetectable in a microarray setup. It would therefore be 
interesting to analyze expression levels of MN1 in well-defined subsets of leukemia by RT-
PCR. Of special interest are the CBF-related leukemias. CBF is a heterodimeric 
transcription factor and both its subunits, AML1 and CBFβ, are subject to translocations. 
Overexpression of MN1 seems to be restricted to the translocation that involves the 
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regulatory subunit CBFβ, the inv(16)-created CBFβ-SMMHC. The importance of MN1 in the 
development of leukemia by the CBFβ-SMMHC fusion protein has been confirmed by mice 
studies. It would be interesting to investigate whether fusion genes of the AML1 subunit are 
similarly promoted by MN1 in their leukemic potential. Five different translocations have 
been described that involve the AML1 subunit of CBF of which AML1-ETO is most frequent. 
It is found in up to 12% of AML patients and, as CBFβ-SMMHC, is associated with AML. 
Several mouse models have been created in order to study the leukemogenic properties of 
AML1-ETO. These have shown that expression of AML1-ETO in the bone marrow alone is 
not sufficient to induce leukemia in mice.14,15,16,17,18 These mice were healthy and only after 
treatment with N-ethyl-N-nitrosourea (ENU), a powerful mutagen, cooperating mutations 
were acquired that were necessary to develop AML. Indications whether MN1 
overexpression in humans is detectable in AML1-ETO patients is deducible from expression 
profiling data that is stored in public databases. Analysis of the data in the Oncomine 
database19 (www.oncomine.org) reveals four independent microarray experiments that have 
analysed RNA of AML1-ETO patient material. None of these experiments, however, report 
MN1 as up or down regulated in AML1-ETO patients. A RT-PCR-based approach to analyse 
AML1-ETO patient samples will elucidate if even a mild overexpression of MN1 is detectable 
in AML1-ETO patient samples. Notably, expression profiling of leukemic cells of patients that 
are diagnosed with CBFβ and AML1 fusions have shown that these translocations are 
associated with distinct expression profiles.20,21 This suggests that, although the two proteins 
CBFβ and AML1 function together as a heterodimer, the fusion proteins that are formed with 
either of these two subunits each have their specific function and pathways involved in 
leukemogenesis. 
Although various studies have identified overexpression of MN1 in bone marrow of 
AML patients, no studies have been conducted so far that have investigated the basis 
behind this upregulation of MN1. In general, upregulation of a gene in cancer can be 
attributed to several different mechanisms: (1) amplification of a gene, (2) upregulation of 
proteins that upregulate the expression of the gene, (3) down regulation of a protein or 
microRNA (miRNA) that normally downregulates the expression of the gene, (4) mutations 
in regulatory sequences of a gene, either leading to less inhibition or increased stimulation, 
(5) placement of transcription-stimulating, regulatory elements derived from another locus 
near the gene by a translocation, (6) the increase of the mRNA stability of the gene by 
mutations in the untranslated regions or (7) demethylation of a promoter region resulting in 
initiation of the expression of the gene. It is unknown which option is responsible for the 
detected overexpression of MN1 in leukemias. Translocations near the MN1 gene possibly 
137 
 
Chapter 6 
 
causing an upregulation of MN1 are not described in leukemia, making this option less likely. 
Two inv(16) patients with high MN1 levels were shown to have a diploid copy number of the 
MN1 locus, ruling out the possibility of amplification of the MN1 gene as a upregulatory 
mechanism in these two patients.13 Which of the other options is valid for the overexpression 
of MN1 that is detected in leukemias is hard to say. Future research will hopefully provide 
clues on the regulation of the MN1 gene. This infomation, combined with array-based 
comparative genomic hybridization (CGH) or large-scale single nucleotide polymorphism 
(SNP) analysis and expression profiling data of inv(16) patients should be able to identify the 
mechanisms behind the upregulation of MN1. It is unknown if any miRNAs target the MN1 
mRNA. Searching the miRNA database (http://microrna.sanger.ac.uk/) revealed two 
miRNAs, namely hsa-miR-512-5p and hsa-miR-31, that possibly target the MN1 mRNA. 
Importantly, target genes of the majority of miRNAs are not well mapped to date, which is 
also evident for the postulated MN1-regulating miRNAs: hsa-miR-512-5p and hsa-miR-31 
have 924 and 810 possible target genes listed, respectively. Additionally, a literature search 
on miRNA expression profiles has not revealed differential expression for either of these two 
miRNAs in leukemia.22,23,24,25,26  
Various mouse studies have provided additional evidence for the important role of 
MN1 overexpression in the pathogenesis of certain subtypes of leukemias. The CBFβ-
SMMHC fusion protein only causes leukemia in adult mice when it is accompanied by MN1 
overexpression. Additionally, two fusion proteins, CALM-AF10 and NUP98-HOXD13, are 
able to induce leukemia in mice, whereby integration of a retrovirus near the MN1 gene 
leading to overexpression of MN1, has been shown to shorten the onset dramatically. 
Analyses of other integration sites have revealed that integrations near the MN1 locus are 
frequently accompanied by integrations near the zinc finger E-box binding homeobox 2 
(Zeb2) gene. CALM-AF10 transgenic mice develop leukemias in the myeloid lineage, 
whereas integrations near the Zeb2 gene result in B-cell ALL, suggesting that expression of 
Zeb2 strongly influences the phenotype of the CALM-AF10 mice. It is unknown if 
overexpression of MN1 in these mice contributes to the Zeb2-mediated B-cell ALL. In 
humans, ALL has been shown to be associated with downregulation of MN1 by methylation 
of the MN1 promoter region. This could represent a species-related difference in pathways 
involved in hematopoiesis.  
Zeb2, also known as Smad-interacting protein (SIP1), is a transcriptional repressor 
that binds to DNA and interacts with SMADs, the downstream signal transducers of the 
transforming growth factor (TGF) family. In several epithelial cell lines, upregulation of MN1 
has been reported in response to TGFβ.27,28 These two observations, namely Mn1 
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overexpression in CALM-AF10 mice that is frequently accompanied by Zeb2 integrations 
and upregulation of Mn1 by TGFβ, make the TGFβ pathway an interesting candidate for 
future studies on MN1. The TGFβ pathway is complex and has been implicated in the 
development and maintenance of various organs. In hematopoiesis, TGFβ has been shown 
to have inhibitory signals on the proliferation of hematopoietic progenitors.29 This seems to 
be in contrast to the role of MN1 during hematopoiesis: it maintains the progenitor state of 
cells and promotes proliferation. Expression of MN1, however, is not limited to the 
hematopoietic system. Expression is found in the developing brain, bone and in adult 
skeletal muscle. An interplay between TGFβ signaling and MN1 is thus still plausible and 
future studies will hopefully unravel if this interplay really exists.  
 
THE MN1-TEL FUSION PROTEIN 
The MN1-TEL fusion protein has been shown to influence both the normal function of TEL 
and MN1. MN1-TEL is able to bind to ETS-responsive elements and subsequently it uses 
the transcription stimulating domains of the MN1 moiety to stimulate promoters that are 
normally repressed by TEL. In addition, MN1-TEL functions as a dominant negative mutant 
of MN1 on RAR-RXR-mediated transcription. In contrast to MN1, the fusion protein is unable 
to cooperate with p300 and RAC3 and prevents MN1 to perform its normal function. 
Expression profiling of the leukemic cell line U937 with inducible expression of MN1-TEL 
has provided additional evidence for these mechanisms. After induction of MN1-TEL, 
inhibition of RA-induced transcription has been detected for many genes. Additionally, a 
small set of genes that are normally repressed by TEL is stimulated by MN1-TEL. Both 
mechanisms, namely the inhibition of RA effects and the stimulation of TEL-regulated 
genes, will contribute to leukemogenesis by MN1-TEL. Mice studies have shown however 
that MN1-TEL expression in bone marrow is not sufficient to cause AML.30,31 Additional 
mutations or activation of other genes, such as HOXA9, are required to develop a leukemic 
phenotype. HOXA9 overexpression in mice bone marrow induces AML, but MN1-TEL is 
able to accelerate the onset dramatically. The upregulation of N-Myc in these mice 
implicates a role for N-Myc in the leukemogenic pathways by MN1-TEL. 
Molecular mechanisms involved in the leukemogenic properties of MN1-TEL rely, at 
least partially, on the fact that the DBD domain of TEL is maintained in the fusion. A number 
of other translocations of TEL have been described in which, as for MN1-TEL, the DNA 
binding domain (DBD) domain of TEL contributes to the fusion. These include TTL-TEL,32 
CHIC2-TEL,33,34 PAX5-TEL,35 EVI1-TEL36,37 and HLXB9-TEL.38,39 The molecular 
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mechanisms for the fusions involving TTL, CHIC2 and EVI genes with TEL are yet unknown. 
Notably, patients with an EVI1-TEL fusion also express the reciprocal fusion. The EVI1, 
PAX5 and HLXB9 genes encode transcription factors and their fusions with TEL possibly 
generate deregulated transcription factors. The fusion of the HLXB9 and TEL genes leads to 
an in-frame fusion in about half of the patients with the t(7;12)(q26;p13). Additionally, it has 
been shown that all patients carrying this translocation have overexpression of the non-
translocated allele of HLXB9, which might contribute to leukemogenesis.40 It is unknown if 
patients carrying a MN1-TEL fusion overexpress the non-translocated MN1 allele. It is, 
however, unlikely that the above mentioned mechanism plays a major role for the MN1-TEL 
fusion: molecular studies have shown that both MN1 and TEL segments of the fusion protein 
are important for oncogenesis by MN1-TEL and, moreover, MN1 expression was not 
detectable in UCSD/AML1, a cell line that harbors a MN1-TEL fusion.41  
Like MN1-TEL, the PAX5-TEL fusion has been shown to create a deregulated 
transcription factor.42 The PAX5 protein binds DNA with its DBD and is both an activator and 
repressor of transcription. The fusion, unlike MN1-TEL, retains the DBD of PAX5 and 
activator/inhibitory domains of PAX5 are lost. The breakpoint within the TEL gene is exactly 
the same as for the MN1-TEL fusion, thereby contributing the DBD to the fusion protein. 
Molecular studies have indicated that PAX5-TEL acts as a repressor through the recruitment 
of the mSin3A co-repressor, which subsequently will attract histone deacetylases (HDACs). 
Our results on MN1-TEL has indicated that the repressive effect of MN1-TEL on RA-
mediated transcription is not caused by recruitment of HDACs but rather the inability of the 
transcription stimulating domains of MN1 to cooperate with coactivators like p300 and 
RAC3. Accordingly, fusion of MN1 to TEL is different compared to the other fusions involving 
TEL: MN1-TEL functions as both an activator and repressor of transcription and this relies 
on both MN1 and TEL sequences. 
 
CONCLUSION 
Over the last years, it has become clear that MN1 is an important oncogene for 
leukemogenesis. Inv(16) leukemias are associated with upregulation of MN1 and in AMLs 
without cytogenetically detectable aberrations upregulation of MN1 is linked to poor survival. 
Future research will bring to light if MN1 is also involved in other subtypes of leukemia.  
Basic research, as described in this thesis, aims to unravel the function of MN1. We 
have shown, amongst others, the important interplay between RA and MN1. RA is used as 
therapy for AML patients and upregulation of MN1 was shown to predict a poor response to 
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RA therapy. Future studies to characterize the cofactor function of MN1 should focus on 
MN1 itself, its binding partners, and its target genes. These studies are crucial to create 
hypotheses as to how to treat patients that present with high MN1 expression. Judging from 
the size of the protein it is expected that MN1 is a multifunctional protein and if these 
different functions are linked to distinct regions, it might be possible to block the oncogenic 
function of MN1.  
Studies aiming to unravel the regulation of the MN1 gene might present ideas for 
future therapy in relation to the upregulation of MN1. It is well possible that miRNAs will be 
identified that regulate the expression of MN1 and these or modified forms of these miRNAs 
might represent important tools for future therapy.  
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SUMMARY 
Leukemia is a cancer of the blood and bone marrow and is characterized by an abnormal 
proliferation of poorly differentiated blood cells. The overgrowth of normal blood cells by 
leukemic cells leads to failure of the blood to perform its normal functions, ultimately 
resulting in symptoms, such as fatigue, easy bleeding and a failure to fight infections. The 
main subgroups of leukemia are classified according to the cell lineage involved (myeloid or 
lymphoid) and the development of the disease (acute or chronic).  
Leukemias are frequently associated with specific chromosomal translocations and 
inversions. These genomic abnormalities lead to fusion proteins that, contributed by other 
mutations, disturb normal hematopoiesis. Some of these aberrations, such as the inversion 
(inv) of chromosome 16, have been detected in up to 12% of acute myeloid leukemia (AML) 
patients, whereas others have been found in only a small number of patients. An example of 
the latter type of translocations is the t(12;22) that fuses the MN1 and TEL genes. The MN1-
TEL fusion gene is one of topics of this thesis. 
MN1's involvement in leukemias is not restricted to the fusion gene MN1-TEL. 
Expression profiling of inv(16) patient samples has shown that the MN1 gene is upregulated 
in these patients. Up or downregulated genes associated with a specific subgroup of 
leukemias are likely to represent genes involved in the molecular mechanisms behind these 
leukemias. Mice studies have indeed confirmed that upregulation of MN1 contributes to 
leukemogenesis: the fusion protein generated by the inv(16) only leads to leukemia in mice 
when it is combined with overexpression of MN1. In addition, MN1 was shown to be 
upregulated in a subset of cytogenetically normal AML patients and within this patient group, 
MN1 overexpression is an independent prognostic marker for poor treatment outcome and 
worse overall survival.  
Retinoic acid (RA) is a crucial stimulator of differentiation for hematopoietic cells, and 
AML patients benefit from treatment with RA in addition to standard chemotherapy. A 
retrospective study has shown that high MN1 expression levels correlate with resistance to 
RA treatment in AML patients, whereby only patients with low levels of MN1 benefit from RA 
treatment. The association between MN1 expression levels and RA treatment is explained 
by the fact that MN1 functions as a cofactor, both stimulatory and inhibitory, for the vitamin A 
receptor. During differentiation of hematopoietic cells, MN1's cofactor activity is mainly 
inhibitory and high MN1 levels thus result in failure to respond to RA treatment. 
In order to unravel the function of the MN1 oncogene and its leukemogenic fusion 
gene MN1-TEL, a whole range of different research lines have been conducted over the last 
years in our laboratory and these form the basis of this thesis. We have studied MN1 
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function during embryogenesis in mice and molecular studies have focused on the 
transcriptional regulation of genes by MN1 and MN1-TEL.  
By homologous recombination, an Mn1 null mice strain has been generated allowing 
us to study the effects of omitting the MN1 gene and in chapter 2 the phenotype of these 
mice is described. The knockout mice are characterized by a palatal defect and severe 
malformations in the cranial/facial bone structures pointing to a role for Mn1 in the formation 
of these bone structures. In mice, palatal defects are not compatible with life, resulting in 
perinatal death of the newborn mice. In heterozygous mice, hypoplastic cranial bones and 
incomplete penetrance of the cleft palate have been observed. In later life, no higher tumor 
incidence or other pathology was observed in heterozygous mice. Two research groups 
have extended these studies focussing on the developing palate and the bone formation 
within the skull. Liu and coworkers have shown differential expression of Mn1 in the 
developing palate and molecular studies have shown that Mn1 regulates the expression of 
Tbx22, a protein important for proper palatal development. MacDonald and coworkers have 
isolated calvarial osteoblasts from Mn1 knockout mice. The osteoblasts were shown to have 
a reduced growth rate and produced less mineralized bone matrix. The function of Mn1 is 
not restricted to the stimulation of osteoblasts. Mn1 also regulates osteoclast function 
through the stimulation of RANKL, a gene involved in regulation of osteoclast function.  
Shortly after cloning of the MN1 gene in 1995, it was realized that MN1 is able to 
activate transcription. The amino acid sequence, however, did not reveal a DNA binding 
domain. In order to identify DNA elements in promoters binding to MN1 directly or indirectly, 
i.e. via other transcription factors, we have performed an oligo selection assay. Amongst 
others, a CACCC-rich element has been identified as a MN1-responsive element. Previous 
northern blots on meningioma samples with probes against MN1 and IGFBP5 have shown 
the coordinated expression of MN1 and IGFBP5 in this type of cancer. The presence of 
CACCC elements in the promoter region of the IGFBP5 gene has prompted us to study the 
possible regulation of IGFBP5 by MN1. Chapter 3 describes that MN1 indeed upregulated 
the IGFBP5 gene. Deletion constructs of the promoter lacking the CACCC elements, located 
140 bp upstream of the transcription start site, failed to be stimulated by MN1. We have 
shown that MN1 does not bind to this sequence directly but most likely interacts with other, 
yet unknown, DNA-binding transcriptional regulators. The CACCC element has also been 
shown to be important for the induction of the IGFBP5 promoter by RA. Induction of IGFBP5 
by RA depends on co-expressed MN1 in the Hep3B liver carcinoma cell line that we used in 
this study. MN1-TEL, the leukemogenic fusion protein, is capable of stimulating the IGFBP5 
promoter, but is unable to cooperate with RA in Hep3B cells, suggesting that effects of RA 
can be negatively affected in leukemias caused by MN1-TEL. 
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The MN1-TEL fusion gene formed by the t(12;22) fuses the 5’ part of the MN1 gene 
with the 3’ part of the TEL gene. TEL is a sequence specific transcriptional repressor and 
member of a large family of transcription factors with highly homologous domains. We have 
previously shown that MN1 is a cofactor for the vitamin A receptor. The fusion protein 
harbors large portions of both proteins including the transcription stimulating domains of 
MN1 and the DNA binding domains of TEL, thus creating a deregulated transcription factor. 
In the study presented in chapter 4 we have studied the characteristics of the MN1-TEL 
fusion protein with respect to MN1 on a viral promoter. We have shown that cofactor MN1 is 
highly stimulated by the coactivators p300 and RAC3, whereas MN1-TEL is not. Using a 
mutant of MN1-TEL that can not bind DNA, we have shown that MN1-TEL functions as a 
dominant-negative mutant of MN1 and blocks vitamin A-mediated transcription. This 
blockage is caused by dysfunctional MN1-derived activation domains rather than by 
recruitment of corepressors by the TEL moiety of the fusion protein. 
Several studies have shown the importance of MN1 expression levels in leukemias. 
Identification of genes regulated by MN1 provides tools to further study the pathways 
underlying these MN1-involved leukemic processes. In chapter 5, we have conducted a 
gene expression profiling study using a leukemic cell line with inducible expression of MN1. 
In the same setup, we have also studied the expression profile resulting from MN1-TEL 
induction. We have shown that MN1 can both stimulate and inhibit transcription. Combining 
MN1 expression with RA showed that MN1 can both enhance and repress RA effects. Many 
of the identified genes are key players in hematopoiesis and leukemogenesis (e.g. MEIS1 
and BMI1). Another interesting target is the DHRS9 gene, which encodes the DHRS9 
protein, an enzyme involved in the synthesis of RA. The strong stimulation of this gene by 
RA is completely abolished by MN1. MN1-TEL induces expression of only a few genes and 
its most profound effect is inhibition of a large group of RA-stimulated genes, including 
DHRS9. In conclusion, both MN1 and MN1-TEL interfere with the RA pathway and this 
might explain the differentiation block in leukemias in which MN1 and MN1-TEL are 
involved. 
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SAMENVATTING 
Leukemie is een kanker van het bloed en het beenmerg die gekenmerkt wordt door een 
hoge proliferatie, gecombineerd met een slechte differentiatie van bloedcellen. De 
abnormale bloedcellen overgroeien de normale bloedcelpopulatie waardoor deze de 
normale functies niet meer kunnen uitvoeren. Dit leidt uiteindelijk tot de symptomen van de 
ziekte, zoals moeheid, slechte bloedstolling en een verminderd vermogen om infecties te 
bestrijden. Leukemieën worden geclassificeerd op grond van het beloop van de ziekte 
(acuut of chronisch) en de betrokken cellen (myeloϊde of lymfoϊde).  
Leukemieën zijn vaak geassocieerd met specifieke chromosomale translocaties en 
inversies. Deze creëren fusiegenen welke, tezamen met andere mutaties in het genoom, 
uiteindelijk leiden tot een verstoorde bloedcelvorming. Ongeveer 15 translocaties vormen 
samen de belangrijkste afwijkingen die bekend zijn in leukemie patiënten. Daarentegen is er 
een grote groep translocaties die zeldzaam zijn en maar in een kleine groepen patiënten 
gevonden worden. Een voorbeeld hiervan is de translocatie van chromosoom 12 en 22, die 
leidt tot een fusie tussen de MN1 en TEL genen. Het fusiegen  MN1-TEL is een van de 
onderwerpen van dit proefschrift. 
De betrokkenheid van MN1 bij leukemieën is niet beperkt tot het fusiegen MN1-TEL. 
Genexpressie profielen van inv(16) leukemie patiënten hebben laten zien dat MN1 hoog tot 
expressie komt in de leukemische cellen. Genen waarvan het expressiepatroon 
geassocieerd is met een bepaalde vorm van leukemie, zouden betrokken kunnen zijn bij de 
moleculaire mechanismen die ten grondslag liggen aan het ontstaan van deze leukemie. 
Met behulp van muismodellen is inderdaad aangetoond dat een verhoogde expressie van 
MN1 een belangrijke bijdrage levert aan het ontstaan van leukemie door het inv(16) 
fusiegen. 
Daarnaast is ook aangetoond dat het MN1 gen tot overexpressie komt in een gedeelte 
van de patiënten waarbij in de leukemische cellen geen chromosomale afwijkingen 
gevonden worden, de zogenaamde cytogenetisch normale leukemie patiënten. In deze 
patiëntengroep is gevonden dat het MN1 expressie niveau een onafhankelijke 
prognostische factor is. Een hoge expressie van MN1 voorspelt zowel een slechte reactie op 
chemotherapie als een slechtere overlevingskans voor de patiënt. 
Vitamine A vervult een belangrijke rol bij de differentiatie van bloedcellen. Een 
verstoorde differentiatie van bloedcelpopulaties is een belangrijk kenmerk van leukemie en 
het is dan ook gebleken dat leukemie patiënten baat hebben bij een behandeling met 
vitamine A naast conventionele chemotherapie.  Een retrospectieve studie toonde dat een 
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hoog expressieniveau van MN1 in patiënten gecorreleerd is met een resistentie voor 
vitamine A behandeling. Alleen patiënten met een lage expressie van het MN1 gen hebben 
daarom baat bij een adjuvante behandeling met vitamine A. De associatie van MN1 met de 
vitamine A behandeling is te verklaren met het feit dat MN1 een cofactor is van de vitamine 
A receptor. MN1 kan zowel stimulerend als remmend werken op de transcriptie die door de  
vitamine A receptor gereguleerd wordt. In het proces van bloedcelvorming werkt MN1 
voornamelijk remmend samen met de vitamine A receptor, waardoor een hoog expressie 
niveau van MN1 een situatie bewerkstelligt waarbij patiënten niet reageren op een 
behandeling met vitamine A. 
De afgelopen jaren zijn er veel verschillende onderzoekslijnen gevolgd om de functie 
van het MN1 gen en het leukemie veroorzakende fusie gen MN1-TEL te bestuderen. Deze 
vormden de basis voor dit proefschrift. Er is onderzocht wat de functie van Mn1 gedurende 
de embryogenese in muizen is en moleculaire studies hadden tot doel de transcriptie 
regulatie door MN1 en MN1-TEL te onderzoeken. 
Met behulp van homologe recombinatie is een muizenlijn gecreëerd die het Mn1 gen 
niet tot expressie brengt; een zogenaamde Mn1 knockout muizenlijn. Het fenotype van deze 
muizen is beschreven in hoofdstuk 2. De muizen lijden aan een gespleten verhemelte en 
vertonen ernstige afwijkingen aan de botten van het aangezicht en het schedeldak. Dit duidt 
op een belangrijke rol voor Mn1 in het ontstaan van deze structuren. Defecten aan het 
verhemelte zijn voor muizen lethaal, waardoor alle Mn1 knockout embryo’s direct na de 
geboorte overlijden. Het overgrote deel van de heterozygote muizen, die dus nog maar 1 
kopie van het Mn1 gen bezitten, blijven na de geboorte in leven en hebben een normale 
levensverwachting. De botten van het gelaat en het schedeldak zijn aangelegd maar zijn 
dunner in vergelijking met de normale muizen. Het deel van de heterozygote muizen die na 
geboorte overlijden bleken een gespleten verhemelte te hebben.  
Twee onafhankelijke onderzoeksgroepen hebben de Mn1 knockout muizenlijn gebruikt 
voor vervolgstudies. Liu en medewerkers hebben de ontwikkeling van het verhemelte 
bestudeerd. In normale muizen bleek Mn1 in verschillende regionen van het verhemelte tot 
expressie te komen. In de Mn1 knockout muizen werd aangetoond dat Mn1 de expressie 
van Tbx22, een belangrijk eiwit voor de ontwikkeling van het verhemelte, reguleert. 
MacDonald en medewerkers hebben de botvorming van de schedel in de Mn1 knockout 
muizen nader onderzocht. Osteoblasten afkomstig van Mn1 knockout muizen vertoonden 
een lage groei snelheid en produceerden minder box matrix. De studie heeft laten zien dat 
de rol van Mn1 in het proces van botvorming zich niet beperkt tot het stimuleren van 
osteoblasten. Ook de functie van osteoclasten wordt gereguleerd door Mn1. 
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Na het kloneren van het MN1 gen in 1995, bleek al snel dat MN1 betrokken is bij 
transcriptieregulatie. De voorspelde aminozuur sequentie gaf echter geen indicaties voor het 
bestaan van een DNA bindend domein in het eiwit. Met behulp van een zogenaamd 
oligoselectie experiment is getracht de DNA sequenties te identificeren die belangrijk zijn 
voor het functioneren van MN1. MN1 zou deze sequenties direct of indirect, dat wil zeggen 
via andere transcriptiefactoren, kunnen binden. Er werd o.a. een CACCC-rijk element 
geïsoleerd wat belangrijk zou kunnen zijn voor de functie van MN1. Eerder was er 
onderzoek gedaan aan meningiomen, een type goedaardige hersentumoren. Studies die 
betrekking hadden op RNA expressie niveaus van verschillende transcripten lieten zien dat 
de expressie niveaus van MN1 en IGFBP5 sterk variëren in meningiomen. Opvallend daarbij 
was dat de expressie van deze twee transcripten aan elkaar gecorreleerd is. De 
aanwezigheid van CACCC elementen in de regulerende sequenties van het IGFBP5 gen 
heeft er toe geleid dat onderzocht is of MN1 de expressie van het IGFBP5 gen kan 
reguleren. Hoofdstuk 3 beschrijft dat MN1 inderdaad het IGFBP5 gen kan stimuleren.  De 
CACCC elementen liggen ongeveer 140 baseparen  voor de positie waar de transcriptie 
gestart wordt en constructen die deze elementen missen worden nauwelijks door MN1 
gestimuleerd. Dit laat zien dat de CACCC elementen in de regulerende sequenties van het 
IGFBP5 gen betrokken zijn bij de stimulatie door MN1. Diezelfde elementen zijn ook 
betrokken bij de stimulatie van IGFBP5 door o.a. vitamine A. We hebben aangetoond dat 
deze stimulatie in de gebruikte cellijn afhankelijk is van de expressie van MN1. Het fusie 
eiwit MN1-TEL is in staat om het IGFBP5 gen te stimuleren, maar kan hierbij niet 
samenwerken met vitamine A zoals MN1 dit wel kan. Dit suggereert dat het niet kunnen 
samenwerken van MN1-TEL met vitamine A op vele andere genen een rol zou kunnen 
spelen in het ontstaan van leukemie door MN1-TEL. 
Het MN1-TEL fusie gen, dat gevormd wordt bij de translocatie tussen chromosoom 12 
en 22, fuseert het voorste deel van het MN1 gen met het achterste deel van het TEL gen. 
TEL is een DNA bindende repressor van transcriptie en behoort tot een grote familie van 
transcriptiefactoren die een aantal goed gedefinieerde, homologe domeinen hebben. MN1 
kan o.a. als cofactor de transcriptie beïnvloeden die door de vitamine A receptor 
gereguleerd wordt. Het fusiegen bevat van beide genen een groot gedeelte waardoor het 
transcriptie stimulerende deel van MN1 en het DNA bindende domein van TEL 
gecombineerd worden. Het fusiegen codeert dus voor een transcriptiefactor met unieke 
nieuwe eigenschappen. In hoofdstuk 4 is de functie van het MN1-TEL fusie-eiwit 
onderzocht in relatie tot het MN1 eiwit. De activiteit van MN1 als cofactor voor de vitamine A 
receptor wordt gestimuleerd door de cofactoren p300/CBP en RAC3. Het fusie-eiwit MN1-
152 
 
Appendices 
 
TEL daarentegen niet. Met behulp van een mutant van MN1-TEL die niet meer aan DNA 
kan binden hebben we laten zien dat MN1-TEL een dominant-negatief effect heeft op MN1 
en transcriptie die door vitamine A gestimuleerd wordt kan remmen. Deze remming wordt 
niet veroorzaakt door het aantrekken van corepressoren met het TEL gedeelte van het fusie 
eiwit, maar door het niet goed functioneren van de stimulerende domeinen uit het MN1 deel 
van het fusie eiwit. 
Een aantal studies heeft laten zien dat MN1 expressie niveaus belangrijk zijn in 
leukemieën. Het identificeren van genen die gereguleerd worden door MN1 levert een  
bijdrage voor het verder bestuderen van de mechanismen die betrokken zijn bij het ontstaan 
van leukemieën waarbij MN1 betrokken is. In hoofdstuk 5 wordt een studie beschreven met 
een leukemische cellijn waarin MN1 tot expressie gebracht kan worden. Er is een 
genexpressie profiel bepaald van deze cellijn onder verschillende condities: in de aan- en 
afwezigheid van MN1 zonder of in combinatie met vitamine A. Op dezelfde manier is ook 
een cellijn gebruikt waarin het MN1-TEL fusie gen tot expressie gebracht kan worden. We 
hebben laten zien dat MN1 zowel transcriptie kan stimuleren als remmen, zowel in aan- als 
afwezigheid van vitamine A. Veel van de geïdentificeerde genen spelen een belangrijke rol 
bij het ontstaan van leukemie in het algemeen. Voorbeelden hiervan zijn MEIS1 en BMI1. 
Een ander interessant gen dat door MN1 gereguleerd wordt is DHRS9. Het gen codeert 
voor een enzym dat betrokken is bij het metabolisme van vitamine A. DHRS9 wordt zelf ook 
gestimuleerd door vitamine A en MN1 neutraliseert deze stimulatie volledig. MN1-TEL 
stimuleert de expressie van maar een selecte groep genen en het belangrijkste effect van 
het fusie-eiwit is de remming van een grote groep genen die gestimuleerd worden door 
vitamine A, waaronder DHRS9. Concluderend kan gezegd worden dat zowel MN1 als MN1-
TEL de vitamine A gereguleerde processen beïnvloeden. Daar vitamine A een cruciale rol 
speelt bij de differentiatie van bloedcellen tijdens de bloedcel vorming zou dit een verklaring 
kunnen zijn voor de blokkering van de bloedcel differentiatie die gezien wordt in leukemieën 
waarbij MN1 en MN1-TEL een rol spelen. 
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